LWZ2218的个人主页 - 老虎社区

LWZ2218

LWZ2218

暂无个人介绍

IP属地：未知

290关注

23粉丝

0主题

0勋章

2021-12-16

Good job

抱歉，原内容已删除

2021-12-15

Buy Buy Buy

抱歉，原内容已删除

2021-12-14

Good time to buy Tesla stock now

Tesla Stock Is in a Bear Market Again. What’s Next for Musk’s EV Firm.<blockquote>特斯拉股票再次陷入熊市。马斯克电动汽车公司的下一步是什么？</blockquote>

2021-12-13

Yes , it will reach 1580 soon

抱歉，原内容已删除

2021-12-10

Huat

抱歉，原内容已删除

2021-12-09

Go Go Pfizer

Pfizer Says Booster Neutralized Omicron but Variant May Elude Two Doses<blockquote>辉瑞称加强剂中和了奥密克戎病毒，但变种可能无法注射两剂</blockquote>

2021-12-08

Yeah dividend !!!! Buy Buy Buy

抱歉，原内容已删除

2021-12-07

Is time to buy !!!

抱歉，原内容已删除

2021-12-05

Is time to buy

Semiconductor stocks slid in morning trading<blockquote>半导体股早盘下跌</blockquote>

2021-12-04

Nice

抱歉，原内容已删除

2021-12-03

Like

抱歉，原内容已删除

2021-12-02

nice

抱歉，原内容已删除

2021-12-01

Pfizer is the best !!!

抱歉，原内容已删除

2021-11-30

okay

抱歉，原内容已删除

2021-11-29

Good

November jobs report: What to know this week<blockquote>11月就业报告：本周需要了解什么</blockquote>

2021-11-28

like

抱歉，原内容已删除

2021-11-26

Nice

抱歉，原内容已删除

2021-11-25

NVDA is the best !!

抱歉，原内容已删除

2021-11-23

NVDA is the best for sure

抱歉，原内容已删除

2021-11-22

Come liao

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3577518888738299","uuid":"3577518888738299","gmtCreate":1614425109777,"gmtModify":1615209275056,"name":"LWZ2218","pinyin":"lwz2218","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/f53fe88ba02bdf3f307a8e715043f7e2","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":23,"headSize":290,"tweetSize":239,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":1,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.67%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.06.28","exceedPercentage":"93.96%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.07.14","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":690010483,"gmtCreate":1639613021232,"gmtModify":1639613021478,"author":{"id":"3577518888738299","authorId":"3577518888738299","name":"LWZ2218","avatar":"https://static.tigerbbs.com/f53fe88ba02bdf3f307a8e715043f7e2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577518888738299","idStr":"3577518888738299"},"themes":[],"htmlText":"Good job","listText":"Good job","text":"Good job","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690010483","repostId":"2191994940","repostType":4,"isVote":1,"tweetType":1,"viewCount":2462,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607824488,"gmtCreate":1639527033295,"gmtModify":1639527033535,"author":{"id":"3577518888738299","authorId":"3577518888738299","name":"LWZ2218","avatar":"https://static.tigerbbs.com/f53fe88ba02bdf3f307a8e715043f7e2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577518888738299","idStr":"3577518888738299"},"themes":[],"htmlText":"Buy Buy Buy","listText":"Buy Buy Buy","text":"Buy Buy Buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/607824488","repostId":"2191329909","repostType":4,"isVote":1,"tweetType":1,"viewCount":3555,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604454369,"gmtCreate":1639441289184,"gmtModify":1639441293892,"author":{"id":"3577518888738299","authorId":"3577518888738299","name":"LWZ2218","avatar":"https://static.tigerbbs.com/f53fe88ba02bdf3f307a8e715043f7e2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577518888738299","idStr":"3577518888738299"},"themes":[],"htmlText":"Good time to buy Tesla stock now","listText":"Good time to buy Tesla stock now","text":"Good time to buy Tesla stock now","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/604454369","repostId":"1114636896","repostType":4,"repost":{"id":"1114636896","kind":"news","pubTimestamp":1639439509,"share":"https://www.laohu8.com/m/news/1114636896?lang=zh_CN&edition=full","pubTime":"2021-12-14 07:51","market":"us","language":"en","title":"Tesla Stock Is in a Bear Market Again. What’s Next for Musk’s EV Firm.<blockquote>特斯拉股票再次陷入熊市。马斯克电动汽车公司的下一步是什么？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1114636896","media":"Barrons","summary":"Shares of electric-vehicle leader Tesla crossed into bear-market territory today. That statement is ","content":"<p>Shares of electric-vehicle leader&nbsp;Tesla&nbsp;crossed into bear-market territory&nbsp;today. That statement is technically true, but also a little tiring. Stocks, individually, don’t have bear or bull markets. That terms should be reserved for, well, the overall market. Still, the big dip in a mega-cap stock is noteworthy leaving investors wondering what might come next.</p><p><blockquote>电动汽车领导者特斯拉的股价今天进入熊市区域。这种说法在技术上是正确的，但也有点累。就个人而言，股票没有熊市或牛市。这些条款应该留给整个市场。尽管如此，大型股的大幅下跌还是值得注意的，让投资者想知道接下来会发生什么。</blockquote></p><p> Tesla (ticker: TSLA) stock closed down 5% at $966.41. The&nbsp;S&amp;P 500 index&nbsp;and&nbsp;Dow Jones Industrial Average&nbsp;both closed down 0.9%.</p><p><blockquote>特斯拉（股票代码：TSLA）股价收盘下跌5%，至966.41美元。标普500指数和道琼斯工业平均指数均收跌0.9%。</blockquote></p><p> The Monday dip sent the company’s market cap below $1 trillion based on the number of shares outstanding, excluding management stock options. Shares are down 21% from the Nov. 4 closing high of $1,229.91. Shares are down 22% from the intraday high of $1,243.49.</p><p><blockquote>根据已发行股票数量（不包括管理层股票期权）计算，周一的下跌使该公司的市值跌破1万亿美元。股价较11月4日收盘高点1,229.91美元下跌21%。股价较盘中高点1,243.49美元下跌22%。</blockquote></p><p> Whether or not bear markets should be measured from a closing high or an intraday high is the source of debate on Wall Street. But again, the debate doesn’t really matter in this instance because individual stocks don’t have bull and bear markets.</p><p><blockquote>熊市应该从收盘高点还是盘中高点来衡量是华尔街争论的焦点。但同样，在这种情况下，争论并不重要，因为个股没有牛市和熊市。</blockquote></p><p> Whether it’s a bear market or not isn’t the point for individual investors. The pain of a 20% drop is real.</p><p><blockquote>对于个人投资者来说，是否是熊市并不是重点。下跌20%的痛苦是真实的。</blockquote></p><p> One of the last times Tesla stock closed in bear-market territory was February 2021. (Yes, <i>Barron’s</i> wrote about the single stock bear market then, too.) Back then, interest rates were rising and highly valued tech stocks took it on the chin. Higher rates hurt the valuation of shares of faster-growing companies more than those of slow-growing mature companies—that’s just the way the math of higher interest rates works out.</p><p><blockquote>特斯拉股票最后一次收于熊市区域是在2021年2月。（是的，<i>巴伦周刊</i>当时也写过关于单股熊市的文章。）当时，利率正在上升，高估值的科技股承受了压力。较高的利率对增长较快的公司股票估值的损害大于增长缓慢的成熟公司的股票估值——这正是较高利率的数学计算方式。</blockquote></p><p> Back then it took about six months for the stock to retake its old highs. If that were to happen again, bullish investors would be waiting until June 2022 to see Tesla stock hit $1,300.</p><p><blockquote>当时，该股花了大约六个月的时间才恢复到旧高点。如果这种情况再次发生，看涨的投资者将等到2022年6月才能看到特斯拉股价触及1,300美元。</blockquote></p><p> That would be a long wait for bulls, and while there is no way to know if that scenario will even unfold, there is a lot going on that could move the stock in the coming couple of months. Bullish and bearish Tesla investors will be watching for the startup of two new plants in Germany and Texas, the impact of those new plants on profit margins, the start of deliveries of the Tesla Cybertruck and the overall growth of EVs in the U.S., Europe, and China.</p><p><blockquote>对于多头来说，这将是一个漫长的等待，虽然没有办法知道这种情况是否会发生，但未来几个月有很多事情可能会影响该股。看涨和看跌的特斯拉投资者将关注德国和德克萨斯两家新工厂的启动、这些新工厂对利润率的影响、特斯拉Cybertruck的开始交付以及美国电动汽车的整体增长、欧洲和中国。</blockquote></p><p> With all that coming, it raising the question of why the shares are struggling.</p><p><blockquote>随之而来的是，这引发了一个问题：为什么股价陷入困境。</blockquote></p><p> Two things might be at work. First, CEO Elon Musk is still selling stock. It creates an overhang. Some bulls might wait to buy until the large sales are over. Musk has at least 5 million or 6 million shares left to sell associated with his expiring stock options. He will probably be done selling by the end of 2021, but he might just Tweet out when he’s done. At current pace, we figure by year-end.</p><p><blockquote>可能有两件事在起作用。首先，首席执行官埃隆·马斯克仍在出售股票。它创造了一个悬垂。一些多头可能会等到大规模抛售结束后再买入。马斯克至少还有500万或600万股与他即将到期的股票期权相关的股票可供出售。他可能会在2021年底完成出售，但他可能会在完成后发布推文。按照目前的速度，我们预计到年底。</blockquote></p><p> Second, there is the issue of Musk being named Time’s Person of the Year.Amazon.com&nbsp;(AMZN) founder Jeff Bezos won that distinction in 1999, near a multiyear peak in that stock. Amazon shares went on to slide, and some investors think Tesla stock could do the same.</p><p><blockquote>其次，还有马斯克被《时代》杂志评为年度人物的问题。亚马逊。com(AMZN)创始人杰夫·贝索斯(Mark Zuckerberg)在1999年获得了这一殊荣，当时该股股价接近多年来的峰值。亚马逊股价继续下滑，一些投资者认为特斯拉股价也可能出现同样的情况。</blockquote></p><p> The Amazon comparison with Tesla doesn’t quite match up, however. The two companies are at very different stages of development when their top executives won Time’s distinction. Amazon had a market capitalization of $27 billion back then. Tesla’s market cap is now hovering around $1 trillion.</p><p><blockquote>然而，亚马逊与特斯拉的比较并不完全匹配。当这两家公司的高管赢得《时代》杂志的殊荣时，它们正处于截然不同的发展阶段。亚马逊当时的市值为270亿美元。特斯拉的市值目前徘徊在1万亿美元左右。</blockquote></p><p> Still, it’s a belief, and traders do odd things from time to time, justified or not. When stocks move upward, or downward, momentum traders will jump on the trend for whatever reason.</p><p><blockquote>尽管如此，这仍然是一种信念，交易者时不时会做一些奇怪的事情，无论是否合理。当股票上涨或下跌时，无论出于何种原因，动量交易者都会顺势而为。</blockquote></p><p></p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla Stock Is in a Bear Market Again. What’s Next for Musk’s EV Firm.<blockquote>特斯拉股票再次陷入熊市。马斯克电动汽车公司的下一步是什么？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla Stock Is in a Bear Market Again. What’s Next for Musk’s EV Firm.<blockquote>特斯拉股票再次陷入熊市。马斯克电动汽车公司的下一步是什么？</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barrons</strong><span class=\"h-time small\">2021-12-14 07:51</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Shares of electric-vehicle leader&nbsp;Tesla&nbsp;crossed into bear-market territory&nbsp;today. That statement is technically true, but also a little tiring. Stocks, individually, don’t have bear or bull markets. That terms should be reserved for, well, the overall market. Still, the big dip in a mega-cap stock is noteworthy leaving investors wondering what might come next.</p><p><blockquote>电动汽车领导者特斯拉的股价今天进入熊市区域。这种说法在技术上是正确的，但也有点累。就个人而言，股票没有熊市或牛市。这些条款应该留给整个市场。尽管如此，大型股的大幅下跌还是值得注意的，让投资者想知道接下来会发生什么。</blockquote></p><p> Tesla (ticker: TSLA) stock closed down 5% at $966.41. The&nbsp;S&amp;P 500 index&nbsp;and&nbsp;Dow Jones Industrial Average&nbsp;both closed down 0.9%.</p><p><blockquote>特斯拉（股票代码：TSLA）股价收盘下跌5%，至966.41美元。标普500指数和道琼斯工业平均指数均收跌0.9%。</blockquote></p><p> The Monday dip sent the company’s market cap below $1 trillion based on the number of shares outstanding, excluding management stock options. Shares are down 21% from the Nov. 4 closing high of $1,229.91. Shares are down 22% from the intraday high of $1,243.49.</p><p><blockquote>根据已发行股票数量（不包括管理层股票期权）计算，周一的下跌使该公司的市值跌破1万亿美元。股价较11月4日收盘高点1,229.91美元下跌21%。股价较盘中高点1,243.49美元下跌22%。</blockquote></p><p> Whether or not bear markets should be measured from a closing high or an intraday high is the source of debate on Wall Street. But again, the debate doesn’t really matter in this instance because individual stocks don’t have bull and bear markets.</p><p><blockquote>熊市应该从收盘高点还是盘中高点来衡量是华尔街争论的焦点。但同样，在这种情况下，争论并不重要，因为个股没有牛市和熊市。</blockquote></p><p> Whether it’s a bear market or not isn’t the point for individual investors. The pain of a 20% drop is real.</p><p><blockquote>对于个人投资者来说，是否是熊市并不是重点。下跌20%的痛苦是真实的。</blockquote></p><p> One of the last times Tesla stock closed in bear-market territory was February 2021. (Yes, <i>Barron’s</i> wrote about the single stock bear market then, too.) Back then, interest rates were rising and highly valued tech stocks took it on the chin. Higher rates hurt the valuation of shares of faster-growing companies more than those of slow-growing mature companies—that’s just the way the math of higher interest rates works out.</p><p><blockquote>特斯拉股票最后一次收于熊市区域是在2021年2月。（是的，<i>巴伦周刊</i>当时也写过关于单股熊市的文章。）当时，利率正在上升，高估值的科技股承受了压力。较高的利率对增长较快的公司股票估值的损害大于增长缓慢的成熟公司的股票估值——这正是较高利率的数学计算方式。</blockquote></p><p> Back then it took about six months for the stock to retake its old highs. If that were to happen again, bullish investors would be waiting until June 2022 to see Tesla stock hit $1,300.</p><p><blockquote>当时，该股花了大约六个月的时间才恢复到旧高点。如果这种情况再次发生，看涨的投资者将等到2022年6月才能看到特斯拉股价触及1,300美元。</blockquote></p><p> That would be a long wait for bulls, and while there is no way to know if that scenario will even unfold, there is a lot going on that could move the stock in the coming couple of months. Bullish and bearish Tesla investors will be watching for the startup of two new plants in Germany and Texas, the impact of those new plants on profit margins, the start of deliveries of the Tesla Cybertruck and the overall growth of EVs in the U.S., Europe, and China.</p><p><blockquote>对于多头来说，这将是一个漫长的等待，虽然没有办法知道这种情况是否会发生，但未来几个月有很多事情可能会影响该股。看涨和看跌的特斯拉投资者将关注德国和德克萨斯两家新工厂的启动、这些新工厂对利润率的影响、特斯拉Cybertruck的开始交付以及美国电动汽车的整体增长、欧洲和中国。</blockquote></p><p> With all that coming, it raising the question of why the shares are struggling.</p><p><blockquote>随之而来的是，这引发了一个问题：为什么股价陷入困境。</blockquote></p><p> Two things might be at work. First, CEO Elon Musk is still selling stock. It creates an overhang. Some bulls might wait to buy until the large sales are over. Musk has at least 5 million or 6 million shares left to sell associated with his expiring stock options. He will probably be done selling by the end of 2021, but he might just Tweet out when he’s done. At current pace, we figure by year-end.</p><p><blockquote>可能有两件事在起作用。首先，首席执行官埃隆·马斯克仍在出售股票。它创造了一个悬垂。一些多头可能会等到大规模抛售结束后再买入。马斯克至少还有500万或600万股与他即将到期的股票期权相关的股票可供出售。他可能会在2021年底完成出售，但他可能会在完成后发布推文。按照目前的速度，我们预计到年底。</blockquote></p><p> Second, there is the issue of Musk being named Time’s Person of the Year.Amazon.com&nbsp;(AMZN) founder Jeff Bezos won that distinction in 1999, near a multiyear peak in that stock. Amazon shares went on to slide, and some investors think Tesla stock could do the same.</p><p><blockquote>其次，还有马斯克被《时代》杂志评为年度人物的问题。亚马逊。com(AMZN)创始人杰夫·贝索斯(Mark Zuckerberg)在1999年获得了这一殊荣，当时该股股价接近多年来的峰值。亚马逊股价继续下滑，一些投资者认为特斯拉股价也可能出现同样的情况。</blockquote></p><p> The Amazon comparison with Tesla doesn’t quite match up, however. The two companies are at very different stages of development when their top executives won Time’s distinction. Amazon had a market capitalization of $27 billion back then. Tesla’s market cap is now hovering around $1 trillion.</p><p><blockquote>然而，亚马逊与特斯拉的比较并不完全匹配。当这两家公司的高管赢得《时代》杂志的殊荣时，它们正处于截然不同的发展阶段。亚马逊当时的市值为270亿美元。特斯拉的市值目前徘徊在1万亿美元左右。</blockquote></p><p> Still, it’s a belief, and traders do odd things from time to time, justified or not. When stocks move upward, or downward, momentum traders will jump on the trend for whatever reason.</p><p><blockquote>尽管如此，这仍然是一种信念，交易者时不时会做一些奇怪的事情，无论是否合理。当股票上涨或下跌时，无论出于何种原因，动量交易者都会顺势而为。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.barrons.com/articles/tesla-stock-bear-musk-51639436863?mod=hp_LATEST\">Barrons</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.barrons.com/articles/tesla-stock-bear-musk-51639436863?mod=hp_LATEST","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1114636896","content_text":"Shares of electric-vehicle leader Tesla crossed into bear-market territory today. That statement is technically true, but also a little tiring. Stocks, individually, don’t have bear or bull markets. That terms should be reserved for, well, the overall market. Still, the big dip in a mega-cap stock is noteworthy leaving investors wondering what might come next.\nTesla (ticker: TSLA) stock closed down 5% at $966.41. The S&P 500 index and Dow Jones Industrial Average both closed down 0.9%.\nThe Monday dip sent the company’s market cap below $1 trillion based on the number of shares outstanding, excluding management stock options. Shares are down 21% from the Nov. 4 closing high of $1,229.91. Shares are down 22% from the intraday high of $1,243.49.\nWhether or not bear markets should be measured from a closing high or an intraday high is the source of debate on Wall Street. But again, the debate doesn’t really matter in this instance because individual stocks don’t have bull and bear markets.\nWhether it’s a bear market or not isn’t the point for individual investors. The pain of a 20% drop is real.\nOne of the last times Tesla stock closed in bear-market territory was February 2021. (Yes, Barron’s wrote about the single stock bear market then, too.) Back then, interest rates were rising and highly valued tech stocks took it on the chin. Higher rates hurt the valuation of shares of faster-growing companies more than those of slow-growing mature companies—that’s just the way the math of higher interest rates works out.\nBack then it took about six months for the stock to retake its old highs. If that were to happen again, bullish investors would be waiting until June 2022 to see Tesla stock hit $1,300.\nThat would be a long wait for bulls, and while there is no way to know if that scenario will even unfold, there is a lot going on that could move the stock in the coming couple of months. Bullish and bearish Tesla investors will be watching for the startup of two new plants in Germany and Texas, the impact of those new plants on profit margins, the start of deliveries of the Tesla Cybertruck and the overall growth of EVs in the U.S., Europe, and China.\nWith all that coming, it raising the question of why the shares are struggling.\nTwo things might be at work. First, CEO Elon Musk is still selling stock. It creates an overhang. Some bulls might wait to buy until the large sales are over. Musk has at least 5 million or 6 million shares left to sell associated with his expiring stock options. He will probably be done selling by the end of 2021, but he might just Tweet out when he’s done. At current pace, we figure by year-end.\nSecond, there is the issue of Musk being named Time’s Person of the Year.Amazon.com (AMZN) founder Jeff Bezos won that distinction in 1999, near a multiyear peak in that stock. Amazon shares went on to slide, and some investors think Tesla stock could do the same.\nThe Amazon comparison with Tesla doesn’t quite match up, however. The two companies are at very different stages of development when their top executives won Time’s distinction. Amazon had a market capitalization of $27 billion back then. Tesla’s market cap is now hovering around $1 trillion.\nStill, it’s a belief, and traders do odd things from time to time, justified or not. When stocks move upward, or downward, momentum traders will jump on the trend for whatever reason.","news_type":1,"symbols_score_info":{"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":4097,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604355502,"gmtCreate":1639354250507,"gmtModify":1639354254429,"author":{"id":"3577518888738299","authorId":"3577518888738299","name":"LWZ2218","avatar":"https://static.tigerbbs.com/f53fe88ba02bdf3f307a8e715043f7e2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577518888738299","idStr":"3577518888738299"},"themes":[],"htmlText":"Yes , it will reach 1580 soon","listText":"Yes , it will reach 1580 soon","text":"Yes , it will reach 1580 soon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/604355502","repostId":"2190677202","repostType":4,"isVote":1,"tweetType":1,"viewCount":2967,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605062446,"gmtCreate":1639094436791,"gmtModify":1639094437052,"author":{"id":"3577518888738299","authorId":"3577518888738299","name":"LWZ2218","avatar":"https://static.tigerbbs.com/f53fe88ba02bdf3f307a8e715043f7e2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577518888738299","idStr":"3577518888738299"},"themes":[],"htmlText":"Huat&nbsp;","listText":"Huat&nbsp;","text":"Huat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605062446","repostId":"2190964556","repostType":4,"isVote":1,"tweetType":1,"viewCount":3952,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602829454,"gmtCreate":1639008282743,"gmtModify":1639008282960,"author":{"id":"3577518888738299","authorId":"3577518888738299","name":"LWZ2218","avatar":"https://static.tigerbbs.com/f53fe88ba02bdf3f307a8e715043f7e2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577518888738299","idStr":"3577518888738299"},"themes":[],"htmlText":"Go Go Pfizer","listText":"Go Go Pfizer","text":"Go Go Pfizer","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/602829454","repostId":"1141815911","repostType":4,"repost":{"id":"1141815911","kind":"news","pubTimestamp":1639007843,"share":"https://www.laohu8.com/m/news/1141815911?lang=zh_CN&edition=full","pubTime":"2021-12-09 07:57","market":"us","language":"en","title":"Pfizer Says Booster Neutralized Omicron but Variant May Elude Two Doses<blockquote>辉瑞称加强剂中和了奥密克戎病毒，但变种可能无法注射两剂</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1141815911","media":"The Wall Street Journal","summary":"Pfizer Inc. PFE -0.62% and BioNTech SE BNTX -3.55% said that a third dose of their Covid-19 vaccine ","content":"<p>Pfizer Inc. PFE -0.62% and BioNTech SE BNTX -3.55% said that a third dose of their Covid-19 vaccine neutralized the Omicron variant in lab tests but that the two-dose regimen was significantly less effective at blocking the virus.</p><p><blockquote>辉瑞公司PFE-0.62%和BioNTech SE BNTX-3.55%表示，他们的第三剂Covid-19疫苗在实验室测试中中和了奥密克戎变种，但两剂方案在阻断病毒方面的效果明显较差。</blockquote></p><p> A third dose increased antibodies 25-fold compared with two doses against the Omicron variant, the companies said. Still, two doses may prove effective in preventing severe illness from Covid-19, they said, because immune cells are able to recognize 80% of parts of the spike protein that the vaccine targets.</p><p><blockquote>两家公司表示，与针对奥密克戎变种的两剂相比，第三剂使抗体增加了25倍。他们说，尽管如此，两剂疫苗可能会有效预防Covid-19引起的严重疾病，因为免疫细胞能够识别疫苗靶向的刺突蛋白的80%部分。</blockquote></p><p> The results were issued in a press release by the companies, and weren’t peer reviewed and published in a scientific journal.</p><p><blockquote>这些结果是在两家公司的新闻稿中发布的，没有经过同行评审也没有发表在科学期刊上。</blockquote></p><p> The findings from the companies’ early study, and one by scientists in South Africa, suggest that three doses will be needed to produce a similar immune response against Omicron as was provided by just two doses in earlier strains of the virus.</p><p><blockquote>两家公司的早期研究结果以及南非科学家的一项研究结果表明，需要三剂疫苗才能产生与早期病毒株仅两剂疫苗类似的针对奥密克戎病毒的免疫反应。</blockquote></p><p> It also bolsters the case for repeated and periodic boosters to maintain people’s immune defenses against an evolving Covid-19, the companies said.</p><p><blockquote>两家公司表示，这也支持了重复和定期加强剂以维持人们对不断发展的Covid-19的免疫防御的理由。</blockquote></p><p> “This is very positive news that should make everyone even more motivated to get vaccinated” and get a booster, said Pfizer Chief Scientific Officer Mikael Dolsten.</p><p><blockquote>辉瑞首席科学官米凯尔·多尔斯滕(Mikael Dolsten)表示，“这是一个非常积极的消息，应该会让每个人都更有动力接种疫苗”并接种加强剂。</blockquote></p><p> The companies’ current vaccine will provide a strong defense against Omicron, especially if people get a booster shot, Dr. Dolsten said. The three-dose regimen, he added, could provide stopgap protection against Omicron through the winter and until a new vaccine targeted directly at the variant would be ready if needed.</p><p><blockquote>多尔斯滕博士说，两家公司目前的疫苗将为奥密克戎提供强有力的防御，特别是如果人们接受加强注射的话。他补充说，三剂方案可以在整个冬季提供针对奥密克戎病毒的权宜之计，直到需要时直接针对该变种的新疫苗准备就绪。</blockquote></p><p> Pfizer and BioNTech are working on an Omicron-specific vaccine that they hope to have available by March 2022 if the variant becomes widespread by then. Researchers started working on the new vaccine on Thanksgiving Day, Nov. 25, shortly after Omicron was identified.</p><p><blockquote>辉瑞和BioNTech正在研究一种针对奥密克戎病毒的疫苗，如果该变种到那时变得广泛传播，他们希望在2022年3月之前上市。奥密克戎病毒被发现后不久，研究人员于11月25日感恩节开始研究这种新疫苗。</blockquote></p><p> The vaccine trains the immune system to fight the virus by generating immune-system soldiers known as antibodies, which attach to the virus and prevent it from replicating in healthy cells. The vaccine also produces other immune-system fighters called T cells that can kick in after infection to help target and clear the virus, preventing more serious disease.</p><p><blockquote>该疫苗通过产生称为抗体的免疫系统士兵来训练免疫系统对抗病毒，抗体附着在病毒上并阻止其在健康细胞中复制。该疫苗还产生其他称为T细胞的免疫系统战士，可以在感染后发挥作用，帮助靶向和清除病毒，预防更严重的疾病。</blockquote></p><p> Pfizer and BioNTech said that Omicron still appears susceptible to T cells produced by the vaccine.</p><p><blockquote>辉瑞和BioNTech表示，奥密克戎似乎仍然容易受到疫苗产生的T细胞的影响。</blockquote></p><p> Dr. Dolsten estimated there is a greater than 50% chance that Omicron becomes the dominant strain spreading in the U.S. by the spring, though it is too soon to know with certainty, he said.</p><p><blockquote>多尔斯滕博士估计，到春季，奥密克戎病毒成为美国传播的主要毒株的可能性超过50%，但现在确定还为时过早。</blockquote></p><p> The preliminary lab data comes from an analysis of blood samples from vaccinated patients measuring antibodies capable of neutralizing the virus causing Covid-19, including the Omicron variant. Blood samples were collected three weeks after patients received their second dose, or one month after receiving their third dose.</p><p><blockquote>初步实验室数据来自对接种疫苗患者血液样本的分析，测量能够中和导致Covid-19的病毒（包括奥密克戎变种）的抗体。在患者接受第二剂后三周或接受第三剂后一个月采集血样。</blockquote></p><p> The number of antibodies generated by a third booster shot against Omicron is similar to two doses against an older strain of the virus, the companies said.</p><p><blockquote>两家公司表示，针对奥密克戎病毒的第三次加强注射产生的抗体数量与针对旧病毒株的两次注射相似。</blockquote></p><p> “These preliminary data appear to show the Pfizer vaccine does in fact protect against Omicron, and that’s very good news,” said Philip Landrigan, director of Boston College’s Global Public Health and the Global Common Good program.</p><p><blockquote>“这些初步数据似乎表明辉瑞疫苗确实可以预防奥密克戎病毒，这是一个非常好的消息，”Boston College全球公共卫生和全球公益项目主任Philip Landrigan说。</blockquote></p><p> Monica Gandhi, a professor of medicine at the University of California, San Francisco, said the results suggested two doses will protect many people from getting bad cases leading to hospitalization or death.</p><p><blockquote>加州大学旧金山分校医学教授莫妮卡·甘地表示，结果表明，两剂疫苗将保护许多人免于出现导致住院或死亡的严重病例。</blockquote></p><p> “Two doses are still effective against severe disease, whether people get boosters or not,” said Dr. Gandhi, who is recommending boosters for high-risk patients, including those with HIV. “For people who are at high risk of severe disease, it’s so important to get them boosted, but I don’t think it’s mandatory for young healthy people.”</p><p><blockquote>甘地博士说：“无论人们是否接种加强剂，两剂疫苗对严重疾病仍然有效。”他建议为包括艾滋病毒感染者在内的高危患者接种加强剂。“对于患有严重疾病的高风险人群来说，给他们注射疫苗非常重要，但我认为这对于年轻的健康人来说并不是强制性的。”</blockquote></p><p> The company’s early findings come a day after scientists in South Africa reported findings from early lab tests indicating a 41-fold reduction in the Pfizer-BioNTech vaccine’s neutralization of Omicron than the original version of the virus.</p><p><blockquote>该公司的早期发现发布前一天，南非科学家报告了早期实验室测试的结果，表明辉瑞-BioNTech疫苗对奥密克戎病毒的中和作用比原始版本的病毒降低了41倍。</blockquote></p><p> The researchers, however, found greater antibody responses against Omicron in blood taken from subjects who were fully vaccinated and had previously been infected with Covid-19.</p><p><blockquote>然而，研究人员发现，从完全接种疫苗且之前感染过Covid-19的受试者身上采集的血液中，针对奥密克戎病毒的抗体反应更强。</blockquote></p><p> The companies will continue to work on a variant vaccine despite the promising signs that boosting with the original shot offers good protection against Omicron, said BioNTech Chief Executive Uğur Şahin. That is because they would need to see more data on how their vaccine holds up against the new variant, including real-world effectiveness data, expected in the coming weeks.</p><p><blockquote>BioNTech首席执行官Uğur Ş ahin表示，尽管有令人鼓舞的迹象表明，使用原始疫苗加强注射可以很好地预防奥密克戎病，但两家公司仍将继续研究变异疫苗。这是因为他们需要看到更多关于他们的疫苗如何抵抗新变种的数据，包括预计在未来几周内的真实世界有效性数据。</blockquote></p><p> “Only in combination will we understand the relevance of this data and potential protection against Omicron-mediated disease and severe disease,” he said.</p><p><blockquote>他说：“只有结合起来，我们才能了解这些数据的相关性以及对奥密克戎病介导的疾病和严重疾病的潜在保护作用。”</blockquote></p><p> Real-world data on vaccine effectiveness against Omicron won’t be available for at least six weeks, Dr. Şahin said, because the case numbers need to be higher before this can be measured.</p><p><blockquote>Ş ahin博士说，有关奥密克戎疫苗有效性的真实数据至少在六周内无法获得，因为病例数需要更高才能衡量。</blockquote></p><p></p><p> Meanwhile, the companies are moving forward with manufacturing an Omicron-specific vaccine. The first doses, for experimental use, will be ready in January, BioNTech executives said.</p><p><blockquote>与此同时，两家公司正在推进奥密克戎专用疫苗的生产。BioNTech高管表示，用于实验用途的第一剂疫苗将于1月份准备就绪。</blockquote></p><p> Omicron was first identified by scientists in South Africa last month. Since then the World Health Organization has deemed it a variant of concern. And it has since been detected around the world, including in the U.S.</p><p><blockquote>上个月，科学家首次在南非发现了奥密克戎病毒。从那时起，世界卫生组织就认为这是一个值得关注的变种。此后，包括美国在内的世界各地都发现了这种病毒。</blockquote></p><p> Researchers have been trying to understand how contagious the new strain is, as well as how well it might be able to evade Covid-19 vaccines and whether it causes severe disease. Some preliminary reports suggest the variant is more contagious but might cause milder disease, though researchers say it is too early to know.</p><p><blockquote>研究人员一直在试图了解这种新毒株的传染性如何，以及它逃避Covid-19疫苗的能力如何，以及它是否会导致严重疾病。一些初步报告表明，这种变异更具传染性，但可能会导致较轻的疾病，尽管研究人员表示现在知道还为时过早。</blockquote></p><p> Pfizer and BioNTech said they expect to make four billion vaccine doses next year, even if an Omicron-specific vaccine is required by then.</p><p><blockquote>辉瑞和BioNTech表示，他们预计明年将生产40亿剂疫苗，即使届时需要奥密克戎专用疫苗。</blockquote></p><p> Dr. Dolsten said that regardless of how widespread Omicron becomes, continued booster shots will likely be needed going forward to provide protection against Covid-19. A fourth booster dose is likely to be needed in the spring or fall of 2022, he said.</p><p><blockquote>多尔斯滕博士说，无论奥密克戎病变得多么普遍，未来可能需要持续的加强注射来提供针对新冠肺炎的保护。他说，2022年春季或秋季可能需要第四次加强剂量。</blockquote></p><p> “It’s increasingly clear you need to have a long-term perspective, with continued boosting to have strong durable immunity,” said Dr. Dolsten. “If the landscape looks similar to today, we will likely continue to boost with the current vaccine.”</p><p><blockquote>多尔斯滕博士说：“越来越明显的是，你需要有长远的眼光，持续增强才能拥有强大持久的免疫力。”“如果情况看起来与今天相似，我们可能会继续使用当前的疫苗加强疫苗。”</blockquote></p><p> Pfizer’s shares rose 1% while BioNTech’s American depositary shares fell 0.2% in morning trading.</p><p><blockquote>辉瑞股价上涨1%，而BioNTech美国存托股早盘下跌0.2%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Says Booster Neutralized Omicron but Variant May Elude Two Doses<blockquote>辉瑞称加强剂中和了奥密克戎病毒，但变种可能无法注射两剂</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Says Booster Neutralized Omicron but Variant May Elude Two Doses<blockquote>辉瑞称加强剂中和了奥密克戎病毒，但变种可能无法注射两剂</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">The Wall Street Journal</strong><span class=\"h-time small\">2021-12-09 07:57</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Pfizer Inc. PFE -0.62% and BioNTech SE BNTX -3.55% said that a third dose of their Covid-19 vaccine neutralized the Omicron variant in lab tests but that the two-dose regimen was significantly less effective at blocking the virus.</p><p><blockquote>辉瑞公司PFE-0.62%和BioNTech SE BNTX-3.55%表示，他们的第三剂Covid-19疫苗在实验室测试中中和了奥密克戎变种，但两剂方案在阻断病毒方面的效果明显较差。</blockquote></p><p> A third dose increased antibodies 25-fold compared with two doses against the Omicron variant, the companies said. Still, two doses may prove effective in preventing severe illness from Covid-19, they said, because immune cells are able to recognize 80% of parts of the spike protein that the vaccine targets.</p><p><blockquote>两家公司表示，与针对奥密克戎变种的两剂相比，第三剂使抗体增加了25倍。他们说，尽管如此，两剂疫苗可能会有效预防Covid-19引起的严重疾病，因为免疫细胞能够识别疫苗靶向的刺突蛋白的80%部分。</blockquote></p><p> The results were issued in a press release by the companies, and weren’t peer reviewed and published in a scientific journal.</p><p><blockquote>这些结果是在两家公司的新闻稿中发布的，没有经过同行评审也没有发表在科学期刊上。</blockquote></p><p> The findings from the companies’ early study, and one by scientists in South Africa, suggest that three doses will be needed to produce a similar immune response against Omicron as was provided by just two doses in earlier strains of the virus.</p><p><blockquote>两家公司的早期研究结果以及南非科学家的一项研究结果表明，需要三剂疫苗才能产生与早期病毒株仅两剂疫苗类似的针对奥密克戎病毒的免疫反应。</blockquote></p><p> It also bolsters the case for repeated and periodic boosters to maintain people’s immune defenses against an evolving Covid-19, the companies said.</p><p><blockquote>两家公司表示，这也支持了重复和定期加强剂以维持人们对不断发展的Covid-19的免疫防御的理由。</blockquote></p><p> “This is very positive news that should make everyone even more motivated to get vaccinated” and get a booster, said Pfizer Chief Scientific Officer Mikael Dolsten.</p><p><blockquote>辉瑞首席科学官米凯尔·多尔斯滕(Mikael Dolsten)表示，“这是一个非常积极的消息，应该会让每个人都更有动力接种疫苗”并接种加强剂。</blockquote></p><p> The companies’ current vaccine will provide a strong defense against Omicron, especially if people get a booster shot, Dr. Dolsten said. The three-dose regimen, he added, could provide stopgap protection against Omicron through the winter and until a new vaccine targeted directly at the variant would be ready if needed.</p><p><blockquote>多尔斯滕博士说，两家公司目前的疫苗将为奥密克戎提供强有力的防御，特别是如果人们接受加强注射的话。他补充说，三剂方案可以在整个冬季提供针对奥密克戎病毒的权宜之计，直到需要时直接针对该变种的新疫苗准备就绪。</blockquote></p><p> Pfizer and BioNTech are working on an Omicron-specific vaccine that they hope to have available by March 2022 if the variant becomes widespread by then. Researchers started working on the new vaccine on Thanksgiving Day, Nov. 25, shortly after Omicron was identified.</p><p><blockquote>辉瑞和BioNTech正在研究一种针对奥密克戎病毒的疫苗，如果该变种到那时变得广泛传播，他们希望在2022年3月之前上市。奥密克戎病毒被发现后不久，研究人员于11月25日感恩节开始研究这种新疫苗。</blockquote></p><p> The vaccine trains the immune system to fight the virus by generating immune-system soldiers known as antibodies, which attach to the virus and prevent it from replicating in healthy cells. The vaccine also produces other immune-system fighters called T cells that can kick in after infection to help target and clear the virus, preventing more serious disease.</p><p><blockquote>该疫苗通过产生称为抗体的免疫系统士兵来训练免疫系统对抗病毒，抗体附着在病毒上并阻止其在健康细胞中复制。该疫苗还产生其他称为T细胞的免疫系统战士，可以在感染后发挥作用，帮助靶向和清除病毒，预防更严重的疾病。</blockquote></p><p> Pfizer and BioNTech said that Omicron still appears susceptible to T cells produced by the vaccine.</p><p><blockquote>辉瑞和BioNTech表示，奥密克戎似乎仍然容易受到疫苗产生的T细胞的影响。</blockquote></p><p> Dr. Dolsten estimated there is a greater than 50% chance that Omicron becomes the dominant strain spreading in the U.S. by the spring, though it is too soon to know with certainty, he said.</p><p><blockquote>多尔斯滕博士估计，到春季，奥密克戎病毒成为美国传播的主要毒株的可能性超过50%，但现在确定还为时过早。</blockquote></p><p> The preliminary lab data comes from an analysis of blood samples from vaccinated patients measuring antibodies capable of neutralizing the virus causing Covid-19, including the Omicron variant. Blood samples were collected three weeks after patients received their second dose, or one month after receiving their third dose.</p><p><blockquote>初步实验室数据来自对接种疫苗患者血液样本的分析，测量能够中和导致Covid-19的病毒（包括奥密克戎变种）的抗体。在患者接受第二剂后三周或接受第三剂后一个月采集血样。</blockquote></p><p> The number of antibodies generated by a third booster shot against Omicron is similar to two doses against an older strain of the virus, the companies said.</p><p><blockquote>两家公司表示，针对奥密克戎病毒的第三次加强注射产生的抗体数量与针对旧病毒株的两次注射相似。</blockquote></p><p> “These preliminary data appear to show the Pfizer vaccine does in fact protect against Omicron, and that’s very good news,” said Philip Landrigan, director of Boston College’s Global Public Health and the Global Common Good program.</p><p><blockquote>“这些初步数据似乎表明辉瑞疫苗确实可以预防奥密克戎病毒，这是一个非常好的消息，”Boston College全球公共卫生和全球公益项目主任Philip Landrigan说。</blockquote></p><p> Monica Gandhi, a professor of medicine at the University of California, San Francisco, said the results suggested two doses will protect many people from getting bad cases leading to hospitalization or death.</p><p><blockquote>加州大学旧金山分校医学教授莫妮卡·甘地表示，结果表明，两剂疫苗将保护许多人免于出现导致住院或死亡的严重病例。</blockquote></p><p> “Two doses are still effective against severe disease, whether people get boosters or not,” said Dr. Gandhi, who is recommending boosters for high-risk patients, including those with HIV. “For people who are at high risk of severe disease, it’s so important to get them boosted, but I don’t think it’s mandatory for young healthy people.”</p><p><blockquote>甘地博士说：“无论人们是否接种加强剂，两剂疫苗对严重疾病仍然有效。”他建议为包括艾滋病毒感染者在内的高危患者接种加强剂。“对于患有严重疾病的高风险人群来说，给他们注射疫苗非常重要，但我认为这对于年轻的健康人来说并不是强制性的。”</blockquote></p><p> The company’s early findings come a day after scientists in South Africa reported findings from early lab tests indicating a 41-fold reduction in the Pfizer-BioNTech vaccine’s neutralization of Omicron than the original version of the virus.</p><p><blockquote>该公司的早期发现发布前一天，南非科学家报告了早期实验室测试的结果，表明辉瑞-BioNTech疫苗对奥密克戎病毒的中和作用比原始版本的病毒降低了41倍。</blockquote></p><p> The researchers, however, found greater antibody responses against Omicron in blood taken from subjects who were fully vaccinated and had previously been infected with Covid-19.</p><p><blockquote>然而，研究人员发现，从完全接种疫苗且之前感染过Covid-19的受试者身上采集的血液中，针对奥密克戎病毒的抗体反应更强。</blockquote></p><p> The companies will continue to work on a variant vaccine despite the promising signs that boosting with the original shot offers good protection against Omicron, said BioNTech Chief Executive Uğur Şahin. That is because they would need to see more data on how their vaccine holds up against the new variant, including real-world effectiveness data, expected in the coming weeks.</p><p><blockquote>BioNTech首席执行官Uğur Ş ahin表示，尽管有令人鼓舞的迹象表明，使用原始疫苗加强注射可以很好地预防奥密克戎病，但两家公司仍将继续研究变异疫苗。这是因为他们需要看到更多关于他们的疫苗如何抵抗新变种的数据，包括预计在未来几周内的真实世界有效性数据。</blockquote></p><p> “Only in combination will we understand the relevance of this data and potential protection against Omicron-mediated disease and severe disease,” he said.</p><p><blockquote>他说：“只有结合起来，我们才能了解这些数据的相关性以及对奥密克戎病介导的疾病和严重疾病的潜在保护作用。”</blockquote></p><p> Real-world data on vaccine effectiveness against Omicron won’t be available for at least six weeks, Dr. Şahin said, because the case numbers need to be higher before this can be measured.</p><p><blockquote>Ş ahin博士说，有关奥密克戎疫苗有效性的真实数据至少在六周内无法获得，因为病例数需要更高才能衡量。</blockquote></p><p></p><p> Meanwhile, the companies are moving forward with manufacturing an Omicron-specific vaccine. The first doses, for experimental use, will be ready in January, BioNTech executives said.</p><p><blockquote>与此同时，两家公司正在推进奥密克戎专用疫苗的生产。BioNTech高管表示，用于实验用途的第一剂疫苗将于1月份准备就绪。</blockquote></p><p> Omicron was first identified by scientists in South Africa last month. Since then the World Health Organization has deemed it a variant of concern. And it has since been detected around the world, including in the U.S.</p><p><blockquote>上个月，科学家首次在南非发现了奥密克戎病毒。从那时起，世界卫生组织就认为这是一个值得关注的变种。此后，包括美国在内的世界各地都发现了这种病毒。</blockquote></p><p> Researchers have been trying to understand how contagious the new strain is, as well as how well it might be able to evade Covid-19 vaccines and whether it causes severe disease. Some preliminary reports suggest the variant is more contagious but might cause milder disease, though researchers say it is too early to know.</p><p><blockquote>研究人员一直在试图了解这种新毒株的传染性如何，以及它逃避Covid-19疫苗的能力如何，以及它是否会导致严重疾病。一些初步报告表明，这种变异更具传染性，但可能会导致较轻的疾病，尽管研究人员表示现在知道还为时过早。</blockquote></p><p> Pfizer and BioNTech said they expect to make four billion vaccine doses next year, even if an Omicron-specific vaccine is required by then.</p><p><blockquote>辉瑞和BioNTech表示，他们预计明年将生产40亿剂疫苗，即使届时需要奥密克戎专用疫苗。</blockquote></p><p> Dr. Dolsten said that regardless of how widespread Omicron becomes, continued booster shots will likely be needed going forward to provide protection against Covid-19. A fourth booster dose is likely to be needed in the spring or fall of 2022, he said.</p><p><blockquote>多尔斯滕博士说，无论奥密克戎病变得多么普遍，未来可能需要持续的加强注射来提供针对新冠肺炎的保护。他说，2022年春季或秋季可能需要第四次加强剂量。</blockquote></p><p> “It’s increasingly clear you need to have a long-term perspective, with continued boosting to have strong durable immunity,” said Dr. Dolsten. “If the landscape looks similar to today, we will likely continue to boost with the current vaccine.”</p><p><blockquote>多尔斯滕博士说：“越来越明显的是，你需要有长远的眼光，持续增强才能拥有强大持久的免疫力。”“如果情况看起来与今天相似，我们可能会继续使用当前的疫苗加强疫苗。”</blockquote></p><p> Pfizer’s shares rose 1% while BioNTech’s American depositary shares fell 0.2% in morning trading.</p><p><blockquote>辉瑞股价上涨1%，而BioNTech美国存托股早盘下跌0.2%。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.wsj.com/articles/pfizer-biontech-covid-19-vaccine-loses-significant-effectiveness-against-omicron-in-early-study-companies-say-11638964121?mod=hp_lead_pos1\">The Wall Street Journal</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BNTX":"BioNTech SE"},"source_url":"https://www.wsj.com/articles/pfizer-biontech-covid-19-vaccine-loses-significant-effectiveness-against-omicron-in-early-study-companies-say-11638964121?mod=hp_lead_pos1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141815911","content_text":"Pfizer Inc. PFE -0.62% and BioNTech SE BNTX -3.55% said that a third dose of their Covid-19 vaccine neutralized the Omicron variant in lab tests but that the two-dose regimen was significantly less effective at blocking the virus.\n\nA third dose increased antibodies 25-fold compared with two doses against the Omicron variant, the companies said. Still, two doses may prove effective in preventing severe illness from Covid-19, they said, because immune cells are able to recognize 80% of parts of the spike protein that the vaccine targets.\n\nThe results were issued in a press release by the companies, and weren’t peer reviewed and published in a scientific journal.\n\nThe findings from the companies’ early study, and one by scientists in South Africa, suggest that three doses will be needed to produce a similar immune response against Omicron as was provided by just two doses in earlier strains of the virus.\n\n\nIt also bolsters the case for repeated and periodic boosters to maintain people’s immune defenses against an evolving Covid-19, the companies said.\n\n“This is very positive news that should make everyone even more motivated to get vaccinated” and get a booster, said Pfizer Chief Scientific Officer Mikael Dolsten.\n\nThe companies’ current vaccine will provide a strong defense against Omicron, especially if people get a booster shot, Dr. Dolsten said. The three-dose regimen, he added, could provide stopgap protection against Omicron through the winter and until a new vaccine targeted directly at the variant would be ready if needed.\n\nPfizer and BioNTech are working on an Omicron-specific vaccine that they hope to have available by March 2022 if the variant becomes widespread by then. Researchers started working on the new vaccine on Thanksgiving Day, Nov. 25, shortly after Omicron was identified.\n\nThe vaccine trains the immune system to fight the virus by generating immune-system soldiers known as antibodies, which attach to the virus and prevent it from replicating in healthy cells. The vaccine also produces other immune-system fighters called T cells that can kick in after infection to help target and clear the virus, preventing more serious disease.\n\nPfizer and BioNTech said that Omicron still appears susceptible to T cells produced by the vaccine.\n\nDr. Dolsten estimated there is a greater than 50% chance that Omicron becomes the dominant strain spreading in the U.S. by the spring, though it is too soon to know with certainty, he said.\n\nThe preliminary lab data comes from an analysis of blood samples from vaccinated patients measuring antibodies capable of neutralizing the virus causing Covid-19, including the Omicron variant. Blood samples were collected three weeks after patients received their second dose, or one month after receiving their third dose.\n\nThe number of antibodies generated by a third booster shot against Omicron is similar to two doses against an older strain of the virus, the companies said.\n\n“These preliminary data appear to show the Pfizer vaccine does in fact protect against Omicron, and that’s very good news,” said Philip Landrigan, director of Boston College’s Global Public Health and the Global Common Good program.\n\n\nMonica Gandhi, a professor of medicine at the University of California, San Francisco, said the results suggested two doses will protect many people from getting bad cases leading to hospitalization or death.\n\n“Two doses are still effective against severe disease, whether people get boosters or not,” said Dr. Gandhi, who is recommending boosters for high-risk patients, including those with HIV. “For people who are at high risk of severe disease, it’s so important to get them boosted, but I don’t think it’s mandatory for young healthy people.”\n\nThe company’s early findings come a day after scientists in South Africa reported findings from early lab tests indicating a 41-fold reduction in the Pfizer-BioNTech vaccine’s neutralization of Omicron than the original version of the virus.\n\n\n\nThe researchers, however, found greater antibody responses against Omicron in blood taken from subjects who were fully vaccinated and had previously been infected with Covid-19.\n\nThe companies will continue to work on a variant vaccine despite the promising signs that boosting with the original shot offers good protection against Omicron, said BioNTech Chief Executive Uğur Şahin. That is because they would need to see more data on how their vaccine holds up against the new variant, including real-world effectiveness data, expected in the coming weeks.\n\n\n“Only in combination will we understand the relevance of this data and potential protection against Omicron-mediated disease and severe disease,” he said.\n\nReal-world data on vaccine effectiveness against Omicron won’t be available for at least six weeks, Dr. Şahin said, because the case numbers need to be higher before this can be measured.\n\nMeanwhile, the companies are moving forward with manufacturing an Omicron-specific vaccine. The first doses, for experimental use, will be ready in January, BioNTech executives said.\n\nOmicron was first identified by scientists in South Africa last month. Since then the World Health Organization has deemed it a variant of concern. And it has since been detected around the world, including in the U.S.\n\nResearchers have been trying to understand how contagious the new strain is, as well as how well it might be able to evade Covid-19 vaccines and whether it causes severe disease. Some preliminary reports suggest the variant is more contagious but might cause milder disease, though researchers say it is too early to know.\n\nPfizer and BioNTech said they expect to make four billion vaccine doses next year, even if an Omicron-specific vaccine is required by then.\n\nDr. Dolsten said that regardless of how widespread Omicron becomes, continued booster shots will likely be needed going forward to provide protection against Covid-19. A fourth booster dose is likely to be needed in the spring or fall of 2022, he said.\n\n“It’s increasingly clear you need to have a long-term perspective, with continued boosting to have strong durable immunity,” said Dr. Dolsten. “If the landscape looks similar to today, we will likely continue to boost with the current vaccine.”\n\nPfizer’s shares rose 1% while BioNTech’s American depositary shares fell 0.2% in morning trading.","news_type":1,"symbols_score_info":{"PFE":0.9,"BNTX":0.9}},"isVote":1,"tweetType":1,"viewCount":3533,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606457819,"gmtCreate":1638922877570,"gmtModify":1638922877802,"author":{"id":"3577518888738299","authorId":"3577518888738299","name":"LWZ2218","avatar":"https://static.tigerbbs.com/f53fe88ba02bdf3f307a8e715043f7e2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577518888738299","idStr":"3577518888738299"},"themes":[],"htmlText":"Yeah dividend !!!! Buy Buy Buy","listText":"Yeah dividend !!!! Buy Buy Buy","text":"Yeah dividend !!!! Buy Buy Buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/606457819","repostId":"2189659313","repostType":4,"isVote":1,"tweetType":1,"viewCount":2586,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606384315,"gmtCreate":1638835331523,"gmtModify":1638835331731,"author":{"id":"3577518888738299","authorId":"3577518888738299","name":"LWZ2218","avatar":"https://static.tigerbbs.com/f53fe88ba02bdf3f307a8e715043f7e2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577518888738299","idStr":"3577518888738299"},"themes":[],"htmlText":"Is time to buy !!!","listText":"Is time to buy !!!","text":"Is time to buy !!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606384315","repostId":"2189868186","repostType":4,"isVote":1,"tweetType":1,"viewCount":4013,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":608669270,"gmtCreate":1638715185292,"gmtModify":1638715185409,"author":{"id":"3577518888738299","authorId":"3577518888738299","name":"LWZ2218","avatar":"https://static.tigerbbs.com/f53fe88ba02bdf3f307a8e715043f7e2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577518888738299","idStr":"3577518888738299"},"themes":[],"htmlText":"Is time to buy","listText":"Is time to buy","text":"Is time to buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/608669270","repostId":"1164103185","repostType":4,"repost":{"id":"1164103185","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638543422,"share":"https://www.laohu8.com/m/news/1164103185?lang=zh_CN&edition=full","pubTime":"2021-12-03 22:57","market":"us","language":"en","title":"Semiconductor stocks slid in morning trading<blockquote>半导体股早盘下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1164103185","media":"Tiger Newspress","summary":"Semiconductor stocks slid in morning trading.Nvidia,TSMC,ASML and AMD fell about 2% while Marvell Te","content":"<p>Semiconductor stocks slid in morning trading.Nvidia,TSMC,ASML&nbsp;and&nbsp;AMD&nbsp;fell&nbsp;about&nbsp;2%&nbsp;while&nbsp;Marvell Technology&nbsp;soared&nbsp;17%.</p><p><blockquote>半导体股早盘下跌。英伟达、台积电、ASML和AMD下跌约2%，而Marvell Technology飙升17%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/e4d133b94a6a4da67cbdefb76522317d\" tg-width=\"405\" tg-height=\"302\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Semiconductor stocks slid in morning trading<blockquote>半导体股早盘下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSemiconductor stocks slid in morning trading<blockquote>半导体股早盘下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-03 22:57</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Semiconductor stocks slid in morning trading.Nvidia,TSMC,ASML&nbsp;and&nbsp;AMD&nbsp;fell&nbsp;about&nbsp;2%&nbsp;while&nbsp;Marvell Technology&nbsp;soared&nbsp;17%.</p><p><blockquote>半导体股早盘下跌。英伟达、台积电、ASML和AMD下跌约2%，而Marvell Technology飙升17%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/e4d133b94a6a4da67cbdefb76522317d\" tg-width=\"405\" tg-height=\"302\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVDA":"英伟达"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164103185","content_text":"Semiconductor stocks slid in morning trading.Nvidia,TSMC,ASML and AMD fell about 2% while Marvell Technology soared 17%.","news_type":1,"symbols_score_info":{"NVDA":0.9}},"isVote":1,"tweetType":1,"viewCount":3464,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":608067268,"gmtCreate":1638583190352,"gmtModify":1638583190500,"author":{"id":"3577518888738299","authorId":"3577518888738299","name":"LWZ2218","avatar":"https://static.tigerbbs.com/f53fe88ba02bdf3f307a8e715043f7e2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577518888738299","idStr":"3577518888738299"},"themes":[],"htmlText":"&nbsp;Nice","listText":"&nbsp;Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/608067268","repostId":"2188057871","repostType":4,"isVote":1,"tweetType":1,"viewCount":3722,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":601339609,"gmtCreate":1638490130432,"gmtModify":1638490130544,"author":{"id":"3577518888738299","authorId":"3577518888738299","name":"LWZ2218","avatar":"https://static.tigerbbs.com/f53fe88ba02bdf3f307a8e715043f7e2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577518888738299","idStr":"3577518888738299"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/601339609","repostId":"1145791541","repostType":4,"isVote":1,"tweetType":1,"viewCount":823,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603691407,"gmtCreate":1638403621238,"gmtModify":1638403645054,"author":{"id":"3577518888738299","authorId":"3577518888738299","name":"LWZ2218","avatar":"https://static.tigerbbs.com/f53fe88ba02bdf3f307a8e715043f7e2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577518888738299","idStr":"3577518888738299"},"themes":[],"htmlText":"nice","listText":"nice","text":"nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/603691407","repostId":"1196358645","repostType":4,"isVote":1,"tweetType":1,"viewCount":1216,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609411804,"gmtCreate":1638317020212,"gmtModify":1638317020328,"author":{"id":"3577518888738299","authorId":"3577518888738299","name":"LWZ2218","avatar":"https://static.tigerbbs.com/f53fe88ba02bdf3f307a8e715043f7e2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577518888738299","idStr":"3577518888738299"},"themes":[],"htmlText":"Pfizer is the best !!!","listText":"Pfizer is the best !!!","text":"Pfizer is the best !!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609411804","repostId":"1135257969","repostType":4,"isVote":1,"tweetType":1,"viewCount":949,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609911831,"gmtCreate":1638230766544,"gmtModify":1638230766898,"author":{"id":"3577518888738299","authorId":"3577518888738299","name":"LWZ2218","avatar":"https://static.tigerbbs.com/f53fe88ba02bdf3f307a8e715043f7e2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577518888738299","idStr":"3577518888738299"},"themes":[],"htmlText":"okay","listText":"okay","text":"okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609911831","repostId":"2187306343","repostType":4,"isVote":1,"tweetType":1,"viewCount":1001,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600695059,"gmtCreate":1638145069469,"gmtModify":1638145069585,"author":{"id":"3577518888738299","authorId":"3577518888738299","name":"LWZ2218","avatar":"https://static.tigerbbs.com/f53fe88ba02bdf3f307a8e715043f7e2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577518888738299","idStr":"3577518888738299"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/600695059","repostId":"1124072014","repostType":4,"repost":{"id":"1124072014","kind":"news","pubTimestamp":1638140765,"share":"https://www.laohu8.com/m/news/1124072014?lang=zh_CN&edition=full","pubTime":"2021-11-29 07:06","market":"us","language":"en","title":"November jobs report: What to know this week<blockquote>11月就业报告：本周需要了解什么</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1124072014","media":"yahoo","summary":"As investors return from the Thanksgiving-shortened trading week, focus will shift to the U.S. labor","content":"<p>As investors return from the Thanksgiving-shortened trading week, focus will shift to the U.S. labor market.</p><p><blockquote>随着投资者从感恩节缩短的交易周回归，焦点将转向美国劳动力市场。</blockquote></p><p> The Labor Department's monthly jobs report due for release on Friday is set to provide an updated snapshot of the strength in hiring and labor force participation in the U.S. economy. Consensus economists are looking for a half-million jobs to have returned in November, with the pace of hiring slowing only slightly from October's 531,000 gain. The unemployment rate is also expected to improve further to 4.5% from October's 4.6%, reaching the lowest level since March 2020.</p><p><blockquote>美国劳工部将于周五发布的月度就业报告将提供美国经济中招聘和劳动力参与实力的最新快照。经济学家一致认为，11月份将有50万个工作岗位回归，招聘速度仅较10月份的531,000个略有放缓。失业率也有望从10月的4.6%进一步改善至4.5%，达到2020年3月以来的最低水平。</blockquote></p><p> \"We expect non-farm payrolls to have risen by 500,000 in November, but the growing risk of a winter COVID wave and a dwindling supply of available workers will weigh on jobs growth soon,\" wrote Paul Ashworth, chief North America economist for Capital Economics, in a note last week.</p><p><blockquote>凯投宏观(Capital Economics)首席北美经济学家保罗·阿什沃斯(Paul Ashworth)写道：“我们预计11月份非农就业人数将增加50万人，但冬季新冠疫情风险不断增加以及可用工人供应减少将很快拖累就业增长。”，在上周的一份报告中。</blockquote></p><p> \"Employment growth can’t continue at this pace for much longer unless the labor force stages a more notable recovery. If anything, labor supply could<i>worsen</i>over the coming months as the federal vaccine mandate covering 100 [million] workers begins on January 4,\" Ashworth added. \"That suggests wage growth will remain strong, and we expect a 0.4% [month-over-month] rise in average hourly earnings in October.\"</p><p><blockquote>“除非劳动力出现更显著的复苏，否则就业增长不可能以这种速度持续太久。如果说有什么不同的话，那就是劳动力供应可以<i>恶化</i>随着覆盖1亿工人的联邦疫苗授权于1月4日开始，未来几个月，”阿什沃斯补充道。“这表明工资增长将保持强劲，我们预计10月份平均时薪将[环比]增长0.4%。”</blockquote></p><p> On a year-over-year basis, average hourly earnings are expected to rise by 5.0%, accelerating even further after October's already marked 4.9% rise and representing the fastest wage growth rate since February.</p><p><blockquote>与去年同期相比，平均时薪预计将增长5.0%，继10月份已经显着增长4.9%之后进一步加速，这是自2月份以来最快的工资增长率。</blockquote></p><p> Growing average wages and a tight labor market — while a positive for consumers and their ability to spend — has also stoked concerns over persistent inflation. Last week's Personal Consumption Expenditures (PCE) deflator from the Bureau of Economic Analysis for October showed an annual jump of 5.0% in the index, or the biggest rise since 1990. And the core PCE, or the Fed's preferred inflation gauge stripping out volatile food and energy prices, rose by 4.1% year-over-year — the most in three decades.</p><p><blockquote>平均工资增长和劳动力市场紧张虽然对消费者及其消费能力有利，但也引发了人们对持续通胀的担忧。上周经济分析局公布的10月份个人消费支出(PCE)平减指数显示，该指数年率上涨5.0%，创1990年以来最大涨幅。核心PCE（即美联储首选的剔除波动较大的食品和能源价格的通胀指标）同比上涨4.1%，为三十年来的最高水平。</blockquote></p><p> Other recent data have homed in on the tight labor market and presaged a potentially strong November jobs report. Last week'sinitial jobless claims fell to a 52-year low of 199,000, taking out both the prior pandemic-era low and pre-pandemic average for new first-time filings. This served as yet another point underscoring the steep competition for labor among U.S. employers, with companies attempting to hire and retain their existing workforces amid widespread labor shortages.</p><p><blockquote>最近的其他数据集中在紧张的劳动力市场上，并预示着11月份就业报告可能强劲。上周首次申请失业救济人数降至19.9万人的52年低点，打破了之前大流行时期的低点和大流行前新首次申请失业救济人数的平均值。这再次凸显了美国雇主之间对劳动力的激烈竞争，在劳动力普遍短缺的情况下，公司试图雇用和留住现有劳动力。</blockquote></p><p> Even given these lingering scarcities, the labor force participation rate has yet to return to pre-pandemic levels. The civilian labor force was still down by nearly 3 million participants compared to February 2020, with lingering concerns over the virus and adesire by many working-age individuals to seek out new roles with better flexibility and benefitsstill keeping many individuals on the sidelines of the workforce. Consensus economists expect the labor force participation rate to tick up only slightly in November to reach 61.7%, growing from October's 61.6% but coming in well below the 63.3% rate from February 2020.</p><p><blockquote>即使考虑到这些挥之不去的短缺，劳动力参与率仍未恢复到大流行前的水平。与2020年2月相比，平民劳动力仍减少了近300万参与者，对病毒的担忧挥之不去，许多工作年龄的人渴望寻找具有更好灵活性和福利的新角色，这仍然使许多人处于劳动力的边缘。经济学家普遍预计，11月份劳动力参与率仅略有上升，达到61.7%，高于10月份的61.6%，但远低于2020年2月的63.3%。</blockquote></p><p> Returning the economy back to pre-pandemic labor force participation levels and ensuring job gains are seen equitably across different groups has become a key focus for the Federal Reserve. And the distance still left to make up on these fronts has also been the biggest factor keeping the Fed ultra-accommodative with its monetary policy support, even after a parade of hotter-than-expected inflation reports that would appear to warrant a more hawkish policy tilt and a quicker-than-expected hike to interest rates.Fed Chair Jerome Powell's renomination to remain as head of the central bankfurther suggests the Fed's focus on the labor market as a critical informing factor for monetary policy will remain.</p><p><blockquote>将经济恢复到大流行前的劳动力参与水平，并确保不同群体公平地看到就业增长，已成为美联储的一个重点关注点。在这些方面仍有待弥补的距离也是美联储货币政策支持保持超宽松的最大因素，即使在一系列高于预期的通胀报告似乎需要采取更强硬的政策倾斜美联储主席杰罗姆·鲍威尔再次被提名继续担任央行行长进一步表明，美联储将继续关注劳动力市场，将其作为货币政策的关键信息因素。</blockquote></p><p> \"Market views for future Fed rate increases have been pulled forward aggressively in response to evidence that elevated inflation pressures are likely to persist for longer,\" wrote Deutsche Bank economist Justin Weidner in a note last week. \"However, as Chair Powell's November press conference made evident, prospects for the labor market to return to maximum employment remain a critical consideration for when the Fed will eventually begin to actively tighten monetary policy.\"</p><p><blockquote>德意志银行经济学家贾斯汀·魏德纳(Justin Weidner)上周在一份报告中写道：“由于有证据表明通胀压力上升可能会持续更长时间，市场对美联储未来加息的看法已大幅提前。”“然而，正如鲍威尔主席11月新闻发布会所表明的那样，劳动力市场恢复最大就业的前景仍然是美联储最终何时开始积极收紧货币政策的关键考虑因素。”</blockquote></p><p> Economic calendar</p><p><blockquote>经济日历</blockquote></p><p> <ul>  <li><b>Monday:</b>Pending home sales, month-over-month, October (0.7% expected, -2.3% in September); Dallas Federal Reserve Manufacturing Activity Index, November (17.0 expected, 14.6 in October)</p><p><blockquote><ul><li><b>星期一：</b>10月份待售房屋环比（预期0.7%，9月份-2.3%）；11月达拉斯联储制造业活动指数（预期17.0，10月14.6）</li></ul></blockquote></p><p></p><p></li>  <li><b>Tuesday:</b>FHFA House Price Index, month-over-month, September (1.2% expected, 1.0% in August); S&amp;P CoreLogic Case-Shiller 20-City Composite Index, month-over-month, September (1.30% expected, 1.17% in August); S&amp;P CoreLogic Case-Shiller 20-City Composite Index, September (19.66% during prior month); MNI Chicago PMI, November (67.0 expected, 68.4 in October); Conference Board Consumer Confidence Index, November (110.0 expected, 113.8 in October)</p><p><blockquote><li><b>星期二：</b>9月FHFA房价指数环比（预期为1.2%，8月为1.0%）；S&amp;P CoreLogic Case-Shiller 20城综合指数，9月环比（预期1.30%，8月1.17%）；S&amp;P CoreLogic Case-Shiller 20城市综合指数，9月（上月为19.66%）；11月MNI芝加哥PMI（预期67.0，10月68.4）；世界大型企业联合会11月消费者信心指数（预期110.0，10月113.8）</li></blockquote></p><p></li>  <li><b>Wednesday:</b>MBA Mortgage Applications, November 26 (1.8% during prior week); ADP Employment Change, November (515,000 expected, 571,000 in October); Markit U.S. Manufacturing PMI, November final (59.1 during prior month); Construction Spending, month-over-month, October (0.5% expected, -0.5% in September); ISM Manufacturing, November (61.0 expected, 60.8 in October); Federal Reserve releases Beige Book</p><p><blockquote><li><b>星期三：</b>MBA抵押贷款申请，11月26日（前一周为1.8%）；11月ADP就业变化（预期51.5万人，10月57.1万人）；Markit美国制造业PMI，11月终值（上月为59.1）；10月份建筑支出环比（预期0.5%，9月份-0.5%）；ISM制造业，11月（预期61.0，10月60.8）；美联储发布褐皮书</li></blockquote></p><p></li>  <li><b>Thursday:</b>Challenger job cuts, November (-71.7% in October); Initial jobless claims, week ended Nov. 27 (199,000 during prior week); Continuing claims, Nov. 20 (2.049 during prior week)</p><p><blockquote><li><b>星期四：</b>挑战者裁员，11月（10月-71.7%）；截至11月27日当周首次申请失业救济人数（前一周为199,000人）；11月20日持续申请失业救济人数（前一周为2.049）</li></blockquote></p><p></li>  <li><b>Friday:</b>Change in non-farm payrolls, November (500,000 expected, 531,000 in October); Unemployment rate, November (4.5% expected, 4.6% in October); Average Hourly Earnings, month-over-month, November (0.4% expected, 0.4% in October); Average Hourly Earnings, year-over-year, November (5.0% expected, 4.9% in October); Markit U.S. Services PMI, November final (57.0 in prior print); Markit U.S. Composite PMI, November final (56.5 in prior print); ISM Services Index, November (65.0 expected, 66.7 in October); Factory Orders, October (0.5% expected, 0.2% in September); Durable Goods Orders, October final (-0.5% in prior print)</p><p><blockquote><li><b>星期五：</b>11月非农就业人数变化（预期50万，10月53.1万）；11月失业率（预期4.5%，10月4.6%）；11月平均时薪环比（预期0.4%，10月0.4%）；11月平均时薪同比（预期5.0%，10月4.9%）；Markit美国服务业PMI，11月最终数据（上一期为57.0）；Markit美国综合PMI，11月最终数据（上一期为56.5）；ISM服务业指数，11月（预期65.0，10月66.7）；10月工厂订单（预期0.5%，9月0.2%）；耐用品订单，10月份最终（上次打印为-0.5%）</li></blockquote></p><p></li> </ul> Earnings calendar</p><p><blockquote>盈利日历</blockquote></p><p> <ul>  <li><b>Monday:</b><i>No notable reports scheduled for release</i></p><p><blockquote><ul><li><b>星期一：</b><i>没有计划发布值得注意的报告</i></li></ul></blockquote></p><p></li>  <li><b>Tuesday:</b>Salesforce.com (CRM) after market close</p><p><blockquote><li><b>星期二：</b>Salesforce.com(CRM)收盘后</li></blockquote></p><p></li>  <li><b>Wednesday:</b>PVH Corp. (PVH) after market close</p><p><blockquote><li><b>星期三：</b>PVH Corp.(PVH)收盘后</li></blockquote></p><p></li>  <li><b>Thursday:</b>Dollar General (DG), Kroger (KR) before market open; Ulta Beauty (ULTA) after market close</p><p><blockquote><li><b>星期四：</b>Dollar General(DG)、Kroger(KR)开盘前；Ulta Beauty(ULTA)收盘后</li></blockquote></p><p></li>  <li><b>Friday:</b><i>No notable reports scheduled for release</i></p><p><blockquote><li><b>星期五：</b><i>没有计划发布值得注意的报告</i></li></blockquote></p><p></li> </ul></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>November jobs report: What to know this week<blockquote>11月就业报告：本周需要了解什么</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovember jobs report: What to know this week<blockquote>11月就业报告：本周需要了解什么</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">yahoo</strong><span class=\"h-time small\">2021-11-29 07:06</span>\n</p>\n</h4>\n</header>\n<article>\n<p>As investors return from the Thanksgiving-shortened trading week, focus will shift to the U.S. labor market.</p><p><blockquote>随着投资者从感恩节缩短的交易周回归，焦点将转向美国劳动力市场。</blockquote></p><p> The Labor Department's monthly jobs report due for release on Friday is set to provide an updated snapshot of the strength in hiring and labor force participation in the U.S. economy. Consensus economists are looking for a half-million jobs to have returned in November, with the pace of hiring slowing only slightly from October's 531,000 gain. The unemployment rate is also expected to improve further to 4.5% from October's 4.6%, reaching the lowest level since March 2020.</p><p><blockquote>美国劳工部将于周五发布的月度就业报告将提供美国经济中招聘和劳动力参与实力的最新快照。经济学家一致认为，11月份将有50万个工作岗位回归，招聘速度仅较10月份的531,000个略有放缓。失业率也有望从10月的4.6%进一步改善至4.5%，达到2020年3月以来的最低水平。</blockquote></p><p> \"We expect non-farm payrolls to have risen by 500,000 in November, but the growing risk of a winter COVID wave and a dwindling supply of available workers will weigh on jobs growth soon,\" wrote Paul Ashworth, chief North America economist for Capital Economics, in a note last week.</p><p><blockquote>凯投宏观(Capital Economics)首席北美经济学家保罗·阿什沃斯(Paul Ashworth)写道：“我们预计11月份非农就业人数将增加50万人，但冬季新冠疫情风险不断增加以及可用工人供应减少将很快拖累就业增长。”，在上周的一份报告中。</blockquote></p><p> \"Employment growth can’t continue at this pace for much longer unless the labor force stages a more notable recovery. If anything, labor supply could<i>worsen</i>over the coming months as the federal vaccine mandate covering 100 [million] workers begins on January 4,\" Ashworth added. \"That suggests wage growth will remain strong, and we expect a 0.4% [month-over-month] rise in average hourly earnings in October.\"</p><p><blockquote>“除非劳动力出现更显著的复苏，否则就业增长不可能以这种速度持续太久。如果说有什么不同的话，那就是劳动力供应可以<i>恶化</i>随着覆盖1亿工人的联邦疫苗授权于1月4日开始，未来几个月，”阿什沃斯补充道。“这表明工资增长将保持强劲，我们预计10月份平均时薪将[环比]增长0.4%。”</blockquote></p><p> On a year-over-year basis, average hourly earnings are expected to rise by 5.0%, accelerating even further after October's already marked 4.9% rise and representing the fastest wage growth rate since February.</p><p><blockquote>与去年同期相比，平均时薪预计将增长5.0%，继10月份已经显着增长4.9%之后进一步加速，这是自2月份以来最快的工资增长率。</blockquote></p><p> Growing average wages and a tight labor market — while a positive for consumers and their ability to spend — has also stoked concerns over persistent inflation. Last week's Personal Consumption Expenditures (PCE) deflator from the Bureau of Economic Analysis for October showed an annual jump of 5.0% in the index, or the biggest rise since 1990. And the core PCE, or the Fed's preferred inflation gauge stripping out volatile food and energy prices, rose by 4.1% year-over-year — the most in three decades.</p><p><blockquote>平均工资增长和劳动力市场紧张虽然对消费者及其消费能力有利，但也引发了人们对持续通胀的担忧。上周经济分析局公布的10月份个人消费支出(PCE)平减指数显示，该指数年率上涨5.0%，创1990年以来最大涨幅。核心PCE（即美联储首选的剔除波动较大的食品和能源价格的通胀指标）同比上涨4.1%，为三十年来的最高水平。</blockquote></p><p> Other recent data have homed in on the tight labor market and presaged a potentially strong November jobs report. Last week'sinitial jobless claims fell to a 52-year low of 199,000, taking out both the prior pandemic-era low and pre-pandemic average for new first-time filings. This served as yet another point underscoring the steep competition for labor among U.S. employers, with companies attempting to hire and retain their existing workforces amid widespread labor shortages.</p><p><blockquote>最近的其他数据集中在紧张的劳动力市场上，并预示着11月份就业报告可能强劲。上周首次申请失业救济人数降至19.9万人的52年低点，打破了之前大流行时期的低点和大流行前新首次申请失业救济人数的平均值。这再次凸显了美国雇主之间对劳动力的激烈竞争，在劳动力普遍短缺的情况下，公司试图雇用和留住现有劳动力。</blockquote></p><p> Even given these lingering scarcities, the labor force participation rate has yet to return to pre-pandemic levels. The civilian labor force was still down by nearly 3 million participants compared to February 2020, with lingering concerns over the virus and adesire by many working-age individuals to seek out new roles with better flexibility and benefitsstill keeping many individuals on the sidelines of the workforce. Consensus economists expect the labor force participation rate to tick up only slightly in November to reach 61.7%, growing from October's 61.6% but coming in well below the 63.3% rate from February 2020.</p><p><blockquote>即使考虑到这些挥之不去的短缺，劳动力参与率仍未恢复到大流行前的水平。与2020年2月相比，平民劳动力仍减少了近300万参与者，对病毒的担忧挥之不去，许多工作年龄的人渴望寻找具有更好灵活性和福利的新角色，这仍然使许多人处于劳动力的边缘。经济学家普遍预计，11月份劳动力参与率仅略有上升，达到61.7%，高于10月份的61.6%，但远低于2020年2月的63.3%。</blockquote></p><p> Returning the economy back to pre-pandemic labor force participation levels and ensuring job gains are seen equitably across different groups has become a key focus for the Federal Reserve. And the distance still left to make up on these fronts has also been the biggest factor keeping the Fed ultra-accommodative with its monetary policy support, even after a parade of hotter-than-expected inflation reports that would appear to warrant a more hawkish policy tilt and a quicker-than-expected hike to interest rates.Fed Chair Jerome Powell's renomination to remain as head of the central bankfurther suggests the Fed's focus on the labor market as a critical informing factor for monetary policy will remain.</p><p><blockquote>将经济恢复到大流行前的劳动力参与水平，并确保不同群体公平地看到就业增长，已成为美联储的一个重点关注点。在这些方面仍有待弥补的距离也是美联储货币政策支持保持超宽松的最大因素，即使在一系列高于预期的通胀报告似乎需要采取更强硬的政策倾斜美联储主席杰罗姆·鲍威尔再次被提名继续担任央行行长进一步表明，美联储将继续关注劳动力市场，将其作为货币政策的关键信息因素。</blockquote></p><p> \"Market views for future Fed rate increases have been pulled forward aggressively in response to evidence that elevated inflation pressures are likely to persist for longer,\" wrote Deutsche Bank economist Justin Weidner in a note last week. \"However, as Chair Powell's November press conference made evident, prospects for the labor market to return to maximum employment remain a critical consideration for when the Fed will eventually begin to actively tighten monetary policy.\"</p><p><blockquote>德意志银行经济学家贾斯汀·魏德纳(Justin Weidner)上周在一份报告中写道：“由于有证据表明通胀压力上升可能会持续更长时间，市场对美联储未来加息的看法已大幅提前。”“然而，正如鲍威尔主席11月新闻发布会所表明的那样，劳动力市场恢复最大就业的前景仍然是美联储最终何时开始积极收紧货币政策的关键考虑因素。”</blockquote></p><p> Economic calendar</p><p><blockquote>经济日历</blockquote></p><p> <ul>  <li><b>Monday:</b>Pending home sales, month-over-month, October (0.7% expected, -2.3% in September); Dallas Federal Reserve Manufacturing Activity Index, November (17.0 expected, 14.6 in October)</p><p><blockquote><ul><li><b>星期一：</b>10月份待售房屋环比（预期0.7%，9月份-2.3%）；11月达拉斯联储制造业活动指数（预期17.0，10月14.6）</li></ul></blockquote></p><p></p><p></li>  <li><b>Tuesday:</b>FHFA House Price Index, month-over-month, September (1.2% expected, 1.0% in August); S&amp;P CoreLogic Case-Shiller 20-City Composite Index, month-over-month, September (1.30% expected, 1.17% in August); S&amp;P CoreLogic Case-Shiller 20-City Composite Index, September (19.66% during prior month); MNI Chicago PMI, November (67.0 expected, 68.4 in October); Conference Board Consumer Confidence Index, November (110.0 expected, 113.8 in October)</p><p><blockquote><li><b>星期二：</b>9月FHFA房价指数环比（预期为1.2%，8月为1.0%）；S&amp;P CoreLogic Case-Shiller 20城综合指数，9月环比（预期1.30%，8月1.17%）；S&amp;P CoreLogic Case-Shiller 20城市综合指数，9月（上月为19.66%）；11月MNI芝加哥PMI（预期67.0，10月68.4）；世界大型企业联合会11月消费者信心指数（预期110.0，10月113.8）</li></blockquote></p><p></li>  <li><b>Wednesday:</b>MBA Mortgage Applications, November 26 (1.8% during prior week); ADP Employment Change, November (515,000 expected, 571,000 in October); Markit U.S. Manufacturing PMI, November final (59.1 during prior month); Construction Spending, month-over-month, October (0.5% expected, -0.5% in September); ISM Manufacturing, November (61.0 expected, 60.8 in October); Federal Reserve releases Beige Book</p><p><blockquote><li><b>星期三：</b>MBA抵押贷款申请，11月26日（前一周为1.8%）；11月ADP就业变化（预期51.5万人，10月57.1万人）；Markit美国制造业PMI，11月终值（上月为59.1）；10月份建筑支出环比（预期0.5%，9月份-0.5%）；ISM制造业，11月（预期61.0，10月60.8）；美联储发布褐皮书</li></blockquote></p><p></li>  <li><b>Thursday:</b>Challenger job cuts, November (-71.7% in October); Initial jobless claims, week ended Nov. 27 (199,000 during prior week); Continuing claims, Nov. 20 (2.049 during prior week)</p><p><blockquote><li><b>星期四：</b>挑战者裁员，11月（10月-71.7%）；截至11月27日当周首次申请失业救济人数（前一周为199,000人）；11月20日持续申请失业救济人数（前一周为2.049）</li></blockquote></p><p></li>  <li><b>Friday:</b>Change in non-farm payrolls, November (500,000 expected, 531,000 in October); Unemployment rate, November (4.5% expected, 4.6% in October); Average Hourly Earnings, month-over-month, November (0.4% expected, 0.4% in October); Average Hourly Earnings, year-over-year, November (5.0% expected, 4.9% in October); Markit U.S. Services PMI, November final (57.0 in prior print); Markit U.S. Composite PMI, November final (56.5 in prior print); ISM Services Index, November (65.0 expected, 66.7 in October); Factory Orders, October (0.5% expected, 0.2% in September); Durable Goods Orders, October final (-0.5% in prior print)</p><p><blockquote><li><b>星期五：</b>11月非农就业人数变化（预期50万，10月53.1万）；11月失业率（预期4.5%，10月4.6%）；11月平均时薪环比（预期0.4%，10月0.4%）；11月平均时薪同比（预期5.0%，10月4.9%）；Markit美国服务业PMI，11月最终数据（上一期为57.0）；Markit美国综合PMI，11月最终数据（上一期为56.5）；ISM服务业指数，11月（预期65.0，10月66.7）；10月工厂订单（预期0.5%，9月0.2%）；耐用品订单，10月份最终（上次打印为-0.5%）</li></blockquote></p><p></li> </ul> Earnings calendar</p><p><blockquote>盈利日历</blockquote></p><p> <ul>  <li><b>Monday:</b><i>No notable reports scheduled for release</i></p><p><blockquote><ul><li><b>星期一：</b><i>没有计划发布值得注意的报告</i></li></ul></blockquote></p><p></li>  <li><b>Tuesday:</b>Salesforce.com (CRM) after market close</p><p><blockquote><li><b>星期二：</b>Salesforce.com(CRM)收盘后</li></blockquote></p><p></li>  <li><b>Wednesday:</b>PVH Corp. (PVH) after market close</p><p><blockquote><li><b>星期三：</b>PVH Corp.(PVH)收盘后</li></blockquote></p><p></li>  <li><b>Thursday:</b>Dollar General (DG), Kroger (KR) before market open; Ulta Beauty (ULTA) after market close</p><p><blockquote><li><b>星期四：</b>Dollar General(DG)、Kroger(KR)开盘前；Ulta Beauty(ULTA)收盘后</li></blockquote></p><p></li>  <li><b>Friday:</b><i>No notable reports scheduled for release</i></p><p><blockquote><li><b>星期五：</b><i>没有计划发布值得注意的报告</i></li></blockquote></p><p></li> </ul></p><p><blockquote></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/november-jobs-report-what-to-know-this-week-144428419.html\">yahoo</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CRM":"赛富时"},"source_url":"https://finance.yahoo.com/news/november-jobs-report-what-to-know-this-week-144428419.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124072014","content_text":"As investors return from the Thanksgiving-shortened trading week, focus will shift to the U.S. labor market.\nThe Labor Department's monthly jobs report due for release on Friday is set to provide an updated snapshot of the strength in hiring and labor force participation in the U.S. economy. Consensus economists are looking for a half-million jobs to have returned in November, with the pace of hiring slowing only slightly from October's 531,000 gain. The unemployment rate is also expected to improve further to 4.5% from October's 4.6%, reaching the lowest level since March 2020.\n\"We expect non-farm payrolls to have risen by 500,000 in November, but the growing risk of a winter COVID wave and a dwindling supply of available workers will weigh on jobs growth soon,\" wrote Paul Ashworth, chief North America economist for Capital Economics, in a note last week.\n\"Employment growth can’t continue at this pace for much longer unless the labor force stages a more notable recovery. If anything, labor supply couldworsenover the coming months as the federal vaccine mandate covering 100 [million] workers begins on January 4,\" Ashworth added. \"That suggests wage growth will remain strong, and we expect a 0.4% [month-over-month] rise in average hourly earnings in October.\"\nOn a year-over-year basis, average hourly earnings are expected to rise by 5.0%, accelerating even further after October's already marked 4.9% rise and representing the fastest wage growth rate since February.\nGrowing average wages and a tight labor market — while a positive for consumers and their ability to spend — has also stoked concerns over persistent inflation. Last week's Personal Consumption Expenditures (PCE) deflator from the Bureau of Economic Analysis for October showed an annual jump of 5.0% in the index, or the biggest rise since 1990. And the core PCE, or the Fed's preferred inflation gauge stripping out volatile food and energy prices, rose by 4.1% year-over-year — the most in three decades.\nOther recent data have homed in on the tight labor market and presaged a potentially strong November jobs report. Last week'sinitial jobless claims fell to a 52-year low of 199,000, taking out both the prior pandemic-era low and pre-pandemic average for new first-time filings. This served as yet another point underscoring the steep competition for labor among U.S. employers, with companies attempting to hire and retain their existing workforces amid widespread labor shortages.\nEven given these lingering scarcities, the labor force participation rate has yet to return to pre-pandemic levels. The civilian labor force was still down by nearly 3 million participants compared to February 2020, with lingering concerns over the virus and adesire by many working-age individuals to seek out new roles with better flexibility and benefitsstill keeping many individuals on the sidelines of the workforce. Consensus economists expect the labor force participation rate to tick up only slightly in November to reach 61.7%, growing from October's 61.6% but coming in well below the 63.3% rate from February 2020.\nReturning the economy back to pre-pandemic labor force participation levels and ensuring job gains are seen equitably across different groups has become a key focus for the Federal Reserve. And the distance still left to make up on these fronts has also been the biggest factor keeping the Fed ultra-accommodative with its monetary policy support, even after a parade of hotter-than-expected inflation reports that would appear to warrant a more hawkish policy tilt and a quicker-than-expected hike to interest rates.Fed Chair Jerome Powell's renomination to remain as head of the central bankfurther suggests the Fed's focus on the labor market as a critical informing factor for monetary policy will remain.\n\"Market views for future Fed rate increases have been pulled forward aggressively in response to evidence that elevated inflation pressures are likely to persist for longer,\" wrote Deutsche Bank economist Justin Weidner in a note last week. \"However, as Chair Powell's November press conference made evident, prospects for the labor market to return to maximum employment remain a critical consideration for when the Fed will eventually begin to actively tighten monetary policy.\"\nEconomic calendar\n\nMonday:Pending home sales, month-over-month, October (0.7% expected, -2.3% in September); Dallas Federal Reserve Manufacturing Activity Index, November (17.0 expected, 14.6 in October)\nTuesday:FHFA House Price Index, month-over-month, September (1.2% expected, 1.0% in August); S&P CoreLogic Case-Shiller 20-City Composite Index, month-over-month, September (1.30% expected, 1.17% in August); S&P CoreLogic Case-Shiller 20-City Composite Index, September (19.66% during prior month); MNI Chicago PMI, November (67.0 expected, 68.4 in October); Conference Board Consumer Confidence Index, November (110.0 expected, 113.8 in October)\nWednesday:MBA Mortgage Applications, November 26 (1.8% during prior week); ADP Employment Change, November (515,000 expected, 571,000 in October); Markit U.S. Manufacturing PMI, November final (59.1 during prior month); Construction Spending, month-over-month, October (0.5% expected, -0.5% in September); ISM Manufacturing, November (61.0 expected, 60.8 in October); Federal Reserve releases Beige Book\nThursday:Challenger job cuts, November (-71.7% in October); Initial jobless claims, week ended Nov. 27 (199,000 during prior week); Continuing claims, Nov. 20 (2.049 during prior week)\nFriday:Change in non-farm payrolls, November (500,000 expected, 531,000 in October); Unemployment rate, November (4.5% expected, 4.6% in October); Average Hourly Earnings, month-over-month, November (0.4% expected, 0.4% in October); Average Hourly Earnings, year-over-year, November (5.0% expected, 4.9% in October); Markit U.S. Services PMI, November final (57.0 in prior print); Markit U.S. Composite PMI, November final (56.5 in prior print); ISM Services Index, November (65.0 expected, 66.7 in October); Factory Orders, October (0.5% expected, 0.2% in September); Durable Goods Orders, October final (-0.5% in prior print)\n\nEarnings calendar\n\nMonday:No notable reports scheduled for release\nTuesday:Salesforce.com (CRM) after market close\nWednesday:PVH Corp. (PVH) after market close\nThursday:Dollar General (DG), Kroger (KR) before market open; Ulta Beauty (ULTA) after market close\nFriday:No notable reports scheduled for release","news_type":1,"symbols_score_info":{"CRM":0.9}},"isVote":1,"tweetType":1,"viewCount":818,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600802056,"gmtCreate":1638111061132,"gmtModify":1638111061285,"author":{"id":"3577518888738299","authorId":"3577518888738299","name":"LWZ2218","avatar":"https://static.tigerbbs.com/f53fe88ba02bdf3f307a8e715043f7e2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577518888738299","idStr":"3577518888738299"},"themes":[],"htmlText":"like","listText":"like","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/600802056","repostId":"1117671420","repostType":4,"isVote":1,"tweetType":1,"viewCount":708,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877302816,"gmtCreate":1637884960709,"gmtModify":1637884960821,"author":{"id":"3577518888738299","authorId":"3577518888738299","name":"LWZ2218","avatar":"https://static.tigerbbs.com/f53fe88ba02bdf3f307a8e715043f7e2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577518888738299","idStr":"3577518888738299"},"themes":[],"htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/877302816","repostId":"1184876136","repostType":4,"isVote":1,"tweetType":1,"viewCount":843,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":874504667,"gmtCreate":1637798755135,"gmtModify":1637798755243,"author":{"id":"3577518888738299","authorId":"3577518888738299","name":"LWZ2218","avatar":"https://static.tigerbbs.com/f53fe88ba02bdf3f307a8e715043f7e2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577518888738299","idStr":"3577518888738299"},"themes":[],"htmlText":"NVDA is the best !!","listText":"NVDA is the best !!","text":"NVDA is the best !!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/874504667","repostId":"2186363038","repostType":4,"isVote":1,"tweetType":1,"viewCount":975,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":875186093,"gmtCreate":1637624974985,"gmtModify":1637624975097,"author":{"id":"3577518888738299","authorId":"3577518888738299","name":"LWZ2218","avatar":"https://static.tigerbbs.com/f53fe88ba02bdf3f307a8e715043f7e2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577518888738299","idStr":"3577518888738299"},"themes":[],"htmlText":"NVDA is the best for sure","listText":"NVDA is the best for sure","text":"NVDA is the best for sure","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/875186093","repostId":"1107351089","repostType":4,"isVote":1,"tweetType":1,"viewCount":1140,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":872561347,"gmtCreate":1637548559907,"gmtModify":1637548560059,"author":{"id":"3577518888738299","authorId":"3577518888738299","name":"LWZ2218","avatar":"https://static.tigerbbs.com/f53fe88ba02bdf3f307a8e715043f7e2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577518888738299","idStr":"3577518888738299"},"themes":[],"htmlText":"Come liao","listText":"Come liao","text":"Come liao","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/872561347","repostId":"1146953835","repostType":4,"isVote":1,"tweetType":1,"viewCount":1023,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":600695059,"gmtCreate":1638145069469,"gmtModify":1638145069585,"author":{"id":"3577518888738299","authorId":"3577518888738299","name":"LWZ2218","avatar":"https://static.tigerbbs.com/f53fe88ba02bdf3f307a8e715043f7e2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577518888738299","idStr":"3577518888738299"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/600695059","repostId":"1124072014","repostType":4,"repost":{"id":"1124072014","kind":"news","pubTimestamp":1638140765,"share":"https://www.laohu8.com/m/news/1124072014?lang=zh_CN&edition=full","pubTime":"2021-11-29 07:06","market":"us","language":"en","title":"November jobs report: What to know this week<blockquote>11月就业报告：本周需要了解什么</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1124072014","media":"yahoo","summary":"As investors return from the Thanksgiving-shortened trading week, focus will shift to the U.S. labor","content":"<p>As investors return from the Thanksgiving-shortened trading week, focus will shift to the U.S. labor market.</p><p><blockquote>随着投资者从感恩节缩短的交易周回归，焦点将转向美国劳动力市场。</blockquote></p><p> The Labor Department's monthly jobs report due for release on Friday is set to provide an updated snapshot of the strength in hiring and labor force participation in the U.S. economy. Consensus economists are looking for a half-million jobs to have returned in November, with the pace of hiring slowing only slightly from October's 531,000 gain. The unemployment rate is also expected to improve further to 4.5% from October's 4.6%, reaching the lowest level since March 2020.</p><p><blockquote>美国劳工部将于周五发布的月度就业报告将提供美国经济中招聘和劳动力参与实力的最新快照。经济学家一致认为，11月份将有50万个工作岗位回归，招聘速度仅较10月份的531,000个略有放缓。失业率也有望从10月的4.6%进一步改善至4.5%，达到2020年3月以来的最低水平。</blockquote></p><p> \"We expect non-farm payrolls to have risen by 500,000 in November, but the growing risk of a winter COVID wave and a dwindling supply of available workers will weigh on jobs growth soon,\" wrote Paul Ashworth, chief North America economist for Capital Economics, in a note last week.</p><p><blockquote>凯投宏观(Capital Economics)首席北美经济学家保罗·阿什沃斯(Paul Ashworth)写道：“我们预计11月份非农就业人数将增加50万人，但冬季新冠疫情风险不断增加以及可用工人供应减少将很快拖累就业增长。”，在上周的一份报告中。</blockquote></p><p> \"Employment growth can’t continue at this pace for much longer unless the labor force stages a more notable recovery. If anything, labor supply could<i>worsen</i>over the coming months as the federal vaccine mandate covering 100 [million] workers begins on January 4,\" Ashworth added. \"That suggests wage growth will remain strong, and we expect a 0.4% [month-over-month] rise in average hourly earnings in October.\"</p><p><blockquote>“除非劳动力出现更显著的复苏，否则就业增长不可能以这种速度持续太久。如果说有什么不同的话，那就是劳动力供应可以<i>恶化</i>随着覆盖1亿工人的联邦疫苗授权于1月4日开始，未来几个月，”阿什沃斯补充道。“这表明工资增长将保持强劲，我们预计10月份平均时薪将[环比]增长0.4%。”</blockquote></p><p> On a year-over-year basis, average hourly earnings are expected to rise by 5.0%, accelerating even further after October's already marked 4.9% rise and representing the fastest wage growth rate since February.</p><p><blockquote>与去年同期相比，平均时薪预计将增长5.0%，继10月份已经显着增长4.9%之后进一步加速，这是自2月份以来最快的工资增长率。</blockquote></p><p> Growing average wages and a tight labor market — while a positive for consumers and their ability to spend — has also stoked concerns over persistent inflation. Last week's Personal Consumption Expenditures (PCE) deflator from the Bureau of Economic Analysis for October showed an annual jump of 5.0% in the index, or the biggest rise since 1990. And the core PCE, or the Fed's preferred inflation gauge stripping out volatile food and energy prices, rose by 4.1% year-over-year — the most in three decades.</p><p><blockquote>平均工资增长和劳动力市场紧张虽然对消费者及其消费能力有利，但也引发了人们对持续通胀的担忧。上周经济分析局公布的10月份个人消费支出(PCE)平减指数显示，该指数年率上涨5.0%，创1990年以来最大涨幅。核心PCE（即美联储首选的剔除波动较大的食品和能源价格的通胀指标）同比上涨4.1%，为三十年来的最高水平。</blockquote></p><p> Other recent data have homed in on the tight labor market and presaged a potentially strong November jobs report. Last week'sinitial jobless claims fell to a 52-year low of 199,000, taking out both the prior pandemic-era low and pre-pandemic average for new first-time filings. This served as yet another point underscoring the steep competition for labor among U.S. employers, with companies attempting to hire and retain their existing workforces amid widespread labor shortages.</p><p><blockquote>最近的其他数据集中在紧张的劳动力市场上，并预示着11月份就业报告可能强劲。上周首次申请失业救济人数降至19.9万人的52年低点，打破了之前大流行时期的低点和大流行前新首次申请失业救济人数的平均值。这再次凸显了美国雇主之间对劳动力的激烈竞争，在劳动力普遍短缺的情况下，公司试图雇用和留住现有劳动力。</blockquote></p><p> Even given these lingering scarcities, the labor force participation rate has yet to return to pre-pandemic levels. The civilian labor force was still down by nearly 3 million participants compared to February 2020, with lingering concerns over the virus and adesire by many working-age individuals to seek out new roles with better flexibility and benefitsstill keeping many individuals on the sidelines of the workforce. Consensus economists expect the labor force participation rate to tick up only slightly in November to reach 61.7%, growing from October's 61.6% but coming in well below the 63.3% rate from February 2020.</p><p><blockquote>即使考虑到这些挥之不去的短缺，劳动力参与率仍未恢复到大流行前的水平。与2020年2月相比，平民劳动力仍减少了近300万参与者，对病毒的担忧挥之不去，许多工作年龄的人渴望寻找具有更好灵活性和福利的新角色，这仍然使许多人处于劳动力的边缘。经济学家普遍预计，11月份劳动力参与率仅略有上升，达到61.7%，高于10月份的61.6%，但远低于2020年2月的63.3%。</blockquote></p><p> Returning the economy back to pre-pandemic labor force participation levels and ensuring job gains are seen equitably across different groups has become a key focus for the Federal Reserve. And the distance still left to make up on these fronts has also been the biggest factor keeping the Fed ultra-accommodative with its monetary policy support, even after a parade of hotter-than-expected inflation reports that would appear to warrant a more hawkish policy tilt and a quicker-than-expected hike to interest rates.Fed Chair Jerome Powell's renomination to remain as head of the central bankfurther suggests the Fed's focus on the labor market as a critical informing factor for monetary policy will remain.</p><p><blockquote>将经济恢复到大流行前的劳动力参与水平，并确保不同群体公平地看到就业增长，已成为美联储的一个重点关注点。在这些方面仍有待弥补的距离也是美联储货币政策支持保持超宽松的最大因素，即使在一系列高于预期的通胀报告似乎需要采取更强硬的政策倾斜美联储主席杰罗姆·鲍威尔再次被提名继续担任央行行长进一步表明，美联储将继续关注劳动力市场，将其作为货币政策的关键信息因素。</blockquote></p><p> \"Market views for future Fed rate increases have been pulled forward aggressively in response to evidence that elevated inflation pressures are likely to persist for longer,\" wrote Deutsche Bank economist Justin Weidner in a note last week. \"However, as Chair Powell's November press conference made evident, prospects for the labor market to return to maximum employment remain a critical consideration for when the Fed will eventually begin to actively tighten monetary policy.\"</p><p><blockquote>德意志银行经济学家贾斯汀·魏德纳(Justin Weidner)上周在一份报告中写道：“由于有证据表明通胀压力上升可能会持续更长时间，市场对美联储未来加息的看法已大幅提前。”“然而，正如鲍威尔主席11月新闻发布会所表明的那样，劳动力市场恢复最大就业的前景仍然是美联储最终何时开始积极收紧货币政策的关键考虑因素。”</blockquote></p><p> Economic calendar</p><p><blockquote>经济日历</blockquote></p><p> <ul>  <li><b>Monday:</b>Pending home sales, month-over-month, October (0.7% expected, -2.3% in September); Dallas Federal Reserve Manufacturing Activity Index, November (17.0 expected, 14.6 in October)</p><p><blockquote><ul><li><b>星期一：</b>10月份待售房屋环比（预期0.7%，9月份-2.3%）；11月达拉斯联储制造业活动指数（预期17.0，10月14.6）</li></ul></blockquote></p><p></p><p></li>  <li><b>Tuesday:</b>FHFA House Price Index, month-over-month, September (1.2% expected, 1.0% in August); S&amp;P CoreLogic Case-Shiller 20-City Composite Index, month-over-month, September (1.30% expected, 1.17% in August); S&amp;P CoreLogic Case-Shiller 20-City Composite Index, September (19.66% during prior month); MNI Chicago PMI, November (67.0 expected, 68.4 in October); Conference Board Consumer Confidence Index, November (110.0 expected, 113.8 in October)</p><p><blockquote><li><b>星期二：</b>9月FHFA房价指数环比（预期为1.2%，8月为1.0%）；S&amp;P CoreLogic Case-Shiller 20城综合指数，9月环比（预期1.30%，8月1.17%）；S&amp;P CoreLogic Case-Shiller 20城市综合指数，9月（上月为19.66%）；11月MNI芝加哥PMI（预期67.0，10月68.4）；世界大型企业联合会11月消费者信心指数（预期110.0，10月113.8）</li></blockquote></p><p></li>  <li><b>Wednesday:</b>MBA Mortgage Applications, November 26 (1.8% during prior week); ADP Employment Change, November (515,000 expected, 571,000 in October); Markit U.S. Manufacturing PMI, November final (59.1 during prior month); Construction Spending, month-over-month, October (0.5% expected, -0.5% in September); ISM Manufacturing, November (61.0 expected, 60.8 in October); Federal Reserve releases Beige Book</p><p><blockquote><li><b>星期三：</b>MBA抵押贷款申请，11月26日（前一周为1.8%）；11月ADP就业变化（预期51.5万人，10月57.1万人）；Markit美国制造业PMI，11月终值（上月为59.1）；10月份建筑支出环比（预期0.5%，9月份-0.5%）；ISM制造业，11月（预期61.0，10月60.8）；美联储发布褐皮书</li></blockquote></p><p></li>  <li><b>Thursday:</b>Challenger job cuts, November (-71.7% in October); Initial jobless claims, week ended Nov. 27 (199,000 during prior week); Continuing claims, Nov. 20 (2.049 during prior week)</p><p><blockquote><li><b>星期四：</b>挑战者裁员，11月（10月-71.7%）；截至11月27日当周首次申请失业救济人数（前一周为199,000人）；11月20日持续申请失业救济人数（前一周为2.049）</li></blockquote></p><p></li>  <li><b>Friday:</b>Change in non-farm payrolls, November (500,000 expected, 531,000 in October); Unemployment rate, November (4.5% expected, 4.6% in October); Average Hourly Earnings, month-over-month, November (0.4% expected, 0.4% in October); Average Hourly Earnings, year-over-year, November (5.0% expected, 4.9% in October); Markit U.S. Services PMI, November final (57.0 in prior print); Markit U.S. Composite PMI, November final (56.5 in prior print); ISM Services Index, November (65.0 expected, 66.7 in October); Factory Orders, October (0.5% expected, 0.2% in September); Durable Goods Orders, October final (-0.5% in prior print)</p><p><blockquote><li><b>星期五：</b>11月非农就业人数变化（预期50万，10月53.1万）；11月失业率（预期4.5%，10月4.6%）；11月平均时薪环比（预期0.4%，10月0.4%）；11月平均时薪同比（预期5.0%，10月4.9%）；Markit美国服务业PMI，11月最终数据（上一期为57.0）；Markit美国综合PMI，11月最终数据（上一期为56.5）；ISM服务业指数，11月（预期65.0，10月66.7）；10月工厂订单（预期0.5%，9月0.2%）；耐用品订单，10月份最终（上次打印为-0.5%）</li></blockquote></p><p></li> </ul> Earnings calendar</p><p><blockquote>盈利日历</blockquote></p><p> <ul>  <li><b>Monday:</b><i>No notable reports scheduled for release</i></p><p><blockquote><ul><li><b>星期一：</b><i>没有计划发布值得注意的报告</i></li></ul></blockquote></p><p></li>  <li><b>Tuesday:</b>Salesforce.com (CRM) after market close</p><p><blockquote><li><b>星期二：</b>Salesforce.com(CRM)收盘后</li></blockquote></p><p></li>  <li><b>Wednesday:</b>PVH Corp. (PVH) after market close</p><p><blockquote><li><b>星期三：</b>PVH Corp.(PVH)收盘后</li></blockquote></p><p></li>  <li><b>Thursday:</b>Dollar General (DG), Kroger (KR) before market open; Ulta Beauty (ULTA) after market close</p><p><blockquote><li><b>星期四：</b>Dollar General(DG)、Kroger(KR)开盘前；Ulta Beauty(ULTA)收盘后</li></blockquote></p><p></li>  <li><b>Friday:</b><i>No notable reports scheduled for release</i></p><p><blockquote><li><b>星期五：</b><i>没有计划发布值得注意的报告</i></li></blockquote></p><p></li> </ul></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>November jobs report: What to know this week<blockquote>11月就业报告：本周需要了解什么</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovember jobs report: What to know this week<blockquote>11月就业报告：本周需要了解什么</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">yahoo</strong><span class=\"h-time small\">2021-11-29 07:06</span>\n</p>\n</h4>\n</header>\n<article>\n<p>As investors return from the Thanksgiving-shortened trading week, focus will shift to the U.S. labor market.</p><p><blockquote>随着投资者从感恩节缩短的交易周回归，焦点将转向美国劳动力市场。</blockquote></p><p> The Labor Department's monthly jobs report due for release on Friday is set to provide an updated snapshot of the strength in hiring and labor force participation in the U.S. economy. Consensus economists are looking for a half-million jobs to have returned in November, with the pace of hiring slowing only slightly from October's 531,000 gain. The unemployment rate is also expected to improve further to 4.5% from October's 4.6%, reaching the lowest level since March 2020.</p><p><blockquote>美国劳工部将于周五发布的月度就业报告将提供美国经济中招聘和劳动力参与实力的最新快照。经济学家一致认为，11月份将有50万个工作岗位回归，招聘速度仅较10月份的531,000个略有放缓。失业率也有望从10月的4.6%进一步改善至4.5%，达到2020年3月以来的最低水平。</blockquote></p><p> \"We expect non-farm payrolls to have risen by 500,000 in November, but the growing risk of a winter COVID wave and a dwindling supply of available workers will weigh on jobs growth soon,\" wrote Paul Ashworth, chief North America economist for Capital Economics, in a note last week.</p><p><blockquote>凯投宏观(Capital Economics)首席北美经济学家保罗·阿什沃斯(Paul Ashworth)写道：“我们预计11月份非农就业人数将增加50万人，但冬季新冠疫情风险不断增加以及可用工人供应减少将很快拖累就业增长。”，在上周的一份报告中。</blockquote></p><p> \"Employment growth can’t continue at this pace for much longer unless the labor force stages a more notable recovery. If anything, labor supply could<i>worsen</i>over the coming months as the federal vaccine mandate covering 100 [million] workers begins on January 4,\" Ashworth added. \"That suggests wage growth will remain strong, and we expect a 0.4% [month-over-month] rise in average hourly earnings in October.\"</p><p><blockquote>“除非劳动力出现更显著的复苏，否则就业增长不可能以这种速度持续太久。如果说有什么不同的话，那就是劳动力供应可以<i>恶化</i>随着覆盖1亿工人的联邦疫苗授权于1月4日开始，未来几个月，”阿什沃斯补充道。“这表明工资增长将保持强劲，我们预计10月份平均时薪将[环比]增长0.4%。”</blockquote></p><p> On a year-over-year basis, average hourly earnings are expected to rise by 5.0%, accelerating even further after October's already marked 4.9% rise and representing the fastest wage growth rate since February.</p><p><blockquote>与去年同期相比，平均时薪预计将增长5.0%，继10月份已经显着增长4.9%之后进一步加速，这是自2月份以来最快的工资增长率。</blockquote></p><p> Growing average wages and a tight labor market — while a positive for consumers and their ability to spend — has also stoked concerns over persistent inflation. Last week's Personal Consumption Expenditures (PCE) deflator from the Bureau of Economic Analysis for October showed an annual jump of 5.0% in the index, or the biggest rise since 1990. And the core PCE, or the Fed's preferred inflation gauge stripping out volatile food and energy prices, rose by 4.1% year-over-year — the most in three decades.</p><p><blockquote>平均工资增长和劳动力市场紧张虽然对消费者及其消费能力有利，但也引发了人们对持续通胀的担忧。上周经济分析局公布的10月份个人消费支出(PCE)平减指数显示，该指数年率上涨5.0%，创1990年以来最大涨幅。核心PCE（即美联储首选的剔除波动较大的食品和能源价格的通胀指标）同比上涨4.1%，为三十年来的最高水平。</blockquote></p><p> Other recent data have homed in on the tight labor market and presaged a potentially strong November jobs report. Last week'sinitial jobless claims fell to a 52-year low of 199,000, taking out both the prior pandemic-era low and pre-pandemic average for new first-time filings. This served as yet another point underscoring the steep competition for labor among U.S. employers, with companies attempting to hire and retain their existing workforces amid widespread labor shortages.</p><p><blockquote>最近的其他数据集中在紧张的劳动力市场上，并预示着11月份就业报告可能强劲。上周首次申请失业救济人数降至19.9万人的52年低点，打破了之前大流行时期的低点和大流行前新首次申请失业救济人数的平均值。这再次凸显了美国雇主之间对劳动力的激烈竞争，在劳动力普遍短缺的情况下，公司试图雇用和留住现有劳动力。</blockquote></p><p> Even given these lingering scarcities, the labor force participation rate has yet to return to pre-pandemic levels. The civilian labor force was still down by nearly 3 million participants compared to February 2020, with lingering concerns over the virus and adesire by many working-age individuals to seek out new roles with better flexibility and benefitsstill keeping many individuals on the sidelines of the workforce. Consensus economists expect the labor force participation rate to tick up only slightly in November to reach 61.7%, growing from October's 61.6% but coming in well below the 63.3% rate from February 2020.</p><p><blockquote>即使考虑到这些挥之不去的短缺，劳动力参与率仍未恢复到大流行前的水平。与2020年2月相比，平民劳动力仍减少了近300万参与者，对病毒的担忧挥之不去，许多工作年龄的人渴望寻找具有更好灵活性和福利的新角色，这仍然使许多人处于劳动力的边缘。经济学家普遍预计，11月份劳动力参与率仅略有上升，达到61.7%，高于10月份的61.6%，但远低于2020年2月的63.3%。</blockquote></p><p> Returning the economy back to pre-pandemic labor force participation levels and ensuring job gains are seen equitably across different groups has become a key focus for the Federal Reserve. And the distance still left to make up on these fronts has also been the biggest factor keeping the Fed ultra-accommodative with its monetary policy support, even after a parade of hotter-than-expected inflation reports that would appear to warrant a more hawkish policy tilt and a quicker-than-expected hike to interest rates.Fed Chair Jerome Powell's renomination to remain as head of the central bankfurther suggests the Fed's focus on the labor market as a critical informing factor for monetary policy will remain.</p><p><blockquote>将经济恢复到大流行前的劳动力参与水平，并确保不同群体公平地看到就业增长，已成为美联储的一个重点关注点。在这些方面仍有待弥补的距离也是美联储货币政策支持保持超宽松的最大因素，即使在一系列高于预期的通胀报告似乎需要采取更强硬的政策倾斜美联储主席杰罗姆·鲍威尔再次被提名继续担任央行行长进一步表明，美联储将继续关注劳动力市场，将其作为货币政策的关键信息因素。</blockquote></p><p> \"Market views for future Fed rate increases have been pulled forward aggressively in response to evidence that elevated inflation pressures are likely to persist for longer,\" wrote Deutsche Bank economist Justin Weidner in a note last week. \"However, as Chair Powell's November press conference made evident, prospects for the labor market to return to maximum employment remain a critical consideration for when the Fed will eventually begin to actively tighten monetary policy.\"</p><p><blockquote>德意志银行经济学家贾斯汀·魏德纳(Justin Weidner)上周在一份报告中写道：“由于有证据表明通胀压力上升可能会持续更长时间，市场对美联储未来加息的看法已大幅提前。”“然而，正如鲍威尔主席11月新闻发布会所表明的那样，劳动力市场恢复最大就业的前景仍然是美联储最终何时开始积极收紧货币政策的关键考虑因素。”</blockquote></p><p> Economic calendar</p><p><blockquote>经济日历</blockquote></p><p> <ul>  <li><b>Monday:</b>Pending home sales, month-over-month, October (0.7% expected, -2.3% in September); Dallas Federal Reserve Manufacturing Activity Index, November (17.0 expected, 14.6 in October)</p><p><blockquote><ul><li><b>星期一：</b>10月份待售房屋环比（预期0.7%，9月份-2.3%）；11月达拉斯联储制造业活动指数（预期17.0，10月14.6）</li></ul></blockquote></p><p></p><p></li>  <li><b>Tuesday:</b>FHFA House Price Index, month-over-month, September (1.2% expected, 1.0% in August); S&amp;P CoreLogic Case-Shiller 20-City Composite Index, month-over-month, September (1.30% expected, 1.17% in August); S&amp;P CoreLogic Case-Shiller 20-City Composite Index, September (19.66% during prior month); MNI Chicago PMI, November (67.0 expected, 68.4 in October); Conference Board Consumer Confidence Index, November (110.0 expected, 113.8 in October)</p><p><blockquote><li><b>星期二：</b>9月FHFA房价指数环比（预期为1.2%，8月为1.0%）；S&amp;P CoreLogic Case-Shiller 20城综合指数，9月环比（预期1.30%，8月1.17%）；S&amp;P CoreLogic Case-Shiller 20城市综合指数，9月（上月为19.66%）；11月MNI芝加哥PMI（预期67.0，10月68.4）；世界大型企业联合会11月消费者信心指数（预期110.0，10月113.8）</li></blockquote></p><p></li>  <li><b>Wednesday:</b>MBA Mortgage Applications, November 26 (1.8% during prior week); ADP Employment Change, November (515,000 expected, 571,000 in October); Markit U.S. Manufacturing PMI, November final (59.1 during prior month); Construction Spending, month-over-month, October (0.5% expected, -0.5% in September); ISM Manufacturing, November (61.0 expected, 60.8 in October); Federal Reserve releases Beige Book</p><p><blockquote><li><b>星期三：</b>MBA抵押贷款申请，11月26日（前一周为1.8%）；11月ADP就业变化（预期51.5万人，10月57.1万人）；Markit美国制造业PMI，11月终值（上月为59.1）；10月份建筑支出环比（预期0.5%，9月份-0.5%）；ISM制造业，11月（预期61.0，10月60.8）；美联储发布褐皮书</li></blockquote></p><p></li>  <li><b>Thursday:</b>Challenger job cuts, November (-71.7% in October); Initial jobless claims, week ended Nov. 27 (199,000 during prior week); Continuing claims, Nov. 20 (2.049 during prior week)</p><p><blockquote><li><b>星期四：</b>挑战者裁员，11月（10月-71.7%）；截至11月27日当周首次申请失业救济人数（前一周为199,000人）；11月20日持续申请失业救济人数（前一周为2.049）</li></blockquote></p><p></li>  <li><b>Friday:</b>Change in non-farm payrolls, November (500,000 expected, 531,000 in October); Unemployment rate, November (4.5% expected, 4.6% in October); Average Hourly Earnings, month-over-month, November (0.4% expected, 0.4% in October); Average Hourly Earnings, year-over-year, November (5.0% expected, 4.9% in October); Markit U.S. Services PMI, November final (57.0 in prior print); Markit U.S. Composite PMI, November final (56.5 in prior print); ISM Services Index, November (65.0 expected, 66.7 in October); Factory Orders, October (0.5% expected, 0.2% in September); Durable Goods Orders, October final (-0.5% in prior print)</p><p><blockquote><li><b>星期五：</b>11月非农就业人数变化（预期50万，10月53.1万）；11月失业率（预期4.5%，10月4.6%）；11月平均时薪环比（预期0.4%，10月0.4%）；11月平均时薪同比（预期5.0%，10月4.9%）；Markit美国服务业PMI，11月最终数据（上一期为57.0）；Markit美国综合PMI，11月最终数据（上一期为56.5）；ISM服务业指数，11月（预期65.0，10月66.7）；10月工厂订单（预期0.5%，9月0.2%）；耐用品订单，10月份最终（上次打印为-0.5%）</li></blockquote></p><p></li> </ul> Earnings calendar</p><p><blockquote>盈利日历</blockquote></p><p> <ul>  <li><b>Monday:</b><i>No notable reports scheduled for release</i></p><p><blockquote><ul><li><b>星期一：</b><i>没有计划发布值得注意的报告</i></li></ul></blockquote></p><p></li>  <li><b>Tuesday:</b>Salesforce.com (CRM) after market close</p><p><blockquote><li><b>星期二：</b>Salesforce.com(CRM)收盘后</li></blockquote></p><p></li>  <li><b>Wednesday:</b>PVH Corp. (PVH) after market close</p><p><blockquote><li><b>星期三：</b>PVH Corp.(PVH)收盘后</li></blockquote></p><p></li>  <li><b>Thursday:</b>Dollar General (DG), Kroger (KR) before market open; Ulta Beauty (ULTA) after market close</p><p><blockquote><li><b>星期四：</b>Dollar General(DG)、Kroger(KR)开盘前；Ulta Beauty(ULTA)收盘后</li></blockquote></p><p></li>  <li><b>Friday:</b><i>No notable reports scheduled for release</i></p><p><blockquote><li><b>星期五：</b><i>没有计划发布值得注意的报告</i></li></blockquote></p><p></li> </ul></p><p><blockquote></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/november-jobs-report-what-to-know-this-week-144428419.html\">yahoo</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CRM":"赛富时"},"source_url":"https://finance.yahoo.com/news/november-jobs-report-what-to-know-this-week-144428419.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124072014","content_text":"As investors return from the Thanksgiving-shortened trading week, focus will shift to the U.S. labor market.\nThe Labor Department's monthly jobs report due for release on Friday is set to provide an updated snapshot of the strength in hiring and labor force participation in the U.S. economy. Consensus economists are looking for a half-million jobs to have returned in November, with the pace of hiring slowing only slightly from October's 531,000 gain. The unemployment rate is also expected to improve further to 4.5% from October's 4.6%, reaching the lowest level since March 2020.\n\"We expect non-farm payrolls to have risen by 500,000 in November, but the growing risk of a winter COVID wave and a dwindling supply of available workers will weigh on jobs growth soon,\" wrote Paul Ashworth, chief North America economist for Capital Economics, in a note last week.\n\"Employment growth can’t continue at this pace for much longer unless the labor force stages a more notable recovery. If anything, labor supply couldworsenover the coming months as the federal vaccine mandate covering 100 [million] workers begins on January 4,\" Ashworth added. \"That suggests wage growth will remain strong, and we expect a 0.4% [month-over-month] rise in average hourly earnings in October.\"\nOn a year-over-year basis, average hourly earnings are expected to rise by 5.0%, accelerating even further after October's already marked 4.9% rise and representing the fastest wage growth rate since February.\nGrowing average wages and a tight labor market — while a positive for consumers and their ability to spend — has also stoked concerns over persistent inflation. Last week's Personal Consumption Expenditures (PCE) deflator from the Bureau of Economic Analysis for October showed an annual jump of 5.0% in the index, or the biggest rise since 1990. And the core PCE, or the Fed's preferred inflation gauge stripping out volatile food and energy prices, rose by 4.1% year-over-year — the most in three decades.\nOther recent data have homed in on the tight labor market and presaged a potentially strong November jobs report. Last week'sinitial jobless claims fell to a 52-year low of 199,000, taking out both the prior pandemic-era low and pre-pandemic average for new first-time filings. This served as yet another point underscoring the steep competition for labor among U.S. employers, with companies attempting to hire and retain their existing workforces amid widespread labor shortages.\nEven given these lingering scarcities, the labor force participation rate has yet to return to pre-pandemic levels. The civilian labor force was still down by nearly 3 million participants compared to February 2020, with lingering concerns over the virus and adesire by many working-age individuals to seek out new roles with better flexibility and benefitsstill keeping many individuals on the sidelines of the workforce. Consensus economists expect the labor force participation rate to tick up only slightly in November to reach 61.7%, growing from October's 61.6% but coming in well below the 63.3% rate from February 2020.\nReturning the economy back to pre-pandemic labor force participation levels and ensuring job gains are seen equitably across different groups has become a key focus for the Federal Reserve. And the distance still left to make up on these fronts has also been the biggest factor keeping the Fed ultra-accommodative with its monetary policy support, even after a parade of hotter-than-expected inflation reports that would appear to warrant a more hawkish policy tilt and a quicker-than-expected hike to interest rates.Fed Chair Jerome Powell's renomination to remain as head of the central bankfurther suggests the Fed's focus on the labor market as a critical informing factor for monetary policy will remain.\n\"Market views for future Fed rate increases have been pulled forward aggressively in response to evidence that elevated inflation pressures are likely to persist for longer,\" wrote Deutsche Bank economist Justin Weidner in a note last week. \"However, as Chair Powell's November press conference made evident, prospects for the labor market to return to maximum employment remain a critical consideration for when the Fed will eventually begin to actively tighten monetary policy.\"\nEconomic calendar\n\nMonday:Pending home sales, month-over-month, October (0.7% expected, -2.3% in September); Dallas Federal Reserve Manufacturing Activity Index, November (17.0 expected, 14.6 in October)\nTuesday:FHFA House Price Index, month-over-month, September (1.2% expected, 1.0% in August); S&P CoreLogic Case-Shiller 20-City Composite Index, month-over-month, September (1.30% expected, 1.17% in August); S&P CoreLogic Case-Shiller 20-City Composite Index, September (19.66% during prior month); MNI Chicago PMI, November (67.0 expected, 68.4 in October); Conference Board Consumer Confidence Index, November (110.0 expected, 113.8 in October)\nWednesday:MBA Mortgage Applications, November 26 (1.8% during prior week); ADP Employment Change, November (515,000 expected, 571,000 in October); Markit U.S. Manufacturing PMI, November final (59.1 during prior month); Construction Spending, month-over-month, October (0.5% expected, -0.5% in September); ISM Manufacturing, November (61.0 expected, 60.8 in October); Federal Reserve releases Beige Book\nThursday:Challenger job cuts, November (-71.7% in October); Initial jobless claims, week ended Nov. 27 (199,000 during prior week); Continuing claims, Nov. 20 (2.049 during prior week)\nFriday:Change in non-farm payrolls, November (500,000 expected, 531,000 in October); Unemployment rate, November (4.5% expected, 4.6% in October); Average Hourly Earnings, month-over-month, November (0.4% expected, 0.4% in October); Average Hourly Earnings, year-over-year, November (5.0% expected, 4.9% in October); Markit U.S. Services PMI, November final (57.0 in prior print); Markit U.S. Composite PMI, November final (56.5 in prior print); ISM Services Index, November (65.0 expected, 66.7 in October); Factory Orders, October (0.5% expected, 0.2% in September); Durable Goods Orders, October final (-0.5% in prior print)\n\nEarnings calendar\n\nMonday:No notable reports scheduled for release\nTuesday:Salesforce.com (CRM) after market close\nWednesday:PVH Corp. (PVH) after market close\nThursday:Dollar General (DG), Kroger (KR) before market open; Ulta Beauty (ULTA) after market close\nFriday:No notable reports scheduled for release","news_type":1,"symbols_score_info":{"CRM":0.9}},"isVote":1,"tweetType":1,"viewCount":818,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":881165616,"gmtCreate":1631318122735,"gmtModify":1631889271155,"author":{"id":"3577518888738299","authorId":"3577518888738299","name":"LWZ2218","avatar":"https://static.tigerbbs.com/f53fe88ba02bdf3f307a8e715043f7e2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577518888738299","idStr":"3577518888738299"},"themes":[],"htmlText":"Buy&nbsp;","listText":"Buy&nbsp;","text":"Buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/881165616","repostId":"2166711943","repostType":4,"isVote":1,"tweetType":1,"viewCount":547,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":604355502,"gmtCreate":1639354250507,"gmtModify":1639354254429,"author":{"id":"3577518888738299","authorId":"3577518888738299","name":"LWZ2218","avatar":"https://static.tigerbbs.com/f53fe88ba02bdf3f307a8e715043f7e2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577518888738299","idStr":"3577518888738299"},"themes":[],"htmlText":"Yes , it will reach 1580 soon","listText":"Yes , it will reach 1580 soon","text":"Yes , it will reach 1580 soon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/604355502","repostId":"2190677202","repostType":4,"isVote":1,"tweetType":1,"viewCount":2967,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":850280543,"gmtCreate":1634602086761,"gmtModify":1634602087256,"author":{"id":"3577518888738299","authorId":"3577518888738299","name":"LWZ2218","avatar":"https://static.tigerbbs.com/f53fe88ba02bdf3f307a8e715043f7e2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577518888738299","idStr":"3577518888738299"},"themes":[],"htmlText":"Go Go Go","listText":"Go Go Go","text":"Go Go Go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/850280543","repostId":"2176120817","repostType":4,"isVote":1,"tweetType":1,"viewCount":461,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":880617126,"gmtCreate":1631054969765,"gmtModify":1632885014773,"author":{"id":"3577518888738299","authorId":"3577518888738299","name":"LWZ2218","avatar":"https://static.tigerbbs.com/f53fe88ba02bdf3f307a8e715043f7e2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577518888738299","idStr":"3577518888738299"},"themes":[],"htmlText":"buy at low price!!&nbsp;","listText":"buy at low price!!&nbsp;","text":"buy at low price!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/880617126","repostId":"1140893024","repostType":4,"repost":{"id":"1140893024","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1631054373,"share":"https://www.laohu8.com/m/news/1140893024?lang=zh_CN&edition=full","pubTime":"2021-09-08 06:39","market":"us","language":"en","title":"Nio shares fall after $2 billion stock offering announced<blockquote>蔚来宣布发行20亿美元股票后股价下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1140893024","media":"Tiger Newspress","summary":"NIO shares slipped 3.5% in extended trading after announcing at-the-market offering of American depo","content":"<p>NIO shares slipped 3.5% in extended trading&nbsp;after&nbsp;announcing at-the-market offering of American depositary shares.</p><p><blockquote>在宣布在市场上发行美国存托股票后，蔚来股价在盘后交易中下跌3.5%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/e0907d5351eb6acc6316886c6ac37011\" tg-width=\"890\" tg-height=\"638\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> NIO Inc. announced that it has filed a prospectus supplement to sell up to an aggregate of US$2,000,000,000 of its American depositary shares (“ADSs”), each representing one Class A ordinary share of the Company, through an at-the-market equity offering program (the “At-The-Market Offering”).</p><p><blockquote>蔚来宣布，已提交招股说明书补充文件，通过市场股票发行计划（“市场发行”）出售最多2,000,000,000美元的美国存托股票（“ADS”），每股代表公司的一股A类普通股。</blockquote></p><p> The ADSs will be offered through Credit Suisse Securities (USA) LLC, Morgan Stanley &amp; Co. LLC, Goldman Sachs (Asia) L.L.C., China International Capital Corporation Hong Kong Securities Limited, Nomura Securities International, Inc. and Guotai Junan Securities (Hong Kong) Limited as sales agents. Some of the sales agents are expected to make offers and sales both inside and outside the United States through their respective selling agents.</p><p><blockquote>ADS将通过瑞士瑞信证券（美国）有限责任公司、摩根士丹利有限责任公司、高盛（亚洲）有限责任公司、中国国际金融香港证券有限公司、野村证券国际有限公司和国泰君安证券（香港）有限公司作为销售代理发售。一些销售代理预计将通过其各自的销售代理在美国内外进行报价和销售。</blockquote></p><p> NIO has entered into an equity distribution agreement with the sales agents relating to the At-The-Market Offering. Sales, if any, of the ADSs under the At-The-Market Offering will be made from time to time, at the Company’s discretion, by means of ordinary broker transactions on or through the New York Stock Exchange (the “NYSE”) or other markets for its ADSs, sales made to or through a market maker other than on an exchange, or otherwise in negotiated transactions, or as otherwise agreed with the sales agents. Sales may be made at market prices prevailing at the time of sale or at negotiated prices. As a result, sales prices may vary.</p><p><blockquote>蔚来已与销售代理就市场发售签订股权分配协议。根据市场发售出售美国存讬股（如有）将不时由公司酌情决定，通过在纽约证券交易所（“纽约证券交易所”）或其美国存讬股的其他市场进行的普通经纪交易、向或通过交易所以外的做市商进行的销售、或以协商交易或与销售代理另行商定的方式进行。销售可以按销售时的现行市价或协商价格进行。因此，销售价格可能会有所不同。</blockquote></p><p> The Company currently plans to use the net proceeds from the At-The-Market Offering to further strengthen its balance sheet, as well as for general corporate purposes.</p><p><blockquote>该公司目前计划将市场发行的净收益用于进一步加强其资产负债表以及一般公司用途。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nio shares fall after $2 billion stock offering announced<blockquote>蔚来宣布发行20亿美元股票后股价下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNio shares fall after $2 billion stock offering announced<blockquote>蔚来宣布发行20亿美元股票后股价下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-09-08 06:39</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>NIO shares slipped 3.5% in extended trading&nbsp;after&nbsp;announcing at-the-market offering of American depositary shares.</p><p><blockquote>在宣布在市场上发行美国存托股票后，蔚来股价在盘后交易中下跌3.5%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/e0907d5351eb6acc6316886c6ac37011\" tg-width=\"890\" tg-height=\"638\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> NIO Inc. announced that it has filed a prospectus supplement to sell up to an aggregate of US$2,000,000,000 of its American depositary shares (“ADSs”), each representing one Class A ordinary share of the Company, through an at-the-market equity offering program (the “At-The-Market Offering”).</p><p><blockquote>蔚来宣布，已提交招股说明书补充文件，通过市场股票发行计划（“市场发行”）出售最多2,000,000,000美元的美国存托股票（“ADS”），每股代表公司的一股A类普通股。</blockquote></p><p> The ADSs will be offered through Credit Suisse Securities (USA) LLC, Morgan Stanley &amp; Co. LLC, Goldman Sachs (Asia) L.L.C., China International Capital Corporation Hong Kong Securities Limited, Nomura Securities International, Inc. and Guotai Junan Securities (Hong Kong) Limited as sales agents. Some of the sales agents are expected to make offers and sales both inside and outside the United States through their respective selling agents.</p><p><blockquote>ADS将通过瑞士瑞信证券（美国）有限责任公司、摩根士丹利有限责任公司、高盛（亚洲）有限责任公司、中国国际金融香港证券有限公司、野村证券国际有限公司和国泰君安证券（香港）有限公司作为销售代理发售。一些销售代理预计将通过其各自的销售代理在美国内外进行报价和销售。</blockquote></p><p> NIO has entered into an equity distribution agreement with the sales agents relating to the At-The-Market Offering. Sales, if any, of the ADSs under the At-The-Market Offering will be made from time to time, at the Company’s discretion, by means of ordinary broker transactions on or through the New York Stock Exchange (the “NYSE”) or other markets for its ADSs, sales made to or through a market maker other than on an exchange, or otherwise in negotiated transactions, or as otherwise agreed with the sales agents. Sales may be made at market prices prevailing at the time of sale or at negotiated prices. As a result, sales prices may vary.</p><p><blockquote>蔚来已与销售代理就市场发售签订股权分配协议。根据市场发售出售美国存讬股（如有）将不时由公司酌情决定，通过在纽约证券交易所（“纽约证券交易所”）或其美国存讬股的其他市场进行的普通经纪交易、向或通过交易所以外的做市商进行的销售、或以协商交易或与销售代理另行商定的方式进行。销售可以按销售时的现行市价或协商价格进行。因此，销售价格可能会有所不同。</blockquote></p><p> The Company currently plans to use the net proceeds from the At-The-Market Offering to further strengthen its balance sheet, as well as for general corporate purposes.</p><p><blockquote>该公司目前计划将市场发行的净收益用于进一步加强其资产负债表以及一般公司用途。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140893024","content_text":"NIO shares slipped 3.5% in extended trading after announcing at-the-market offering of American depositary shares.\n\nNIO Inc. announced that it has filed a prospectus supplement to sell up to an aggregate of US$2,000,000,000 of its American depositary shares (“ADSs”), each representing one Class A ordinary share of the Company, through an at-the-market equity offering program (the “At-The-Market Offering”).\nThe ADSs will be offered through Credit Suisse Securities (USA) LLC, Morgan Stanley & Co. LLC, Goldman Sachs (Asia) L.L.C., China International Capital Corporation Hong Kong Securities Limited, Nomura Securities International, Inc. and Guotai Junan Securities (Hong Kong) Limited as sales agents. Some of the sales agents are expected to make offers and sales both inside and outside the United States through their respective selling agents.\nNIO has entered into an equity distribution agreement with the sales agents relating to the At-The-Market Offering. Sales, if any, of the ADSs under the At-The-Market Offering will be made from time to time, at the Company’s discretion, by means of ordinary broker transactions on or through the New York Stock Exchange (the “NYSE”) or other markets for its ADSs, sales made to or through a market maker other than on an exchange, or otherwise in negotiated transactions, or as otherwise agreed with the sales agents. Sales may be made at market prices prevailing at the time of sale or at negotiated prices. As a result, sales prices may vary.\nThe Company currently plans to use the net proceeds from the At-The-Market Offering to further strengthen its balance sheet, as well as for general corporate purposes.","news_type":1,"symbols_score_info":{"NIO":0.9}},"isVote":1,"tweetType":1,"viewCount":523,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":602829454,"gmtCreate":1639008282743,"gmtModify":1639008282960,"author":{"id":"3577518888738299","authorId":"3577518888738299","name":"LWZ2218","avatar":"https://static.tigerbbs.com/f53fe88ba02bdf3f307a8e715043f7e2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577518888738299","idStr":"3577518888738299"},"themes":[],"htmlText":"Go Go Pfizer","listText":"Go Go Pfizer","text":"Go Go Pfizer","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/602829454","repostId":"1141815911","repostType":4,"repost":{"id":"1141815911","kind":"news","pubTimestamp":1639007843,"share":"https://www.laohu8.com/m/news/1141815911?lang=zh_CN&edition=full","pubTime":"2021-12-09 07:57","market":"us","language":"en","title":"Pfizer Says Booster Neutralized Omicron but Variant May Elude Two Doses<blockquote>辉瑞称加强剂中和了奥密克戎病毒，但变种可能无法注射两剂</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1141815911","media":"The Wall Street Journal","summary":"Pfizer Inc. PFE -0.62% and BioNTech SE BNTX -3.55% said that a third dose of their Covid-19 vaccine ","content":"<p>Pfizer Inc. PFE -0.62% and BioNTech SE BNTX -3.55% said that a third dose of their Covid-19 vaccine neutralized the Omicron variant in lab tests but that the two-dose regimen was significantly less effective at blocking the virus.</p><p><blockquote>辉瑞公司PFE-0.62%和BioNTech SE BNTX-3.55%表示，他们的第三剂Covid-19疫苗在实验室测试中中和了奥密克戎变种，但两剂方案在阻断病毒方面的效果明显较差。</blockquote></p><p> A third dose increased antibodies 25-fold compared with two doses against the Omicron variant, the companies said. Still, two doses may prove effective in preventing severe illness from Covid-19, they said, because immune cells are able to recognize 80% of parts of the spike protein that the vaccine targets.</p><p><blockquote>两家公司表示，与针对奥密克戎变种的两剂相比，第三剂使抗体增加了25倍。他们说，尽管如此，两剂疫苗可能会有效预防Covid-19引起的严重疾病，因为免疫细胞能够识别疫苗靶向的刺突蛋白的80%部分。</blockquote></p><p> The results were issued in a press release by the companies, and weren’t peer reviewed and published in a scientific journal.</p><p><blockquote>这些结果是在两家公司的新闻稿中发布的，没有经过同行评审也没有发表在科学期刊上。</blockquote></p><p> The findings from the companies’ early study, and one by scientists in South Africa, suggest that three doses will be needed to produce a similar immune response against Omicron as was provided by just two doses in earlier strains of the virus.</p><p><blockquote>两家公司的早期研究结果以及南非科学家的一项研究结果表明，需要三剂疫苗才能产生与早期病毒株仅两剂疫苗类似的针对奥密克戎病毒的免疫反应。</blockquote></p><p> It also bolsters the case for repeated and periodic boosters to maintain people’s immune defenses against an evolving Covid-19, the companies said.</p><p><blockquote>两家公司表示，这也支持了重复和定期加强剂以维持人们对不断发展的Covid-19的免疫防御的理由。</blockquote></p><p> “This is very positive news that should make everyone even more motivated to get vaccinated” and get a booster, said Pfizer Chief Scientific Officer Mikael Dolsten.</p><p><blockquote>辉瑞首席科学官米凯尔·多尔斯滕(Mikael Dolsten)表示，“这是一个非常积极的消息，应该会让每个人都更有动力接种疫苗”并接种加强剂。</blockquote></p><p> The companies’ current vaccine will provide a strong defense against Omicron, especially if people get a booster shot, Dr. Dolsten said. The three-dose regimen, he added, could provide stopgap protection against Omicron through the winter and until a new vaccine targeted directly at the variant would be ready if needed.</p><p><blockquote>多尔斯滕博士说，两家公司目前的疫苗将为奥密克戎提供强有力的防御，特别是如果人们接受加强注射的话。他补充说，三剂方案可以在整个冬季提供针对奥密克戎病毒的权宜之计，直到需要时直接针对该变种的新疫苗准备就绪。</blockquote></p><p> Pfizer and BioNTech are working on an Omicron-specific vaccine that they hope to have available by March 2022 if the variant becomes widespread by then. Researchers started working on the new vaccine on Thanksgiving Day, Nov. 25, shortly after Omicron was identified.</p><p><blockquote>辉瑞和BioNTech正在研究一种针对奥密克戎病毒的疫苗，如果该变种到那时变得广泛传播，他们希望在2022年3月之前上市。奥密克戎病毒被发现后不久，研究人员于11月25日感恩节开始研究这种新疫苗。</blockquote></p><p> The vaccine trains the immune system to fight the virus by generating immune-system soldiers known as antibodies, which attach to the virus and prevent it from replicating in healthy cells. The vaccine also produces other immune-system fighters called T cells that can kick in after infection to help target and clear the virus, preventing more serious disease.</p><p><blockquote>该疫苗通过产生称为抗体的免疫系统士兵来训练免疫系统对抗病毒，抗体附着在病毒上并阻止其在健康细胞中复制。该疫苗还产生其他称为T细胞的免疫系统战士，可以在感染后发挥作用，帮助靶向和清除病毒，预防更严重的疾病。</blockquote></p><p> Pfizer and BioNTech said that Omicron still appears susceptible to T cells produced by the vaccine.</p><p><blockquote>辉瑞和BioNTech表示，奥密克戎似乎仍然容易受到疫苗产生的T细胞的影响。</blockquote></p><p> Dr. Dolsten estimated there is a greater than 50% chance that Omicron becomes the dominant strain spreading in the U.S. by the spring, though it is too soon to know with certainty, he said.</p><p><blockquote>多尔斯滕博士估计，到春季，奥密克戎病毒成为美国传播的主要毒株的可能性超过50%，但现在确定还为时过早。</blockquote></p><p> The preliminary lab data comes from an analysis of blood samples from vaccinated patients measuring antibodies capable of neutralizing the virus causing Covid-19, including the Omicron variant. Blood samples were collected three weeks after patients received their second dose, or one month after receiving their third dose.</p><p><blockquote>初步实验室数据来自对接种疫苗患者血液样本的分析，测量能够中和导致Covid-19的病毒（包括奥密克戎变种）的抗体。在患者接受第二剂后三周或接受第三剂后一个月采集血样。</blockquote></p><p> The number of antibodies generated by a third booster shot against Omicron is similar to two doses against an older strain of the virus, the companies said.</p><p><blockquote>两家公司表示，针对奥密克戎病毒的第三次加强注射产生的抗体数量与针对旧病毒株的两次注射相似。</blockquote></p><p> “These preliminary data appear to show the Pfizer vaccine does in fact protect against Omicron, and that’s very good news,” said Philip Landrigan, director of Boston College’s Global Public Health and the Global Common Good program.</p><p><blockquote>“这些初步数据似乎表明辉瑞疫苗确实可以预防奥密克戎病毒，这是一个非常好的消息，”Boston College全球公共卫生和全球公益项目主任Philip Landrigan说。</blockquote></p><p> Monica Gandhi, a professor of medicine at the University of California, San Francisco, said the results suggested two doses will protect many people from getting bad cases leading to hospitalization or death.</p><p><blockquote>加州大学旧金山分校医学教授莫妮卡·甘地表示，结果表明，两剂疫苗将保护许多人免于出现导致住院或死亡的严重病例。</blockquote></p><p> “Two doses are still effective against severe disease, whether people get boosters or not,” said Dr. Gandhi, who is recommending boosters for high-risk patients, including those with HIV. “For people who are at high risk of severe disease, it’s so important to get them boosted, but I don’t think it’s mandatory for young healthy people.”</p><p><blockquote>甘地博士说：“无论人们是否接种加强剂，两剂疫苗对严重疾病仍然有效。”他建议为包括艾滋病毒感染者在内的高危患者接种加强剂。“对于患有严重疾病的高风险人群来说，给他们注射疫苗非常重要，但我认为这对于年轻的健康人来说并不是强制性的。”</blockquote></p><p> The company’s early findings come a day after scientists in South Africa reported findings from early lab tests indicating a 41-fold reduction in the Pfizer-BioNTech vaccine’s neutralization of Omicron than the original version of the virus.</p><p><blockquote>该公司的早期发现发布前一天，南非科学家报告了早期实验室测试的结果，表明辉瑞-BioNTech疫苗对奥密克戎病毒的中和作用比原始版本的病毒降低了41倍。</blockquote></p><p> The researchers, however, found greater antibody responses against Omicron in blood taken from subjects who were fully vaccinated and had previously been infected with Covid-19.</p><p><blockquote>然而，研究人员发现，从完全接种疫苗且之前感染过Covid-19的受试者身上采集的血液中，针对奥密克戎病毒的抗体反应更强。</blockquote></p><p> The companies will continue to work on a variant vaccine despite the promising signs that boosting with the original shot offers good protection against Omicron, said BioNTech Chief Executive Uğur Şahin. That is because they would need to see more data on how their vaccine holds up against the new variant, including real-world effectiveness data, expected in the coming weeks.</p><p><blockquote>BioNTech首席执行官Uğur Ş ahin表示，尽管有令人鼓舞的迹象表明，使用原始疫苗加强注射可以很好地预防奥密克戎病，但两家公司仍将继续研究变异疫苗。这是因为他们需要看到更多关于他们的疫苗如何抵抗新变种的数据，包括预计在未来几周内的真实世界有效性数据。</blockquote></p><p> “Only in combination will we understand the relevance of this data and potential protection against Omicron-mediated disease and severe disease,” he said.</p><p><blockquote>他说：“只有结合起来，我们才能了解这些数据的相关性以及对奥密克戎病介导的疾病和严重疾病的潜在保护作用。”</blockquote></p><p> Real-world data on vaccine effectiveness against Omicron won’t be available for at least six weeks, Dr. Şahin said, because the case numbers need to be higher before this can be measured.</p><p><blockquote>Ş ahin博士说，有关奥密克戎疫苗有效性的真实数据至少在六周内无法获得，因为病例数需要更高才能衡量。</blockquote></p><p></p><p> Meanwhile, the companies are moving forward with manufacturing an Omicron-specific vaccine. The first doses, for experimental use, will be ready in January, BioNTech executives said.</p><p><blockquote>与此同时，两家公司正在推进奥密克戎专用疫苗的生产。BioNTech高管表示，用于实验用途的第一剂疫苗将于1月份准备就绪。</blockquote></p><p> Omicron was first identified by scientists in South Africa last month. Since then the World Health Organization has deemed it a variant of concern. And it has since been detected around the world, including in the U.S.</p><p><blockquote>上个月，科学家首次在南非发现了奥密克戎病毒。从那时起，世界卫生组织就认为这是一个值得关注的变种。此后，包括美国在内的世界各地都发现了这种病毒。</blockquote></p><p> Researchers have been trying to understand how contagious the new strain is, as well as how well it might be able to evade Covid-19 vaccines and whether it causes severe disease. Some preliminary reports suggest the variant is more contagious but might cause milder disease, though researchers say it is too early to know.</p><p><blockquote>研究人员一直在试图了解这种新毒株的传染性如何，以及它逃避Covid-19疫苗的能力如何，以及它是否会导致严重疾病。一些初步报告表明，这种变异更具传染性，但可能会导致较轻的疾病，尽管研究人员表示现在知道还为时过早。</blockquote></p><p> Pfizer and BioNTech said they expect to make four billion vaccine doses next year, even if an Omicron-specific vaccine is required by then.</p><p><blockquote>辉瑞和BioNTech表示，他们预计明年将生产40亿剂疫苗，即使届时需要奥密克戎专用疫苗。</blockquote></p><p> Dr. Dolsten said that regardless of how widespread Omicron becomes, continued booster shots will likely be needed going forward to provide protection against Covid-19. A fourth booster dose is likely to be needed in the spring or fall of 2022, he said.</p><p><blockquote>多尔斯滕博士说，无论奥密克戎病变得多么普遍，未来可能需要持续的加强注射来提供针对新冠肺炎的保护。他说，2022年春季或秋季可能需要第四次加强剂量。</blockquote></p><p> “It’s increasingly clear you need to have a long-term perspective, with continued boosting to have strong durable immunity,” said Dr. Dolsten. “If the landscape looks similar to today, we will likely continue to boost with the current vaccine.”</p><p><blockquote>多尔斯滕博士说：“越来越明显的是，你需要有长远的眼光，持续增强才能拥有强大持久的免疫力。”“如果情况看起来与今天相似，我们可能会继续使用当前的疫苗加强疫苗。”</blockquote></p><p> Pfizer’s shares rose 1% while BioNTech’s American depositary shares fell 0.2% in morning trading.</p><p><blockquote>辉瑞股价上涨1%，而BioNTech美国存托股早盘下跌0.2%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Says Booster Neutralized Omicron but Variant May Elude Two Doses<blockquote>辉瑞称加强剂中和了奥密克戎病毒，但变种可能无法注射两剂</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Says Booster Neutralized Omicron but Variant May Elude Two Doses<blockquote>辉瑞称加强剂中和了奥密克戎病毒，但变种可能无法注射两剂</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">The Wall Street Journal</strong><span class=\"h-time small\">2021-12-09 07:57</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Pfizer Inc. PFE -0.62% and BioNTech SE BNTX -3.55% said that a third dose of their Covid-19 vaccine neutralized the Omicron variant in lab tests but that the two-dose regimen was significantly less effective at blocking the virus.</p><p><blockquote>辉瑞公司PFE-0.62%和BioNTech SE BNTX-3.55%表示，他们的第三剂Covid-19疫苗在实验室测试中中和了奥密克戎变种，但两剂方案在阻断病毒方面的效果明显较差。</blockquote></p><p> A third dose increased antibodies 25-fold compared with two doses against the Omicron variant, the companies said. Still, two doses may prove effective in preventing severe illness from Covid-19, they said, because immune cells are able to recognize 80% of parts of the spike protein that the vaccine targets.</p><p><blockquote>两家公司表示，与针对奥密克戎变种的两剂相比，第三剂使抗体增加了25倍。他们说，尽管如此，两剂疫苗可能会有效预防Covid-19引起的严重疾病，因为免疫细胞能够识别疫苗靶向的刺突蛋白的80%部分。</blockquote></p><p> The results were issued in a press release by the companies, and weren’t peer reviewed and published in a scientific journal.</p><p><blockquote>这些结果是在两家公司的新闻稿中发布的，没有经过同行评审也没有发表在科学期刊上。</blockquote></p><p> The findings from the companies’ early study, and one by scientists in South Africa, suggest that three doses will be needed to produce a similar immune response against Omicron as was provided by just two doses in earlier strains of the virus.</p><p><blockquote>两家公司的早期研究结果以及南非科学家的一项研究结果表明，需要三剂疫苗才能产生与早期病毒株仅两剂疫苗类似的针对奥密克戎病毒的免疫反应。</blockquote></p><p> It also bolsters the case for repeated and periodic boosters to maintain people’s immune defenses against an evolving Covid-19, the companies said.</p><p><blockquote>两家公司表示，这也支持了重复和定期加强剂以维持人们对不断发展的Covid-19的免疫防御的理由。</blockquote></p><p> “This is very positive news that should make everyone even more motivated to get vaccinated” and get a booster, said Pfizer Chief Scientific Officer Mikael Dolsten.</p><p><blockquote>辉瑞首席科学官米凯尔·多尔斯滕(Mikael Dolsten)表示，“这是一个非常积极的消息，应该会让每个人都更有动力接种疫苗”并接种加强剂。</blockquote></p><p> The companies’ current vaccine will provide a strong defense against Omicron, especially if people get a booster shot, Dr. Dolsten said. The three-dose regimen, he added, could provide stopgap protection against Omicron through the winter and until a new vaccine targeted directly at the variant would be ready if needed.</p><p><blockquote>多尔斯滕博士说，两家公司目前的疫苗将为奥密克戎提供强有力的防御，特别是如果人们接受加强注射的话。他补充说，三剂方案可以在整个冬季提供针对奥密克戎病毒的权宜之计，直到需要时直接针对该变种的新疫苗准备就绪。</blockquote></p><p> Pfizer and BioNTech are working on an Omicron-specific vaccine that they hope to have available by March 2022 if the variant becomes widespread by then. Researchers started working on the new vaccine on Thanksgiving Day, Nov. 25, shortly after Omicron was identified.</p><p><blockquote>辉瑞和BioNTech正在研究一种针对奥密克戎病毒的疫苗，如果该变种到那时变得广泛传播，他们希望在2022年3月之前上市。奥密克戎病毒被发现后不久，研究人员于11月25日感恩节开始研究这种新疫苗。</blockquote></p><p> The vaccine trains the immune system to fight the virus by generating immune-system soldiers known as antibodies, which attach to the virus and prevent it from replicating in healthy cells. The vaccine also produces other immune-system fighters called T cells that can kick in after infection to help target and clear the virus, preventing more serious disease.</p><p><blockquote>该疫苗通过产生称为抗体的免疫系统士兵来训练免疫系统对抗病毒，抗体附着在病毒上并阻止其在健康细胞中复制。该疫苗还产生其他称为T细胞的免疫系统战士，可以在感染后发挥作用，帮助靶向和清除病毒，预防更严重的疾病。</blockquote></p><p> Pfizer and BioNTech said that Omicron still appears susceptible to T cells produced by the vaccine.</p><p><blockquote>辉瑞和BioNTech表示，奥密克戎似乎仍然容易受到疫苗产生的T细胞的影响。</blockquote></p><p> Dr. Dolsten estimated there is a greater than 50% chance that Omicron becomes the dominant strain spreading in the U.S. by the spring, though it is too soon to know with certainty, he said.</p><p><blockquote>多尔斯滕博士估计，到春季，奥密克戎病毒成为美国传播的主要毒株的可能性超过50%，但现在确定还为时过早。</blockquote></p><p> The preliminary lab data comes from an analysis of blood samples from vaccinated patients measuring antibodies capable of neutralizing the virus causing Covid-19, including the Omicron variant. Blood samples were collected three weeks after patients received their second dose, or one month after receiving their third dose.</p><p><blockquote>初步实验室数据来自对接种疫苗患者血液样本的分析，测量能够中和导致Covid-19的病毒（包括奥密克戎变种）的抗体。在患者接受第二剂后三周或接受第三剂后一个月采集血样。</blockquote></p><p> The number of antibodies generated by a third booster shot against Omicron is similar to two doses against an older strain of the virus, the companies said.</p><p><blockquote>两家公司表示，针对奥密克戎病毒的第三次加强注射产生的抗体数量与针对旧病毒株的两次注射相似。</blockquote></p><p> “These preliminary data appear to show the Pfizer vaccine does in fact protect against Omicron, and that’s very good news,” said Philip Landrigan, director of Boston College’s Global Public Health and the Global Common Good program.</p><p><blockquote>“这些初步数据似乎表明辉瑞疫苗确实可以预防奥密克戎病毒，这是一个非常好的消息，”Boston College全球公共卫生和全球公益项目主任Philip Landrigan说。</blockquote></p><p> Monica Gandhi, a professor of medicine at the University of California, San Francisco, said the results suggested two doses will protect many people from getting bad cases leading to hospitalization or death.</p><p><blockquote>加州大学旧金山分校医学教授莫妮卡·甘地表示，结果表明，两剂疫苗将保护许多人免于出现导致住院或死亡的严重病例。</blockquote></p><p> “Two doses are still effective against severe disease, whether people get boosters or not,” said Dr. Gandhi, who is recommending boosters for high-risk patients, including those with HIV. “For people who are at high risk of severe disease, it’s so important to get them boosted, but I don’t think it’s mandatory for young healthy people.”</p><p><blockquote>甘地博士说：“无论人们是否接种加强剂，两剂疫苗对严重疾病仍然有效。”他建议为包括艾滋病毒感染者在内的高危患者接种加强剂。“对于患有严重疾病的高风险人群来说，给他们注射疫苗非常重要，但我认为这对于年轻的健康人来说并不是强制性的。”</blockquote></p><p> The company’s early findings come a day after scientists in South Africa reported findings from early lab tests indicating a 41-fold reduction in the Pfizer-BioNTech vaccine’s neutralization of Omicron than the original version of the virus.</p><p><blockquote>该公司的早期发现发布前一天，南非科学家报告了早期实验室测试的结果，表明辉瑞-BioNTech疫苗对奥密克戎病毒的中和作用比原始版本的病毒降低了41倍。</blockquote></p><p> The researchers, however, found greater antibody responses against Omicron in blood taken from subjects who were fully vaccinated and had previously been infected with Covid-19.</p><p><blockquote>然而，研究人员发现，从完全接种疫苗且之前感染过Covid-19的受试者身上采集的血液中，针对奥密克戎病毒的抗体反应更强。</blockquote></p><p> The companies will continue to work on a variant vaccine despite the promising signs that boosting with the original shot offers good protection against Omicron, said BioNTech Chief Executive Uğur Şahin. That is because they would need to see more data on how their vaccine holds up against the new variant, including real-world effectiveness data, expected in the coming weeks.</p><p><blockquote>BioNTech首席执行官Uğur Ş ahin表示，尽管有令人鼓舞的迹象表明，使用原始疫苗加强注射可以很好地预防奥密克戎病，但两家公司仍将继续研究变异疫苗。这是因为他们需要看到更多关于他们的疫苗如何抵抗新变种的数据，包括预计在未来几周内的真实世界有效性数据。</blockquote></p><p> “Only in combination will we understand the relevance of this data and potential protection against Omicron-mediated disease and severe disease,” he said.</p><p><blockquote>他说：“只有结合起来，我们才能了解这些数据的相关性以及对奥密克戎病介导的疾病和严重疾病的潜在保护作用。”</blockquote></p><p> Real-world data on vaccine effectiveness against Omicron won’t be available for at least six weeks, Dr. Şahin said, because the case numbers need to be higher before this can be measured.</p><p><blockquote>Ş ahin博士说，有关奥密克戎疫苗有效性的真实数据至少在六周内无法获得，因为病例数需要更高才能衡量。</blockquote></p><p></p><p> Meanwhile, the companies are moving forward with manufacturing an Omicron-specific vaccine. The first doses, for experimental use, will be ready in January, BioNTech executives said.</p><p><blockquote>与此同时，两家公司正在推进奥密克戎专用疫苗的生产。BioNTech高管表示，用于实验用途的第一剂疫苗将于1月份准备就绪。</blockquote></p><p> Omicron was first identified by scientists in South Africa last month. Since then the World Health Organization has deemed it a variant of concern. And it has since been detected around the world, including in the U.S.</p><p><blockquote>上个月，科学家首次在南非发现了奥密克戎病毒。从那时起，世界卫生组织就认为这是一个值得关注的变种。此后，包括美国在内的世界各地都发现了这种病毒。</blockquote></p><p> Researchers have been trying to understand how contagious the new strain is, as well as how well it might be able to evade Covid-19 vaccines and whether it causes severe disease. Some preliminary reports suggest the variant is more contagious but might cause milder disease, though researchers say it is too early to know.</p><p><blockquote>研究人员一直在试图了解这种新毒株的传染性如何，以及它逃避Covid-19疫苗的能力如何，以及它是否会导致严重疾病。一些初步报告表明，这种变异更具传染性，但可能会导致较轻的疾病，尽管研究人员表示现在知道还为时过早。</blockquote></p><p> Pfizer and BioNTech said they expect to make four billion vaccine doses next year, even if an Omicron-specific vaccine is required by then.</p><p><blockquote>辉瑞和BioNTech表示，他们预计明年将生产40亿剂疫苗，即使届时需要奥密克戎专用疫苗。</blockquote></p><p> Dr. Dolsten said that regardless of how widespread Omicron becomes, continued booster shots will likely be needed going forward to provide protection against Covid-19. A fourth booster dose is likely to be needed in the spring or fall of 2022, he said.</p><p><blockquote>多尔斯滕博士说，无论奥密克戎病变得多么普遍，未来可能需要持续的加强注射来提供针对新冠肺炎的保护。他说，2022年春季或秋季可能需要第四次加强剂量。</blockquote></p><p> “It’s increasingly clear you need to have a long-term perspective, with continued boosting to have strong durable immunity,” said Dr. Dolsten. “If the landscape looks similar to today, we will likely continue to boost with the current vaccine.”</p><p><blockquote>多尔斯滕博士说：“越来越明显的是，你需要有长远的眼光，持续增强才能拥有强大持久的免疫力。”“如果情况看起来与今天相似，我们可能会继续使用当前的疫苗加强疫苗。”</blockquote></p><p> Pfizer’s shares rose 1% while BioNTech’s American depositary shares fell 0.2% in morning trading.</p><p><blockquote>辉瑞股价上涨1%，而BioNTech美国存托股早盘下跌0.2%。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.wsj.com/articles/pfizer-biontech-covid-19-vaccine-loses-significant-effectiveness-against-omicron-in-early-study-companies-say-11638964121?mod=hp_lead_pos1\">The Wall Street Journal</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BNTX":"BioNTech SE"},"source_url":"https://www.wsj.com/articles/pfizer-biontech-covid-19-vaccine-loses-significant-effectiveness-against-omicron-in-early-study-companies-say-11638964121?mod=hp_lead_pos1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141815911","content_text":"Pfizer Inc. PFE -0.62% and BioNTech SE BNTX -3.55% said that a third dose of their Covid-19 vaccine neutralized the Omicron variant in lab tests but that the two-dose regimen was significantly less effective at blocking the virus.\n\nA third dose increased antibodies 25-fold compared with two doses against the Omicron variant, the companies said. Still, two doses may prove effective in preventing severe illness from Covid-19, they said, because immune cells are able to recognize 80% of parts of the spike protein that the vaccine targets.\n\nThe results were issued in a press release by the companies, and weren’t peer reviewed and published in a scientific journal.\n\nThe findings from the companies’ early study, and one by scientists in South Africa, suggest that three doses will be needed to produce a similar immune response against Omicron as was provided by just two doses in earlier strains of the virus.\n\n\nIt also bolsters the case for repeated and periodic boosters to maintain people’s immune defenses against an evolving Covid-19, the companies said.\n\n“This is very positive news that should make everyone even more motivated to get vaccinated” and get a booster, said Pfizer Chief Scientific Officer Mikael Dolsten.\n\nThe companies’ current vaccine will provide a strong defense against Omicron, especially if people get a booster shot, Dr. Dolsten said. The three-dose regimen, he added, could provide stopgap protection against Omicron through the winter and until a new vaccine targeted directly at the variant would be ready if needed.\n\nPfizer and BioNTech are working on an Omicron-specific vaccine that they hope to have available by March 2022 if the variant becomes widespread by then. Researchers started working on the new vaccine on Thanksgiving Day, Nov. 25, shortly after Omicron was identified.\n\nThe vaccine trains the immune system to fight the virus by generating immune-system soldiers known as antibodies, which attach to the virus and prevent it from replicating in healthy cells. The vaccine also produces other immune-system fighters called T cells that can kick in after infection to help target and clear the virus, preventing more serious disease.\n\nPfizer and BioNTech said that Omicron still appears susceptible to T cells produced by the vaccine.\n\nDr. Dolsten estimated there is a greater than 50% chance that Omicron becomes the dominant strain spreading in the U.S. by the spring, though it is too soon to know with certainty, he said.\n\nThe preliminary lab data comes from an analysis of blood samples from vaccinated patients measuring antibodies capable of neutralizing the virus causing Covid-19, including the Omicron variant. Blood samples were collected three weeks after patients received their second dose, or one month after receiving their third dose.\n\nThe number of antibodies generated by a third booster shot against Omicron is similar to two doses against an older strain of the virus, the companies said.\n\n“These preliminary data appear to show the Pfizer vaccine does in fact protect against Omicron, and that’s very good news,” said Philip Landrigan, director of Boston College’s Global Public Health and the Global Common Good program.\n\n\nMonica Gandhi, a professor of medicine at the University of California, San Francisco, said the results suggested two doses will protect many people from getting bad cases leading to hospitalization or death.\n\n“Two doses are still effective against severe disease, whether people get boosters or not,” said Dr. Gandhi, who is recommending boosters for high-risk patients, including those with HIV. “For people who are at high risk of severe disease, it’s so important to get them boosted, but I don’t think it’s mandatory for young healthy people.”\n\nThe company’s early findings come a day after scientists in South Africa reported findings from early lab tests indicating a 41-fold reduction in the Pfizer-BioNTech vaccine’s neutralization of Omicron than the original version of the virus.\n\n\n\nThe researchers, however, found greater antibody responses against Omicron in blood taken from subjects who were fully vaccinated and had previously been infected with Covid-19.\n\nThe companies will continue to work on a variant vaccine despite the promising signs that boosting with the original shot offers good protection against Omicron, said BioNTech Chief Executive Uğur Şahin. That is because they would need to see more data on how their vaccine holds up against the new variant, including real-world effectiveness data, expected in the coming weeks.\n\n\n“Only in combination will we understand the relevance of this data and potential protection against Omicron-mediated disease and severe disease,” he said.\n\nReal-world data on vaccine effectiveness against Omicron won’t be available for at least six weeks, Dr. Şahin said, because the case numbers need to be higher before this can be measured.\n\nMeanwhile, the companies are moving forward with manufacturing an Omicron-specific vaccine. The first doses, for experimental use, will be ready in January, BioNTech executives said.\n\nOmicron was first identified by scientists in South Africa last month. Since then the World Health Organization has deemed it a variant of concern. And it has since been detected around the world, including in the U.S.\n\nResearchers have been trying to understand how contagious the new strain is, as well as how well it might be able to evade Covid-19 vaccines and whether it causes severe disease. Some preliminary reports suggest the variant is more contagious but might cause milder disease, though researchers say it is too early to know.\n\nPfizer and BioNTech said they expect to make four billion vaccine doses next year, even if an Omicron-specific vaccine is required by then.\n\nDr. Dolsten said that regardless of how widespread Omicron becomes, continued booster shots will likely be needed going forward to provide protection against Covid-19. A fourth booster dose is likely to be needed in the spring or fall of 2022, he said.\n\n“It’s increasingly clear you need to have a long-term perspective, with continued boosting to have strong durable immunity,” said Dr. Dolsten. “If the landscape looks similar to today, we will likely continue to boost with the current vaccine.”\n\nPfizer’s shares rose 1% while BioNTech’s American depositary shares fell 0.2% in morning trading.","news_type":1,"symbols_score_info":{"PFE":0.9,"BNTX":0.9}},"isVote":1,"tweetType":1,"viewCount":3533,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":858364509,"gmtCreate":1634984359933,"gmtModify":1634984360191,"author":{"id":"3577518888738299","authorId":"3577518888738299","name":"LWZ2218","avatar":"https://static.tigerbbs.com/f53fe88ba02bdf3f307a8e715043f7e2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577518888738299","idStr":"3577518888738299"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/858364509","repostId":"2177121214","repostType":4,"isVote":1,"tweetType":1,"viewCount":596,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":827063860,"gmtCreate":1634371475916,"gmtModify":1634371515387,"author":{"id":"3577518888738299","authorId":"3577518888738299","name":"LWZ2218","avatar":"https://static.tigerbbs.com/f53fe88ba02bdf3f307a8e715043f7e2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577518888738299","idStr":"3577518888738299"},"themes":[],"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/827063860","repostId":"2175146556","repostType":4,"isVote":1,"tweetType":1,"viewCount":698,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":875186093,"gmtCreate":1637624974985,"gmtModify":1637624975097,"author":{"id":"3577518888738299","authorId":"3577518888738299","name":"LWZ2218","avatar":"https://static.tigerbbs.com/f53fe88ba02bdf3f307a8e715043f7e2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577518888738299","idStr":"3577518888738299"},"themes":[],"htmlText":"NVDA is the best for sure","listText":"NVDA is the best for sure","text":"NVDA is the best for sure","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/875186093","repostId":"1107351089","repostType":4,"isVote":1,"tweetType":1,"viewCount":1140,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848417724,"gmtCreate":1636019447224,"gmtModify":1636019549853,"author":{"id":"3577518888738299","authorId":"3577518888738299","name":"LWZ2218","avatar":"https://static.tigerbbs.com/f53fe88ba02bdf3f307a8e715043f7e2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577518888738299","idStr":"3577518888738299"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848417724","repostId":"1189037300","repostType":4,"repost":{"id":"1189037300","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1636018960,"share":"https://www.laohu8.com/m/news/1189037300?lang=zh_CN&edition=full","pubTime":"2021-11-04 17:42","market":"us","language":"en","title":"5 Stocks To Watch For November 4, 2021<blockquote>2021年11月4日值得关注的5只股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1189037300","media":"Benzinga","summary":"Some of the stocks that may grab investor focus today are:\n\nWall Street expects Moderna, Inc. to rep","content":"<p>Some of the stocks that may grab investor focus today are:</p><p><blockquote>今天可能引起投资者关注的一些股票包括：</blockquote></p><p> <ul>  <li>Wall Street expects&nbsp;<b>Moderna, Inc.</b>&nbsp;to report quarterly earnings at $8.95 per share on revenue of $6.45 billion before the opening bell. Moderna shares rose 0.2% to $346.66 in pre-market trading.</li>  <li><b>Booking Holdings Inc.</b>&nbsp;reported upbeat earnings for the third quarter. Booking shares gained 4.3% to $2,540.00 in the pre-market trading session.</li>  <li>Analysts are expecting&nbsp;<b>ViacomCBS Inc.</b>&nbsp;to have earned $0.76 per share on revenue of $6.60 billion for the latest quarter. The company will release earnings before the markets open. ViacomCBS shares rose 0.7% to 37.80 in pre-market trading.</li> </ul> <ul>  <li><b>Qualcomm Inc</b>&nbsp;posted upbeat results for its recent quarter and issued a strong forecast for its current quarter. Qualcomm shares climbed 6.7% to $147.80 in the pre-market trading session.</li>  <li>Analysts expect&nbsp;<b>Airbnb, Inc.</b>&nbsp;to post quarterly earnings at $0.84 per share on revenue of $2.04 billion after the closing bell. Airbnb shares rose 2.2% to 176.64 in pre-market trading.</li> </ul></p><p><blockquote><ul><li>华尔街预计<b>莫德纳公司。</b>开盘前公布季度收益为每股8.95美元，营收为64.5亿美元。Moderna股价在盘前交易中上涨0.2%，至346.66美元。</li><li><b>预订控股公司。</b>报告了乐观的第三季度收益。Booking股价在盘前交易时段上涨4.3%，至2,540.00美元。</li><li>分析师预计<b>维亚康姆哥伦比亚广播公司。</b>最近一个季度的营收为66亿美元，每股收益为0.76美元。该公司将在开市前发布财报。ViacomCBS股价在盘前交易中上涨0.7%，至37.80点。</li></ul><ul><li><b>高通公司</b>公布了最近一个季度的乐观业绩，并发布了对本季度的强劲预测。高通股价在盘前交易时段上涨6.7%至147.80美元。</li><li>分析师预计<b>爱彼迎公司。</b>收盘后公布季度收益为每股0.84美元，营收为20.4亿美元。爱彼迎股价在盘前交易中上涨2.2%至176.64点。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Stocks To Watch For November 4, 2021<blockquote>2021年11月4日值得关注的5只股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Stocks To Watch For November 4, 2021<blockquote>2021年11月4日值得关注的5只股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-11-04 17:42</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p>Some of the stocks that may grab investor focus today are:</p><p><blockquote>今天可能引起投资者关注的一些股票包括：</blockquote></p><p> <ul>  <li>Wall Street expects&nbsp;<b>Moderna, Inc.</b>&nbsp;to report quarterly earnings at $8.95 per share on revenue of $6.45 billion before the opening bell. Moderna shares rose 0.2% to $346.66 in pre-market trading.</li>  <li><b>Booking Holdings Inc.</b>&nbsp;reported upbeat earnings for the third quarter. Booking shares gained 4.3% to $2,540.00 in the pre-market trading session.</li>  <li>Analysts are expecting&nbsp;<b>ViacomCBS Inc.</b>&nbsp;to have earned $0.76 per share on revenue of $6.60 billion for the latest quarter. The company will release earnings before the markets open. ViacomCBS shares rose 0.7% to 37.80 in pre-market trading.</li> </ul> <ul>  <li><b>Qualcomm Inc</b>&nbsp;posted upbeat results for its recent quarter and issued a strong forecast for its current quarter. Qualcomm shares climbed 6.7% to $147.80 in the pre-market trading session.</li>  <li>Analysts expect&nbsp;<b>Airbnb, Inc.</b>&nbsp;to post quarterly earnings at $0.84 per share on revenue of $2.04 billion after the closing bell. Airbnb shares rose 2.2% to 176.64 in pre-market trading.</li> </ul></p><p><blockquote><ul><li>华尔街预计<b>莫德纳公司。</b>开盘前公布季度收益为每股8.95美元，营收为64.5亿美元。Moderna股价在盘前交易中上涨0.2%，至346.66美元。</li><li><b>预订控股公司。</b>报告了乐观的第三季度收益。Booking股价在盘前交易时段上涨4.3%，至2,540.00美元。</li><li>分析师预计<b>维亚康姆哥伦比亚广播公司。</b>最近一个季度的营收为66亿美元，每股收益为0.76美元。该公司将在开市前发布财报。ViacomCBS股价在盘前交易中上涨0.7%，至37.80点。</li></ul><ul><li><b>高通公司</b>公布了最近一个季度的乐观业绩，并发布了对本季度的强劲预测。高通股价在盘前交易时段上涨6.7%至147.80美元。</li><li>分析师预计<b>爱彼迎公司。</b>收盘后公布季度收益为每股0.84美元，营收为20.4亿美元。爱彼迎股价在盘前交易中上涨2.2%至176.64点。</li></ul></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"QCOM":"高通","MRNA":"Moderna, Inc.","ABNB":"爱彼迎","BKNG":"Booking Holdings"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1189037300","content_text":"Some of the stocks that may grab investor focus today are:\n\nWall Street expects Moderna, Inc. to report quarterly earnings at $8.95 per share on revenue of $6.45 billion before the opening bell. Moderna shares rose 0.2% to $346.66 in pre-market trading.\nBooking Holdings Inc. reported upbeat earnings for the third quarter. Booking shares gained 4.3% to $2,540.00 in the pre-market trading session.\nAnalysts are expecting ViacomCBS Inc. to have earned $0.76 per share on revenue of $6.60 billion for the latest quarter. The company will release earnings before the markets open. ViacomCBS shares rose 0.7% to 37.80 in pre-market trading.\n\n\nQualcomm Inc posted upbeat results for its recent quarter and issued a strong forecast for its current quarter. Qualcomm shares climbed 6.7% to $147.80 in the pre-market trading session.\nAnalysts expect Airbnb, Inc. to post quarterly earnings at $0.84 per share on revenue of $2.04 billion after the closing bell. Airbnb shares rose 2.2% to 176.64 in pre-market trading.","news_type":1,"symbols_score_info":{"MRNA":0.9,"QCOM":0.9,"ABNB":0.9,"VIAC":0.9,"BKNG":0.9}},"isVote":1,"tweetType":1,"viewCount":362,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":851068363,"gmtCreate":1634859784324,"gmtModify":1634859784626,"author":{"id":"3577518888738299","authorId":"3577518888738299","name":"LWZ2218","avatar":"https://static.tigerbbs.com/f53fe88ba02bdf3f307a8e715043f7e2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577518888738299","idStr":"3577518888738299"},"themes":[],"htmlText":"Fly to the moon","listText":"Fly to the moon","text":"Fly to the moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/851068363","repostId":"2177462128","repostType":4,"isVote":1,"tweetType":1,"viewCount":510,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":865346606,"gmtCreate":1632957846098,"gmtModify":1632957846334,"author":{"id":"3577518888738299","authorId":"3577518888738299","name":"LWZ2218","avatar":"https://static.tigerbbs.com/f53fe88ba02bdf3f307a8e715043f7e2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577518888738299","idStr":"3577518888738299"},"themes":[],"htmlText":"Sell plz","listText":"Sell plz","text":"Sell plz","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/865346606","repostId":"2171300933","repostType":4,"isVote":1,"tweetType":1,"viewCount":335,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605062446,"gmtCreate":1639094436791,"gmtModify":1639094437052,"author":{"id":"3577518888738299","authorId":"3577518888738299","name":"LWZ2218","avatar":"https://static.tigerbbs.com/f53fe88ba02bdf3f307a8e715043f7e2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577518888738299","idStr":"3577518888738299"},"themes":[],"htmlText":"Huat&nbsp;","listText":"Huat&nbsp;","text":"Huat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605062446","repostId":"2190964556","repostType":4,"isVote":1,"tweetType":1,"viewCount":3952,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606457819,"gmtCreate":1638922877570,"gmtModify":1638922877802,"author":{"id":"3577518888738299","authorId":"3577518888738299","name":"LWZ2218","avatar":"https://static.tigerbbs.com/f53fe88ba02bdf3f307a8e715043f7e2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577518888738299","idStr":"3577518888738299"},"themes":[],"htmlText":"Yeah dividend !!!! Buy Buy Buy","listText":"Yeah dividend !!!! Buy Buy Buy","text":"Yeah dividend !!!! Buy Buy Buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/606457819","repostId":"2189659313","repostType":4,"isVote":1,"tweetType":1,"viewCount":2586,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876413569,"gmtCreate":1637337801124,"gmtModify":1637337801489,"author":{"id":"3577518888738299","authorId":"3577518888738299","name":"LWZ2218","avatar":"https://static.tigerbbs.com/f53fe88ba02bdf3f307a8e715043f7e2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577518888738299","idStr":"3577518888738299"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/876413569","repostId":"1114542201","repostType":4,"isVote":1,"tweetType":1,"viewCount":464,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":854501928,"gmtCreate":1635466080736,"gmtModify":1635466081051,"author":{"id":"3577518888738299","authorId":"3577518888738299","name":"LWZ2218","avatar":"https://static.tigerbbs.com/f53fe88ba02bdf3f307a8e715043f7e2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577518888738299","idStr":"3577518888738299"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/854501928","repostId":"2179291938","repostType":4,"isVote":1,"tweetType":1,"viewCount":438,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":828611768,"gmtCreate":1633909588026,"gmtModify":1633909588097,"author":{"id":"3577518888738299","authorId":"3577518888738299","name":"LWZ2218","avatar":"https://static.tigerbbs.com/f53fe88ba02bdf3f307a8e715043f7e2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577518888738299","idStr":"3577518888738299"},"themes":[],"htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/828611768","repostId":"2174716729","repostType":4,"isVote":1,"tweetType":1,"viewCount":287,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":187217419,"gmtCreate":1623755294731,"gmtModify":1634028965614,"author":{"id":"3577518888738299","authorId":"3577518888738299","name":"LWZ2218","avatar":"https://static.tigerbbs.com/f53fe88ba02bdf3f307a8e715043f7e2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577518888738299","idStr":"3577518888738299"},"themes":[],"htmlText":"Pfizer is worth to invest!!&nbsp;","listText":"Pfizer is worth to invest!!&nbsp;","text":"Pfizer is worth to invest!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/187217419","repostId":"1167457915","repostType":4,"repost":{"id":"1167457915","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1623750756,"share":"https://www.laohu8.com/m/news/1167457915?lang=zh_CN&edition=full","pubTime":"2021-06-15 17:52","market":"us","language":"en","title":"Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up<blockquote>Novavax与辉瑞与Moderna：COVID-19疫苗如何叠加</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1167457915","media":"Benzinga","summary":"It was \"better late than never\" for Novavax, Inc.NVAX, as the biopharma finally got around to announ","content":"<p>It was \"better late than never\" for&nbsp;<b>Novavax, Inc.</b>NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.</p><p><blockquote>“迟到总比不到好”<b>诺瓦瓦克斯公司。</b>NVAX，这家生物制药公司终于抽出时间宣布了NVX-CoV2371（其针对新型冠状病毒病的候选疫苗）3期研究美国和墨西哥部分的中期结果。</blockquote></p><p> Here's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namely<b>Pfizer Inc.</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>Moderna, Inc.</b>MRNA, both of which have authorized vaccines in the market.</p><p><blockquote>以下是Novavax候选疫苗和领跑者的比较视角，即<b>辉瑞公司。</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>莫德纳公司。</b>MRNA，两者都有授权疫苗上市。</blockquote></p><p> <b>Vaccine Type:</b>&nbsp;Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.</p><p><blockquote><b>疫苗类型：</b>Novavax的NVX-CoV2371是一种基于重组纳米颗粒蛋白的COVID-19疫苗，与该公司专有的Matrix-M佐剂包装在一起。</blockquote></p><p> The Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern&nbsp;vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.</p><p><blockquote>辉瑞-BioNTech和Moderna的产品是mRNA疫苗，或通过使用一种称为mRNA的遗传密码来发挥作用的现代疫苗，这种遗传密码指示我们的免疫细胞制造刺突蛋白，刺突蛋白存在于导致新冠肺炎的病毒表面。</blockquote></p><p> This spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.</p><p><blockquote>这种刺突蛋白虽然无害，但能够触发我们的免疫系统产生抗体，防止未来的感染。</blockquote></p><p> Novavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle&nbsp;that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.</p><p><blockquote>Novavax的疫苗是一种蛋白质佐剂，含有冠状病毒本身的刺突蛋白，但配方为纳米颗粒，不会导致疾病。然后，注射的疫苗刺激免疫系统产生抗体和T细胞免疫反应。</blockquote></p><p> <b>The Vaccine Doses:</b>&nbsp;The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.</p><p><blockquote><b>疫苗剂量：</b>这三家公司的疫苗都需要接种两剂。辉瑞的每剂由30 mcg和Moderna的100 mcg组成，而Novavax的每剂疫苗由5 mcg NVX-CoV2371和50 mcg Matrix-M1佐剂组成，它们是共同配制的。</blockquote></p><p> The interval between the two doses —&nbsp;the priming and booster dose —&nbsp;is 21 days each for Pfizer and Novavax and 28 days for Moderna.</p><p><blockquote>辉瑞和Novavax的两种剂量（初免剂量和加强剂量）之间的间隔为21天，Moderna为28天。</blockquote></p><p> <b>The Target Population:</b>&nbsp;The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants&nbsp;ages 16 years and older. The trial enrolled 43,448 participants.</p><p><blockquote><b>目标人群：</b>辉瑞-BioNTech最初的后期试验在16岁及以上的参与者中评估了疫苗。该试验招募了43,448名参与者。</blockquote></p><p> Moderna'sPhase 3 COVE study enrolled 30,000 participants&nbsp;ages 18 years and up.</p><p><blockquote>Moderna的3期COVE研究招募了30,000名18岁及以上的参与者。</blockquote></p><p> Since then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.</p><p><blockquote>此后，这两家公司获得了各自疫苗用于青少年的授权。</blockquote></p><p> Bothcompanieshave also initiated studies in the pediatric population.</p><p><blockquote>两家公司还启动了针对儿科人群的研究。</blockquote></p><p> Novavax's study enrolled 29,960 participants&nbsp;18 years of age and older&nbsp;across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.</p><p><blockquote>Novavax的研究在美国和墨西哥的119个地点招募了29,960名18岁及以上的参与者。PREVENT-19的安慰剂对照部分继续在12岁至18岁以下的青少年中进行，最近完成了2,248名参与者的招募。</blockquote></p><p> <b>Vaccine Logistics:</b>&nbsp;Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.</p><p><blockquote><b>疫苗物流：</b>辉瑞公司最近获得了FDA的授权，可以将未稀释、解冻的疫苗瓶在2°C至8°C的冰箱中储存长达一个月。</blockquote></p><p> Previously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five&nbsp;days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.</p><p><blockquote>以前，解冻、未稀释的疫苗瓶可以在冰箱中储存长达五天。Moderna的疫苗在首次使用前可以在2至8°C的冰箱中储存长达30天。</blockquote></p><p> NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.</p><p><blockquote>NVX-CoV2373在2°-8°C下储存稳定，允许使用现有的疫苗供应链渠道进行分销。它被包装在10剂小瓶中的即用型液体制剂中。</blockquote></p><p> <b>Vaccine Efficacy:</b>&nbsp;Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven&nbsp;days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.</p><p><blockquote><b>疫苗效力：</b>辉瑞-BioNTech去年12月发布的3期试验中期数据显示，该疫苗耐受性良好，在第二剂疫苗接种后7天或更长时间内，在预防新冠肺炎方面表现出95%的功效。第二次给药后长达六个月发布的更新顶线结果证实疗效为91.3%。</blockquote></p><p> The vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.</p><p><blockquote>该疫苗被发现对美国疾病控制和预防中心定义的严重疾病100%有效，对FDA定义的严重新冠肺炎95.3%有效。在实验室研究中，它也被证明对英国菌株有效。</blockquote></p><p> Moderna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.</p><p><blockquote>Moderna的疫苗对新冠肺炎的有效性为94.1%。该公司于5月宣布了其2期研究的初步数据，显示向先前接种疫苗的个体给予50微克剂量的mRNA-1273或mRNA-1273.351作为加强剂，增加了针对新型冠状病毒病毒和两种令人担忧的变异体的中和抗体滴度反应，B.1.351，首次在南非发现，P.1，首次在巴西发现。</blockquote></p><p> Novavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.</p><p><blockquote>Novavax的研究疫苗对中度和重度疾病表现出100%的保护作用，不涉及令人担忧的变异体或感兴趣的变异体。</blockquote></p><p> Against variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.</p><p><blockquote>针对关注变异体和感兴趣变异体，疗效为93.2%，在高危人群（定义为65岁以上或65岁以下，患有某些合并症或经常暴露于新冠肺炎的情况）中，疗效为91%。</blockquote></p><p> Overall efficacy was 90.4%, meeting the primary endpoint.</p><p><blockquote>总疗效为90.4%，达到主要终点。</blockquote></p><p></p><p> <b>Cantor Fitzgerald On Novavax's Vaccine:</b>A differentiating factor for NVX-2373&nbsp;is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.</p><p><blockquote><b>坎托·菲茨杰拉德谈Novavax的疫苗：</b>Cantor Fitzgerald分析师Charles Duncan在周一早间报告中表示，NVX-2373的一个与众不同之处在于，它对VoC/VoI表现出93.2%的疫苗效力，这证明了对多种新型冠状病毒毒株的保护作用。</blockquote></p><p> \"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.</p><p><blockquote>该分析师表示：“总体而言，这些结果增强了我们对新型冠状病毒候选疫苗‘2373具有差异化临床和物流特征的信念。”</blockquote></p><p> Showing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.</p><p><blockquote>他说，在两项3期临床试验中显示出对新毒株的功效，而不是从培养皿中进行的中和抗体测定中推断出潜在功效，这将NVX-CoV2373与其他获得紧急使用授权的疫苗区分开来。</blockquote></p><p> This profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.</p><p><blockquote>Cantor表示，这一概况降低了'2373新型冠状病毒预防性候选疫苗的监管/商业风险，并且随着2020年3月报告的NanoFlu 3期积极数据，应该会提高Novavax平台的整体形象。</blockquote></p><p> <b>Vaccine Safety Data:</b>Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from&nbsp;BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.</p><p><blockquote><b>疫苗安全性数据：</b>辉瑞-BioNTech的疫苗显示出良好的耐受性和安全性，BNT 162 b 2最常见的不良事件是注射部位的短暂、轻度至中度疼痛、疲劳和头痛，这些通常在两天内消退。</blockquote></p><p> For Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.</p><p><blockquote>对于Moderna，最常见的不良反应包括注射部位疼痛、疲劳、肌痛、关节痛、头痛和注射部位红斑/发红。在第二次给药后，mRNA-1273组中引起的不良反应的频率和严重程度增加。</blockquote></p><p> Preliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.</p><p><blockquote>Novavax试验的初步安全性数据显示，该疫苗总体耐受性良好。严重和严重不良事件的数量较少，并且在疫苗组和安慰剂组之间平衡。</blockquote></p><p> In assessing reactogenicity seven&nbsp;days after dose one&nbsp;and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.</p><p><blockquote>在第1剂和第2剂后7天评估反应原性时，注射部位疼痛和压痛（通常严重程度为轻度至中度）是最常见的局部症状，持续时间少于3天。疲劳、头痛和肌肉疼痛是最常见的全身症状，持续时间不到两天。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up<blockquote>Novavax与辉瑞与Moderna：COVID-19疫苗如何叠加</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up<blockquote>Novavax与辉瑞与Moderna：COVID-19疫苗如何叠加</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-06-15 17:52</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p>It was \"better late than never\" for&nbsp;<b>Novavax, Inc.</b>NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.</p><p><blockquote>“迟到总比不到好”<b>诺瓦瓦克斯公司。</b>NVAX，这家生物制药公司终于抽出时间宣布了NVX-CoV2371（其针对新型冠状病毒病的候选疫苗）3期研究美国和墨西哥部分的中期结果。</blockquote></p><p> Here's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namely<b>Pfizer Inc.</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>Moderna, Inc.</b>MRNA, both of which have authorized vaccines in the market.</p><p><blockquote>以下是Novavax候选疫苗和领跑者的比较视角，即<b>辉瑞公司。</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>莫德纳公司。</b>MRNA，两者都有授权疫苗上市。</blockquote></p><p> <b>Vaccine Type:</b>&nbsp;Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.</p><p><blockquote><b>疫苗类型：</b>Novavax的NVX-CoV2371是一种基于重组纳米颗粒蛋白的COVID-19疫苗，与该公司专有的Matrix-M佐剂包装在一起。</blockquote></p><p> The Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern&nbsp;vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.</p><p><blockquote>辉瑞-BioNTech和Moderna的产品是mRNA疫苗，或通过使用一种称为mRNA的遗传密码来发挥作用的现代疫苗，这种遗传密码指示我们的免疫细胞制造刺突蛋白，刺突蛋白存在于导致新冠肺炎的病毒表面。</blockquote></p><p> This spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.</p><p><blockquote>这种刺突蛋白虽然无害，但能够触发我们的免疫系统产生抗体，防止未来的感染。</blockquote></p><p> Novavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle&nbsp;that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.</p><p><blockquote>Novavax的疫苗是一种蛋白质佐剂，含有冠状病毒本身的刺突蛋白，但配方为纳米颗粒，不会导致疾病。然后，注射的疫苗刺激免疫系统产生抗体和T细胞免疫反应。</blockquote></p><p> <b>The Vaccine Doses:</b>&nbsp;The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.</p><p><blockquote><b>疫苗剂量：</b>这三家公司的疫苗都需要接种两剂。辉瑞的每剂由30 mcg和Moderna的100 mcg组成，而Novavax的每剂疫苗由5 mcg NVX-CoV2371和50 mcg Matrix-M1佐剂组成，它们是共同配制的。</blockquote></p><p> The interval between the two doses —&nbsp;the priming and booster dose —&nbsp;is 21 days each for Pfizer and Novavax and 28 days for Moderna.</p><p><blockquote>辉瑞和Novavax的两种剂量（初免剂量和加强剂量）之间的间隔为21天，Moderna为28天。</blockquote></p><p> <b>The Target Population:</b>&nbsp;The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants&nbsp;ages 16 years and older. The trial enrolled 43,448 participants.</p><p><blockquote><b>目标人群：</b>辉瑞-BioNTech最初的后期试验在16岁及以上的参与者中评估了疫苗。该试验招募了43,448名参与者。</blockquote></p><p> Moderna'sPhase 3 COVE study enrolled 30,000 participants&nbsp;ages 18 years and up.</p><p><blockquote>Moderna的3期COVE研究招募了30,000名18岁及以上的参与者。</blockquote></p><p> Since then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.</p><p><blockquote>此后，这两家公司获得了各自疫苗用于青少年的授权。</blockquote></p><p> Bothcompanieshave also initiated studies in the pediatric population.</p><p><blockquote>两家公司还启动了针对儿科人群的研究。</blockquote></p><p> Novavax's study enrolled 29,960 participants&nbsp;18 years of age and older&nbsp;across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.</p><p><blockquote>Novavax的研究在美国和墨西哥的119个地点招募了29,960名18岁及以上的参与者。PREVENT-19的安慰剂对照部分继续在12岁至18岁以下的青少年中进行，最近完成了2,248名参与者的招募。</blockquote></p><p> <b>Vaccine Logistics:</b>&nbsp;Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.</p><p><blockquote><b>疫苗物流：</b>辉瑞公司最近获得了FDA的授权，可以将未稀释、解冻的疫苗瓶在2°C至8°C的冰箱中储存长达一个月。</blockquote></p><p> Previously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five&nbsp;days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.</p><p><blockquote>以前，解冻、未稀释的疫苗瓶可以在冰箱中储存长达五天。Moderna的疫苗在首次使用前可以在2至8°C的冰箱中储存长达30天。</blockquote></p><p> NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.</p><p><blockquote>NVX-CoV2373在2°-8°C下储存稳定，允许使用现有的疫苗供应链渠道进行分销。它被包装在10剂小瓶中的即用型液体制剂中。</blockquote></p><p> <b>Vaccine Efficacy:</b>&nbsp;Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven&nbsp;days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.</p><p><blockquote><b>疫苗效力：</b>辉瑞-BioNTech去年12月发布的3期试验中期数据显示，该疫苗耐受性良好，在第二剂疫苗接种后7天或更长时间内，在预防新冠肺炎方面表现出95%的功效。第二次给药后长达六个月发布的更新顶线结果证实疗效为91.3%。</blockquote></p><p> The vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.</p><p><blockquote>该疫苗被发现对美国疾病控制和预防中心定义的严重疾病100%有效，对FDA定义的严重新冠肺炎95.3%有效。在实验室研究中，它也被证明对英国菌株有效。</blockquote></p><p> Moderna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.</p><p><blockquote>Moderna的疫苗对新冠肺炎的有效性为94.1%。该公司于5月宣布了其2期研究的初步数据，显示向先前接种疫苗的个体给予50微克剂量的mRNA-1273或mRNA-1273.351作为加强剂，增加了针对新型冠状病毒病毒和两种令人担忧的变异体的中和抗体滴度反应，B.1.351，首次在南非发现，P.1，首次在巴西发现。</blockquote></p><p> Novavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.</p><p><blockquote>Novavax的研究疫苗对中度和重度疾病表现出100%的保护作用，不涉及令人担忧的变异体或感兴趣的变异体。</blockquote></p><p> Against variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.</p><p><blockquote>针对关注变异体和感兴趣变异体，疗效为93.2%，在高危人群（定义为65岁以上或65岁以下，患有某些合并症或经常暴露于新冠肺炎的情况）中，疗效为91%。</blockquote></p><p> Overall efficacy was 90.4%, meeting the primary endpoint.</p><p><blockquote>总疗效为90.4%，达到主要终点。</blockquote></p><p></p><p> <b>Cantor Fitzgerald On Novavax's Vaccine:</b>A differentiating factor for NVX-2373&nbsp;is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.</p><p><blockquote><b>坎托·菲茨杰拉德谈Novavax的疫苗：</b>Cantor Fitzgerald分析师Charles Duncan在周一早间报告中表示，NVX-2373的一个与众不同之处在于，它对VoC/VoI表现出93.2%的疫苗效力，这证明了对多种新型冠状病毒毒株的保护作用。</blockquote></p><p> \"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.</p><p><blockquote>该分析师表示：“总体而言，这些结果增强了我们对新型冠状病毒候选疫苗‘2373具有差异化临床和物流特征的信念。”</blockquote></p><p> Showing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.</p><p><blockquote>他说，在两项3期临床试验中显示出对新毒株的功效，而不是从培养皿中进行的中和抗体测定中推断出潜在功效，这将NVX-CoV2373与其他获得紧急使用授权的疫苗区分开来。</blockquote></p><p> This profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.</p><p><blockquote>Cantor表示，这一概况降低了'2373新型冠状病毒预防性候选疫苗的监管/商业风险，并且随着2020年3月报告的NanoFlu 3期积极数据，应该会提高Novavax平台的整体形象。</blockquote></p><p> <b>Vaccine Safety Data:</b>Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from&nbsp;BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.</p><p><blockquote><b>疫苗安全性数据：</b>辉瑞-BioNTech的疫苗显示出良好的耐受性和安全性，BNT 162 b 2最常见的不良事件是注射部位的短暂、轻度至中度疼痛、疲劳和头痛，这些通常在两天内消退。</blockquote></p><p> For Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.</p><p><blockquote>对于Moderna，最常见的不良反应包括注射部位疼痛、疲劳、肌痛、关节痛、头痛和注射部位红斑/发红。在第二次给药后，mRNA-1273组中引起的不良反应的频率和严重程度增加。</blockquote></p><p> Preliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.</p><p><blockquote>Novavax试验的初步安全性数据显示，该疫苗总体耐受性良好。严重和严重不良事件的数量较少，并且在疫苗组和安慰剂组之间平衡。</blockquote></p><p> In assessing reactogenicity seven&nbsp;days after dose one&nbsp;and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.</p><p><blockquote>在第1剂和第2剂后7天评估反应原性时，注射部位疼痛和压痛（通常严重程度为轻度至中度）是最常见的局部症状，持续时间少于3天。疲劳、头痛和肌肉疼痛是最常见的全身症状，持续时间不到两天。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","MRNA":"Moderna, Inc.","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167457915","content_text":"It was \"better late than never\" for Novavax, Inc.NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.\nHere's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namelyPfizer Inc.PFE 0.05%-BioNTech SEBNTXandModerna, Inc.MRNA, both of which have authorized vaccines in the market.\nVaccine Type: Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.\nThe Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.\nThis spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.\nNovavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.\nThe Vaccine Doses: The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.\nThe interval between the two doses — the priming and booster dose — is 21 days each for Pfizer and Novavax and 28 days for Moderna.\nThe Target Population: The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants ages 16 years and older. The trial enrolled 43,448 participants.\nModerna'sPhase 3 COVE study enrolled 30,000 participants ages 18 years and up.\nSince then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.\nBothcompanieshave also initiated studies in the pediatric population.\nNovavax's study enrolled 29,960 participants 18 years of age and older across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.\nVaccine Logistics: Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.\nPreviously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.\nNVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.\nVaccine Efficacy: Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.\nThe vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.\nModerna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.\nNovavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.\nAgainst variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.\nOverall efficacy was 90.4%, meeting the primary endpoint.\nCantor Fitzgerald On Novavax's Vaccine:A differentiating factor for NVX-2373 is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.\n\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.\nShowing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.\nThis profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.\nVaccine Safety Data:Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.\nFor Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.\nPreliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.\nIn assessing reactogenicity seven days after dose one and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.","news_type":1,"symbols_score_info":{"NVAX":0.9,"MRNA":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":441,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":690010483,"gmtCreate":1639613021232,"gmtModify":1639613021478,"author":{"id":"3577518888738299","authorId":"3577518888738299","name":"LWZ2218","avatar":"https://static.tigerbbs.com/f53fe88ba02bdf3f307a8e715043f7e2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577518888738299","idStr":"3577518888738299"},"themes":[],"htmlText":"Good job","listText":"Good job","text":"Good job","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690010483","repostId":"2191994940","repostType":4,"isVote":1,"tweetType":1,"viewCount":2462,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604454369,"gmtCreate":1639441289184,"gmtModify":1639441293892,"author":{"id":"3577518888738299","authorId":"3577518888738299","name":"LWZ2218","avatar":"https://static.tigerbbs.com/f53fe88ba02bdf3f307a8e715043f7e2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577518888738299","idStr":"3577518888738299"},"themes":[],"htmlText":"Good time to buy Tesla stock now","listText":"Good time to buy Tesla stock now","text":"Good time to buy Tesla stock now","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/604454369","repostId":"1114636896","repostType":4,"repost":{"id":"1114636896","kind":"news","pubTimestamp":1639439509,"share":"https://www.laohu8.com/m/news/1114636896?lang=zh_CN&edition=full","pubTime":"2021-12-14 07:51","market":"us","language":"en","title":"Tesla Stock Is in a Bear Market Again. What’s Next for Musk’s EV Firm.<blockquote>特斯拉股票再次陷入熊市。马斯克电动汽车公司的下一步是什么？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1114636896","media":"Barrons","summary":"Shares of electric-vehicle leader Tesla crossed into bear-market territory today. That statement is ","content":"<p>Shares of electric-vehicle leader&nbsp;Tesla&nbsp;crossed into bear-market territory&nbsp;today. That statement is technically true, but also a little tiring. Stocks, individually, don’t have bear or bull markets. That terms should be reserved for, well, the overall market. Still, the big dip in a mega-cap stock is noteworthy leaving investors wondering what might come next.</p><p><blockquote>电动汽车领导者特斯拉的股价今天进入熊市区域。这种说法在技术上是正确的，但也有点累。就个人而言，股票没有熊市或牛市。这些条款应该留给整个市场。尽管如此，大型股的大幅下跌还是值得注意的，让投资者想知道接下来会发生什么。</blockquote></p><p> Tesla (ticker: TSLA) stock closed down 5% at $966.41. The&nbsp;S&amp;P 500 index&nbsp;and&nbsp;Dow Jones Industrial Average&nbsp;both closed down 0.9%.</p><p><blockquote>特斯拉（股票代码：TSLA）股价收盘下跌5%，至966.41美元。标普500指数和道琼斯工业平均指数均收跌0.9%。</blockquote></p><p> The Monday dip sent the company’s market cap below $1 trillion based on the number of shares outstanding, excluding management stock options. Shares are down 21% from the Nov. 4 closing high of $1,229.91. Shares are down 22% from the intraday high of $1,243.49.</p><p><blockquote>根据已发行股票数量（不包括管理层股票期权）计算，周一的下跌使该公司的市值跌破1万亿美元。股价较11月4日收盘高点1,229.91美元下跌21%。股价较盘中高点1,243.49美元下跌22%。</blockquote></p><p> Whether or not bear markets should be measured from a closing high or an intraday high is the source of debate on Wall Street. But again, the debate doesn’t really matter in this instance because individual stocks don’t have bull and bear markets.</p><p><blockquote>熊市应该从收盘高点还是盘中高点来衡量是华尔街争论的焦点。但同样，在这种情况下，争论并不重要，因为个股没有牛市和熊市。</blockquote></p><p> Whether it’s a bear market or not isn’t the point for individual investors. The pain of a 20% drop is real.</p><p><blockquote>对于个人投资者来说，是否是熊市并不是重点。下跌20%的痛苦是真实的。</blockquote></p><p> One of the last times Tesla stock closed in bear-market territory was February 2021. (Yes, <i>Barron’s</i> wrote about the single stock bear market then, too.) Back then, interest rates were rising and highly valued tech stocks took it on the chin. Higher rates hurt the valuation of shares of faster-growing companies more than those of slow-growing mature companies—that’s just the way the math of higher interest rates works out.</p><p><blockquote>特斯拉股票最后一次收于熊市区域是在2021年2月。（是的，<i>巴伦周刊</i>当时也写过关于单股熊市的文章。）当时，利率正在上升，高估值的科技股承受了压力。较高的利率对增长较快的公司股票估值的损害大于增长缓慢的成熟公司的股票估值——这正是较高利率的数学计算方式。</blockquote></p><p> Back then it took about six months for the stock to retake its old highs. If that were to happen again, bullish investors would be waiting until June 2022 to see Tesla stock hit $1,300.</p><p><blockquote>当时，该股花了大约六个月的时间才恢复到旧高点。如果这种情况再次发生，看涨的投资者将等到2022年6月才能看到特斯拉股价触及1,300美元。</blockquote></p><p> That would be a long wait for bulls, and while there is no way to know if that scenario will even unfold, there is a lot going on that could move the stock in the coming couple of months. Bullish and bearish Tesla investors will be watching for the startup of two new plants in Germany and Texas, the impact of those new plants on profit margins, the start of deliveries of the Tesla Cybertruck and the overall growth of EVs in the U.S., Europe, and China.</p><p><blockquote>对于多头来说，这将是一个漫长的等待，虽然没有办法知道这种情况是否会发生，但未来几个月有很多事情可能会影响该股。看涨和看跌的特斯拉投资者将关注德国和德克萨斯两家新工厂的启动、这些新工厂对利润率的影响、特斯拉Cybertruck的开始交付以及美国电动汽车的整体增长、欧洲和中国。</blockquote></p><p> With all that coming, it raising the question of why the shares are struggling.</p><p><blockquote>随之而来的是，这引发了一个问题：为什么股价陷入困境。</blockquote></p><p> Two things might be at work. First, CEO Elon Musk is still selling stock. It creates an overhang. Some bulls might wait to buy until the large sales are over. Musk has at least 5 million or 6 million shares left to sell associated with his expiring stock options. He will probably be done selling by the end of 2021, but he might just Tweet out when he’s done. At current pace, we figure by year-end.</p><p><blockquote>可能有两件事在起作用。首先，首席执行官埃隆·马斯克仍在出售股票。它创造了一个悬垂。一些多头可能会等到大规模抛售结束后再买入。马斯克至少还有500万或600万股与他即将到期的股票期权相关的股票可供出售。他可能会在2021年底完成出售，但他可能会在完成后发布推文。按照目前的速度，我们预计到年底。</blockquote></p><p> Second, there is the issue of Musk being named Time’s Person of the Year.Amazon.com&nbsp;(AMZN) founder Jeff Bezos won that distinction in 1999, near a multiyear peak in that stock. Amazon shares went on to slide, and some investors think Tesla stock could do the same.</p><p><blockquote>其次，还有马斯克被《时代》杂志评为年度人物的问题。亚马逊。com(AMZN)创始人杰夫·贝索斯(Mark Zuckerberg)在1999年获得了这一殊荣，当时该股股价接近多年来的峰值。亚马逊股价继续下滑，一些投资者认为特斯拉股价也可能出现同样的情况。</blockquote></p><p> The Amazon comparison with Tesla doesn’t quite match up, however. The two companies are at very different stages of development when their top executives won Time’s distinction. Amazon had a market capitalization of $27 billion back then. Tesla’s market cap is now hovering around $1 trillion.</p><p><blockquote>然而，亚马逊与特斯拉的比较并不完全匹配。当这两家公司的高管赢得《时代》杂志的殊荣时，它们正处于截然不同的发展阶段。亚马逊当时的市值为270亿美元。特斯拉的市值目前徘徊在1万亿美元左右。</blockquote></p><p> Still, it’s a belief, and traders do odd things from time to time, justified or not. When stocks move upward, or downward, momentum traders will jump on the trend for whatever reason.</p><p><blockquote>尽管如此，这仍然是一种信念，交易者时不时会做一些奇怪的事情，无论是否合理。当股票上涨或下跌时，无论出于何种原因，动量交易者都会顺势而为。</blockquote></p><p></p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla Stock Is in a Bear Market Again. What’s Next for Musk’s EV Firm.<blockquote>特斯拉股票再次陷入熊市。马斯克电动汽车公司的下一步是什么？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla Stock Is in a Bear Market Again. What’s Next for Musk’s EV Firm.<blockquote>特斯拉股票再次陷入熊市。马斯克电动汽车公司的下一步是什么？</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barrons</strong><span class=\"h-time small\">2021-12-14 07:51</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Shares of electric-vehicle leader&nbsp;Tesla&nbsp;crossed into bear-market territory&nbsp;today. That statement is technically true, but also a little tiring. Stocks, individually, don’t have bear or bull markets. That terms should be reserved for, well, the overall market. Still, the big dip in a mega-cap stock is noteworthy leaving investors wondering what might come next.</p><p><blockquote>电动汽车领导者特斯拉的股价今天进入熊市区域。这种说法在技术上是正确的，但也有点累。就个人而言，股票没有熊市或牛市。这些条款应该留给整个市场。尽管如此，大型股的大幅下跌还是值得注意的，让投资者想知道接下来会发生什么。</blockquote></p><p> Tesla (ticker: TSLA) stock closed down 5% at $966.41. The&nbsp;S&amp;P 500 index&nbsp;and&nbsp;Dow Jones Industrial Average&nbsp;both closed down 0.9%.</p><p><blockquote>特斯拉（股票代码：TSLA）股价收盘下跌5%，至966.41美元。标普500指数和道琼斯工业平均指数均收跌0.9%。</blockquote></p><p> The Monday dip sent the company’s market cap below $1 trillion based on the number of shares outstanding, excluding management stock options. Shares are down 21% from the Nov. 4 closing high of $1,229.91. Shares are down 22% from the intraday high of $1,243.49.</p><p><blockquote>根据已发行股票数量（不包括管理层股票期权）计算，周一的下跌使该公司的市值跌破1万亿美元。股价较11月4日收盘高点1,229.91美元下跌21%。股价较盘中高点1,243.49美元下跌22%。</blockquote></p><p> Whether or not bear markets should be measured from a closing high or an intraday high is the source of debate on Wall Street. But again, the debate doesn’t really matter in this instance because individual stocks don’t have bull and bear markets.</p><p><blockquote>熊市应该从收盘高点还是盘中高点来衡量是华尔街争论的焦点。但同样，在这种情况下，争论并不重要，因为个股没有牛市和熊市。</blockquote></p><p> Whether it’s a bear market or not isn’t the point for individual investors. The pain of a 20% drop is real.</p><p><blockquote>对于个人投资者来说，是否是熊市并不是重点。下跌20%的痛苦是真实的。</blockquote></p><p> One of the last times Tesla stock closed in bear-market territory was February 2021. (Yes, <i>Barron’s</i> wrote about the single stock bear market then, too.) Back then, interest rates were rising and highly valued tech stocks took it on the chin. Higher rates hurt the valuation of shares of faster-growing companies more than those of slow-growing mature companies—that’s just the way the math of higher interest rates works out.</p><p><blockquote>特斯拉股票最后一次收于熊市区域是在2021年2月。（是的，<i>巴伦周刊</i>当时也写过关于单股熊市的文章。）当时，利率正在上升，高估值的科技股承受了压力。较高的利率对增长较快的公司股票估值的损害大于增长缓慢的成熟公司的股票估值——这正是较高利率的数学计算方式。</blockquote></p><p> Back then it took about six months for the stock to retake its old highs. If that were to happen again, bullish investors would be waiting until June 2022 to see Tesla stock hit $1,300.</p><p><blockquote>当时，该股花了大约六个月的时间才恢复到旧高点。如果这种情况再次发生，看涨的投资者将等到2022年6月才能看到特斯拉股价触及1,300美元。</blockquote></p><p> That would be a long wait for bulls, and while there is no way to know if that scenario will even unfold, there is a lot going on that could move the stock in the coming couple of months. Bullish and bearish Tesla investors will be watching for the startup of two new plants in Germany and Texas, the impact of those new plants on profit margins, the start of deliveries of the Tesla Cybertruck and the overall growth of EVs in the U.S., Europe, and China.</p><p><blockquote>对于多头来说，这将是一个漫长的等待，虽然没有办法知道这种情况是否会发生，但未来几个月有很多事情可能会影响该股。看涨和看跌的特斯拉投资者将关注德国和德克萨斯两家新工厂的启动、这些新工厂对利润率的影响、特斯拉Cybertruck的开始交付以及美国电动汽车的整体增长、欧洲和中国。</blockquote></p><p> With all that coming, it raising the question of why the shares are struggling.</p><p><blockquote>随之而来的是，这引发了一个问题：为什么股价陷入困境。</blockquote></p><p> Two things might be at work. First, CEO Elon Musk is still selling stock. It creates an overhang. Some bulls might wait to buy until the large sales are over. Musk has at least 5 million or 6 million shares left to sell associated with his expiring stock options. He will probably be done selling by the end of 2021, but he might just Tweet out when he’s done. At current pace, we figure by year-end.</p><p><blockquote>可能有两件事在起作用。首先，首席执行官埃隆·马斯克仍在出售股票。它创造了一个悬垂。一些多头可能会等到大规模抛售结束后再买入。马斯克至少还有500万或600万股与他即将到期的股票期权相关的股票可供出售。他可能会在2021年底完成出售，但他可能会在完成后发布推文。按照目前的速度，我们预计到年底。</blockquote></p><p> Second, there is the issue of Musk being named Time’s Person of the Year.Amazon.com&nbsp;(AMZN) founder Jeff Bezos won that distinction in 1999, near a multiyear peak in that stock. Amazon shares went on to slide, and some investors think Tesla stock could do the same.</p><p><blockquote>其次，还有马斯克被《时代》杂志评为年度人物的问题。亚马逊。com(AMZN)创始人杰夫·贝索斯(Mark Zuckerberg)在1999年获得了这一殊荣，当时该股股价接近多年来的峰值。亚马逊股价继续下滑，一些投资者认为特斯拉股价也可能出现同样的情况。</blockquote></p><p> The Amazon comparison with Tesla doesn’t quite match up, however. The two companies are at very different stages of development when their top executives won Time’s distinction. Amazon had a market capitalization of $27 billion back then. Tesla’s market cap is now hovering around $1 trillion.</p><p><blockquote>然而，亚马逊与特斯拉的比较并不完全匹配。当这两家公司的高管赢得《时代》杂志的殊荣时，它们正处于截然不同的发展阶段。亚马逊当时的市值为270亿美元。特斯拉的市值目前徘徊在1万亿美元左右。</blockquote></p><p> Still, it’s a belief, and traders do odd things from time to time, justified or not. When stocks move upward, or downward, momentum traders will jump on the trend for whatever reason.</p><p><blockquote>尽管如此，这仍然是一种信念，交易者时不时会做一些奇怪的事情，无论是否合理。当股票上涨或下跌时，无论出于何种原因，动量交易者都会顺势而为。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.barrons.com/articles/tesla-stock-bear-musk-51639436863?mod=hp_LATEST\">Barrons</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.barrons.com/articles/tesla-stock-bear-musk-51639436863?mod=hp_LATEST","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1114636896","content_text":"Shares of electric-vehicle leader Tesla crossed into bear-market territory today. That statement is technically true, but also a little tiring. Stocks, individually, don’t have bear or bull markets. That terms should be reserved for, well, the overall market. Still, the big dip in a mega-cap stock is noteworthy leaving investors wondering what might come next.\nTesla (ticker: TSLA) stock closed down 5% at $966.41. The S&P 500 index and Dow Jones Industrial Average both closed down 0.9%.\nThe Monday dip sent the company’s market cap below $1 trillion based on the number of shares outstanding, excluding management stock options. Shares are down 21% from the Nov. 4 closing high of $1,229.91. Shares are down 22% from the intraday high of $1,243.49.\nWhether or not bear markets should be measured from a closing high or an intraday high is the source of debate on Wall Street. But again, the debate doesn’t really matter in this instance because individual stocks don’t have bull and bear markets.\nWhether it’s a bear market or not isn’t the point for individual investors. The pain of a 20% drop is real.\nOne of the last times Tesla stock closed in bear-market territory was February 2021. (Yes, Barron’s wrote about the single stock bear market then, too.) Back then, interest rates were rising and highly valued tech stocks took it on the chin. Higher rates hurt the valuation of shares of faster-growing companies more than those of slow-growing mature companies—that’s just the way the math of higher interest rates works out.\nBack then it took about six months for the stock to retake its old highs. If that were to happen again, bullish investors would be waiting until June 2022 to see Tesla stock hit $1,300.\nThat would be a long wait for bulls, and while there is no way to know if that scenario will even unfold, there is a lot going on that could move the stock in the coming couple of months. Bullish and bearish Tesla investors will be watching for the startup of two new plants in Germany and Texas, the impact of those new plants on profit margins, the start of deliveries of the Tesla Cybertruck and the overall growth of EVs in the U.S., Europe, and China.\nWith all that coming, it raising the question of why the shares are struggling.\nTwo things might be at work. First, CEO Elon Musk is still selling stock. It creates an overhang. Some bulls might wait to buy until the large sales are over. Musk has at least 5 million or 6 million shares left to sell associated with his expiring stock options. He will probably be done selling by the end of 2021, but he might just Tweet out when he’s done. At current pace, we figure by year-end.\nSecond, there is the issue of Musk being named Time’s Person of the Year.Amazon.com (AMZN) founder Jeff Bezos won that distinction in 1999, near a multiyear peak in that stock. Amazon shares went on to slide, and some investors think Tesla stock could do the same.\nThe Amazon comparison with Tesla doesn’t quite match up, however. The two companies are at very different stages of development when their top executives won Time’s distinction. Amazon had a market capitalization of $27 billion back then. Tesla’s market cap is now hovering around $1 trillion.\nStill, it’s a belief, and traders do odd things from time to time, justified or not. When stocks move upward, or downward, momentum traders will jump on the trend for whatever reason.","news_type":1,"symbols_score_info":{"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":4097,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}